<html lang="en"><head>
	<!-- Required meta tags -->
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

	<!-- Favicon -->
	<!-- cpcommit -->
	<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

	<script>
		(function () {
			var hostName = window.location.hostname;

			var browserAccepted = function () {

				var ua = window.navigator.userAgent;
				var trident = ua.indexOf('Trident/'); //IE 11;
				var msie = ua.indexOf('MSIE '); // IE 10 or older
				if (msie > 0) {
					return false;
				}
				return true;
			}();

			var pathToLibs = './js';
			var pathToError = './';
			// uncomment following lines only when running ix symlink to ix.xhtml on *.sec.gov
			/* commented out for running ix redirector script
			if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
				pathToLibs = './ixviewer/js';
				pathToError = '/ixviewer/';
			}
			*/
			if (browserAccepted) {

				// css
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

				// js
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.7.1.slim.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

				var date = new Date();
				var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
				document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
			} else {
				// user us on a browser that we do not support
				var currentUrl = window.location.href.split('?')[0];
				var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
				browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
				window.location.href = browserError;
			}
		})();
	</script><link rel="stylesheet" href="./js/css/custom-bootstrap.css"><link rel="stylesheet" href="./js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="./js/css/app.css"><script type="text/javascript" src="./js/lib/jquery-3.7.1.slim.min.js"></script><script type="text/javascript" src="./js/lib/popper.min.js"></script><script type="text/javascript" src="./js/lib/bootstrap.min.js"></script><script type="text/javascript" src="./js/lib/moment.js"></script><script type="text/javascript" src="./js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="./js/lib/he.js"></script><script type="text/javascript" defer="true" src="./js/production.min.js?d=22-4-2024"></script>
	<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} #dynamic-xbrl-form .text-block-indicator-left{border-left:.75rem solid ##003768;} #dynamic-xbrl-form .text-block-indicator-right{border-right:.75rem solid ##003768;} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>

<body>
	<noscript>This application relies heavily on JavaScript, you
		will need to allow JavaScript to use this application.</noscript>
	<nav class="reboot navbar navbar-expand-md navbar-dark navbar-height bg-sec fixed-top w-100 pl-0">
		<button class="reboot navbar-toggler ml-1" type="button" data-test="" data-toggle="collapse" data-target="#main-navbar" aria-controls="main-navbar" aria-expanded="false" aria-label="Toggle navigation">Inline Viewer</button>
		<div class="reboot navbar-height collapse navbar-collapse bg-sec w-100" data-test="main-navbar" id="main-navbar">
			<ul class="reboot navbar-nav mr-auto bg-inherit">
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a id="menu-dropdown-link" data-test="menu-dropdown-link" class="reboot nav-link dropdown-toggle click disabled" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="1" accesskey="1">
						<i class="reboot nav-loading fas fa-bars" title="Menu"></i>
						<span class="reboot d-md-none d-lg-inline">Menu</span>
						<span class="reboot sr-only sr-only-focusable">Menu</span>
					</a>
					<div class="reboot dropdown-menu">
						<a id="menu-dropdown-information" data-test="menu-dropdown-information" class="reboot dropdown-item click text-body" tabindex="1">Information</a>
						<a id="form-information-instance" data-test="form-information-instance" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL
							Instance</a>
						<a id="form-information-zip" data-test="form-information-zip" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL Zip
							File</a>
						<a id="form-information-html" data-test="form-information-html" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Open as HTML</a>
						<a id="menu-dropdown-settings" data-test="menu-dropdown-settings" class="reboot dropdown-item click text-body" tabindex="1">Settings</a>
						<a id="form-information-help" data-test="form-information-help" class="reboot dropdown-item click text-body" tabindex="1">Help</a>
						<span id="form-information-version" class="reboot dropdown-item-text text-body" tabindex="1"></span>
					</div>
				</li>
				<li class="reboot nav-item my-auto ml-1">
					<a id="sections-dropdown-link" data-test="sections-dropdown-link" class="reboot nav-link click disabled meta-required" tabindex="2" accesskey="2">
						<i class="reboot fas fa-layer-group" title="Sections"></i>
						<span class="reboot d-md-none d-lg-inline">Sections</span>
						<span class="reboot sr-only sr-only-focusable">Sections</span>
					</a>
				</li>
				<li class="reboot nav-item my-auto ml-1 mr-1">
					<form id="global-search-form" data-test="global-search-form" class="reboot my-2 my-lg-0 input-group disabled" novalidate="">
						<div class="reboot input-group-prepend">
							<button data-name="global-search-options" class="reboot dropdown btn btn-outline-light disabled" type="button" data-toggle="dropdown" tabindex="3">
								<i class="reboot nav-loading fas fa-cog" title="Additional Search Options">
									<span class="reboot sr-only sr-only-focusable">Additional
										Search Options</span>
								</i>
							</button>
							<div class="reboot dropdown-menu px-2">
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="1" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Name</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="2" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Content</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="3" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Labels</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="4" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Definitions</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="5" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Dimensions</span>
									</label>
								</div>
								<div class="reboot bg-light border p-1">
									<span class="reboot dropdown-item-text">Reference
										Options</span>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="6" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="7" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Sub-Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="8" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Paragraph</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="9" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Publisher</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="10" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="disabled">Include Section</span>
										</label>
									</div>
								</div>
								<div class="reboot form-check">
									<input class="reboot form-check-input" type="checkbox" name="search-options" value="11" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Match Case</span>
									</label>
								</div>
							</div>
						</div>
						<input type="text" class="reboot form-control disabled" id="global-search" data-test="global-search" placeholder="Search Facts" disabled="" aria-label="Search all Facts and highlight them accordingly." tabindex="4">
						<div class="reboot input-group-append">
							<button id="search-btn-clear" data-name="global-search-clear" class="reboot btn btn-outline-light disabled" type="button" tabindex="5">
								<i class="reboot nav-loading fas fa-times-circle" title="Clear Search"></i>
								<span class="reboot sr-only sr-only-focusable">Clear
									Search</span>
							</button>
							<button class="reboot btn btn-outline-light disabled" type="submit" tabindex="6">
								<i class="reboot nav-loading fas fa-search" title="Submit Search"></i>
								<span class="reboot sr-only sr-only-focusable">Submit
									Search</span>
							</button>
						</div>
					</form>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-data" data-test="nav-filter-data" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="7" accesskey="3">
						<i class="reboot nav-loading fas fa-list-alt" title="Data"></i>
						<span class="reboot d-md-none d-lg-inline">Data</span>
						<span class="reboot sr-only sr-only-focusable">Data</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-dropdown" data-name="data-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="0" checked="" tabindex="7">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="1" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Amounts Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="2" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Text Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="data-radios" value="3" disabled="" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Calculations Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="4" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Negatives Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="5" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Additional Items Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-tags" data-test="nav-filter-tags" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="8" accesskey="4">
						<i class="reboot nav-loading fas fa-tags" title="Tags"></i>
						<span class="reboot d-md-none d-lg-inline">Tags</span>
						<span class="reboot sr-only sr-only-focusable">Tags</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-tags-dropdown" data-name="tags-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="0" aria-label="Radio Button for All Tag Types" checked="" tabindex="8">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="1" aria-label="Radio Button for Standard Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span>Standard Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="tags-radios" value="2" disabled="" aria-label="Radio Button for Custom Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="Facts whose tags are outside the realm of DEI, US-GAAP, etc." class="reboot far fa-question-circle"></i>
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Custom Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-more" data-test="nav-filter-more" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="9" accesskey="5">
						<i id="loading-more-filters" class="reboot nav-loading fas fa-filter" title="More Filters"></i>
						<span class="reboot d-md-none d-lg-inline">More Filters</span>
						<span class="reboot sr-only sr-only-focusable">More Filters</span>
						<span title="Total active filters." class="reboot badge badge-warning"></span>
					</a>
					<div class="reboot dropdown-menu dropdown-menu-width">
						<label class="reboot dropdown-item-text d-none performance-concern">
							Selecting any of the below will take a few moments.</label>
						<div class="reboot accordion" id="more-filters-accordion">
							<form class="reboot" data-test="more-filters-form">
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Period" data-target="#user-filters-periods" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Periods</span>
											<span data-test="Period-count" id="filters-periods-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-periods" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Measures" data-target="#user-filters-measures" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Measures</span>
											<span data-test="Measures-count" id="filters-measures-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-measures" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot  px-0 py-0">
										<a href="#" data-test="Axis" data-target="#user-filters-axis" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Axis</span>
											<span data-test="Axis-count" id="filters-axis-count" class="reboot badge badge-secondary">
												<i class="fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-axis" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Members" data-target="#user-filters-members" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Members</span>
											<span data-test="Members-count" id="filters-members-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-members" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Scale" data-target="#user-filters-scales" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Scale</span>
											<span data-test="Scale-count" id="filters-scales-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-scales" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Balance" data-target="#user-filters-balances" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Balance</span>
											<span data-test="Balance-count" id="filters-balances-count" class="reboot badge badge-secondary">2</span>
										</a>
									</div>
									<div id="user-filters-balances" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-debit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Debit</label>
											</div>
										</div>
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-credit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Credit</label>
											</div>
										</div>
									</div>
								</div>
							</form>
						</div>
					</div>
				</li>
				<li id="current-filters-reset" data-test="current-filters-reset" class="reboot nav-item d-none my-auto ml-1">
					<a href="#" id="current-filters-reset-all" data-name="current-filters-reset" class="reboot nav-link dropdown-toggle text-danger disabled click" tabindex="11" accesskey="7">
						<i class="reboot nav-loading fas fa-redo"></i>
						<span class="reboot d-md-none d-lg-inline">Reset All
							Filters</span>
					</a>
				</li>
				<li id="links-dropdown" data-test="links-dropdown" class="reboot nav-item dropdown d-none my-auto ml-1">
					<a href="#" id="additional-links-dropdown" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="12" accesskey="8">
						<i class="reboot nav-loading fas fa-link"></i>
						<span class="reboot d-md-none d-lg-inline">Links</span>
					</a>
					<div id="links-dropdown-content" class="reboot dropdown-menu dropdown-menu-width w-auto"></div>
				</li>
			</ul>
			<ul class="reboot navbar-nav pull-right bg-inherit">
				<li class="reboot nav-item my-auto ml-1">
					<a id="facts-menu" data-test="facts-menu" class="reboot nav-link click" tabindex="13" accesskey="9">
						Facts
						<span class="reboot taxonomy-total-count badge badge-light"><i class="fas fa-spinner fa-spin"></i></span>
					</a>
				</li>
			</ul>
		</div>
	</nav>
	<div class="reboot main-container">
		<div id="error-container" data-test="error-container" class="reboot px-0"></div>
		<div id="xbrl-form-loading" data-test="xbrl-form-loading" class="reboot jumbotron h-100 d-none">
			<h2 class="reboot display-4 text-center">
				<i class="reboot fas fa-spinner fa-spin"></i>
				Loading Inline Form.
			</h2>
		</div>
		<div id="sections-menu" data-test="sections-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">
			<div class="reboot mb-2">
				<span class="reboot lead">Tagged Sections</span>
				<a id="sections-menu-toggle" class="reboot float-right click color-inherit" tabindex="2">
					<i class="reboot fas fa-times-circle mt-2 text-dark"></i>
				</a>
			</div>
			<form id="sections-menu-search-submit" data-name="sections-menu-search" class="reboot my-2 my-lg-0 input-group" novalidate="">
				<div id="sections-search-additional" class="reboot input-group-prepend d-none">
					<button class="reboot dropdown btn btn-sec" type="button" data-toggle="dropdown" tabindex="2">
						<i class="reboot nav-loading fas fa-cog"></i>
					</button>
					<div class="reboot dropdown-menu px-2">
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="1" checked="" tabindex="2">
							<label class="reboot form-check-label">Search in All.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="2" tabindex="2">
							<label class="reboot form-check-label">Search in Internal
								Sections Only.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="3" tabindex="2">
							<label class="reboot form-check-label">Search in External
								Sections Only.</label>
						</div>
					</div>
				</div>
				<input type="text" class="reboot form-control" id="sections-search" data-test="sections-search" placeholder="Search Sections" aria-label="Search all Sections by their associated label." name="search-sections" tabindex="2" required="">
				<div class="reboot input-group-append">
					<button id="section-menu-search-btn-clear" data-name="sections-menu-search-clear" class="reboot btn btn-sec" type="button" tabindex="2">
						<i class="nav-loading fas fa-times-circle" title="Clear Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Clear
							Sections Search</span>
					</button>
					<button class="reboot btn btn-sec" type="submit" tabindex="2">
						<i class="reboot nav-loading fas fa-search" title="Submit Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Submit
							Sections Search</span>
					</button>
				</div>
			</form>
			<hr>

			<div class="reboot accordion" id="tagged-sections">
				<!-- Below is populated dynamically VIA JS -->
			</div>
		</div>



		<div id="help-menu" data-test="help-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">

			<div class="reboot mb-2">
				<span class="reboot lead">Help</span> <a id="help-menu-close" data-test="help-menu-close" class="reboot float-right click"> <i class="reboot fas fa-times-circle mt-2"></i>
				</a>
			</div>
			<div class="reboot accordion" id="help-sections">
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-getting-started">
								<span class="reboot font-size-1 ">Getting Started</span>
							</button>
						</h5>
					</div>
					<div id="help-getting-started" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Inline XBRL viewer allows a user
							to quickly and easily review details of the tagged information in
							an Inline document by automatically placing a top and bottom
							highlight border around each tagged numeric fact and left and
							right border for each block tagged fact. Hovering over a tagged
							fact will highlight (shade) all content related to the tagged
							fact, and clicking on a tagged fact will reveal its tagging
							details in the Fact Review Window. Navigation, search and filter
							options are also provided to easily refine and identify specific
							types of tagged information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-fact-review-window">
								<span class="reboot font-size-1">Fact Review Window</span>
							</button>
						</h5>
					</div>
					<div id="help-fact-review-window" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Fact Review Window shows the tagging
							details for the currently selected fact, which is highlighted
							with a solid blue border. There are four categories of fact detail
							which can be viewed; an "N/A" value indicates there is no
							available information for the item within the given category:</p>
						<ul class="reboot">
							<li class="reboot">Attributes - All primary information (as
								applicable) describing the tagged fact including period, sign,
								decimals, dimensional detail (axes and members), scale, measure
								and data type.</li>
							<li class="reboot">Labels - Detailed documentation
								(definition) for the tag used, and other labels.</li>
							<li class="reboot">References - Authoritative reference
								information (as applicable) for the selected tag.</li>
							<li class="reboot">Calculation - Balance and calculation
								hierarchy details (numeric non-dimensioned items only).</li>
						</ul>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-search">
								<span class="reboot font-size-1">Searching</span>
							</button>
						</h5>
					</div>
					<div id="help-search" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">There are two ways to search the
							document: FACTS AND SECTIONS. To search information, enter a
							keyword in a search box and select the magnifying glass icon to
							return matching results. Search operators "and" (via "AND" or
							"&amp;") and "or" (via "OR" or "|") are available to further refine a
							search.</p>
						<p class="reboot m-2">
							<strong>FACTS</strong>
						</p>
						<p class="reboot m-2">The Search Facts box can be used to find
							tagged facts matching entered keywords. By default, tag name, tag
							labels, and tagged content are included in Search. Tagged facts
							matching the search criteria are shown with a yellow-colored
							(default) shading on the page and appear in the Facts List.
							Select the "X" button to the left of the magnifying glass icon to
							clear the search.</p>
						<p class="reboot m-2">The content included in Search can be increased to
							included tag definitions, dimensions, and authoritative
							references by selecting the cog / wheel icon to the left of the
							search box. See Settings for more information.</p>

						<p class="reboot m-2">
							<strong>SECTIONS</strong>
						</p>
						<p class="reboot m-2">The Search Sections box can be used to
							filter the tagged sections of the financial statements.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-filter">
								<span class="reboot font-size-1">Filters</span>
							</button>
						</h5>
					</div>
					<div id="help-filter" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">Filters change the number of highlighted
							facts and items in the fact list by providing several ways to
							review and pinpoint certain tagged information. Multiple filters
							can be used at once.</p>
						<p class="reboot m-2">
							<strong>DATA FILTERS</strong>
						</p>
						<p class="reboot m-2">These filter options allow the user to
							refine the highlighted tagged facts by data type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Amounts Only - Numeric facts only</li>
							<li class="reboot">Text Only - Textual facts only</li>
							<li class="reboot">Calculations Only - Numeric facts
								participating in a calculation only</li>
							<li class="reboot">Negatives Only - Negative Numeric amounts
								only</li>
							<li class="reboot">Additional Items Only - Tagged facts
								without a corresponding HTML presentation (i.e., hidden facts)
								only</li>
						</ul>
						<p class="reboot m-2">
							<strong>TAGS FILTER</strong>
						</p>
						<p class="reboot m-2">These filters allow the user to refine
							the highlighted facts by tag type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Standard Only- Facts with standard tags
								from a common taxonomy (e.g., US_GAAP, IFRS, DEI).</li>
							<li class="reboot">Custom Only - Facts with extension
								"custom" tags unique to the entity's document.</li>
						</ul>
						<p class="reboot m-2">
							<strong>MORE FILTERS</strong>
						</p>
						<p class="reboot m-2">Additional filters that allow user to
							further refine the highlighted facts:</p>
						<ul class="reboot">
							<li class="reboot">Periods - List of all used context years
								and reporting periods</li>
							<li class="reboot">Measures - List of all used units of
								measure (e.g., US Dollars); as applicable</li>
							<li class="reboot">Axis - List of all used axis
								(dimensions); as applicable (dimensions); as applicable</li>
							<li class="reboot">Scale - List of all used scaled options
								(e.g., thousands, millions); as applicable</li>
							<li class="reboot">Balance - Debit, credit; as applicable</li>
						</ul>
						<p class="reboot m-2">Multiple filters work in conjunction
							with each other. For example, selecting the "Amounts Only" Data
							filter and "Custom Only" Tags filter will highlight only numeric
							tagged facts using custom tags and list them in the fact list.
							Active filters are displayed in the Filter toolbar as they are
							selected. Active filters can be removed individually by
							unchecking or selecting ALL option for each filter, or all at
							once via the "Reset All Filters" option.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-facts-results-list">
								<span class="reboot font-size-1">Facts List (Results)</span>
							</button>
						</h5>
					</div>
					<div id="help-facts-results-list" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">On the toolbar, select the "count" to
							the right of the word Facts (e.g., Facts 234) to reveal the Facts
							List results - a navigable listing of all currently highlighted
							tagged facts. The count represents the current number of facts.</p>
						<p class="reboot m-2">By default, all tagged facts are
							displayed in the Fact List Results. The list content and count
							reflects the currently highlighted facts (i.e., both Filters and
							Search criteria refine the list to match the highlighted tagged
							facts). Navigation controls are available to move through the
							list as well as move the current view to the corresponding
							highlighted fact location automatically. When a fact in the Facts
							Results List is selected, it will reveal the Fact Review Window.</p>
						<p class="reboot m-2">Certain letters may appear to the right
							of an item in the Fact Result list to indicate a certain
							property. If the letter "A" appears for a fact, it indicates the
							fact is additional data (i.e., hidden with potentially no
							corresponding HTML presentation). If the letter "C" appears, the
							fact is tagged with a custom tag. If the letter "D" appears, the
							fact is tagged with dimensional information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-sections">
								<span class="reboot font-size-1">Sections</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-sections" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The SECTIONS toolbar item provides a
							listing of the tagged sections of the Inline document. Sections
							are divided into three groups:</p>
						<ul class="reboot">
							<li class="reboot">Document &amp; Entity Information</li>
							<li class="reboot">Financial Statements</li>
							<li class="reboot">Notes to the Financial Statements</li>
						</ul>
						<p class="reboot m-2">By expanding a group and selecting a
							section item in the listing, Inline XBRL viewer will navigate to that section.
							When the Tagged Sections feature is open, the Search Sections box
							will additionally filter the list of sections to only those
							sections that match the entered criteria.</p>
					</div>
				</div>

				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-menu">
								<span class="reboot font-size-1">Menu</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-menu" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">
							<strong>Information</strong>
						</p>
						<p class="reboot m-2">The Information menu item provides
							additional detail about the current Inline document and
							customizable viewer settings.</p>
						<ul class="reboot">
							<li class="reboot">Company and Document - Basic company and document
								information</li>
							<li class="reboot">Tags - Fact and tag (standard and custom)
								information</li>
							<li class="reboot">Files - Files used</li>
							<li class="reboot">Additional Items - Additional hidden data
								that's been tagged but potentially does not have a corresponding
								location in the HTML</li>
						</ul>
						<p class="reboot m-2">
							<strong>Save XBRL Instance</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Instance menu item allows
							an XBRL instance document (*.xml) that is extracted from the
							Inline document to be saved locally for use by software
							supporting the XBRL format.</p>
						<p class="reboot m-2">
							<strong>Save XBRL Zip</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Zip menu item allows a zip
							file (*.zip) that contains the as-provided XBRL instance document
							and related custom taxonomy files to be saved locally.</p>
						<p class="reboot m-2">
							<strong>Settings</strong>
						</p>
						<p class="reboot m-2">The Settings menu item provides the
							ability to customize Viewer features.</p>
						<p class="reboot m-2">
							<strong>Tagged Fact Hover</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">On - Displays the hover fact review
								window for any tagged fact*</li>
							<li class="reboot">Off - Hides the hover fact review window
								for any tagged fact (default)</li>
						</ul>
						<p class="reboot m-2">* May impact performance with certain
							web browsers.</p>
						<p class="reboot m-2">
							<strong>Auto Scrolling Position </strong>(This setting will have
							no effect on IE 10 or Safari)
						</p>
						<ul class="reboot">
							<li class="reboot">Top - Selecting a fact from the Sections
								Menu or the Fact Menu will automatically scroll that element to
								the Top of the Inline XBRL viewer window (default)</li>
							<li class="reboot">Center - Selecting a fact from the
								Sections Menu or the Fact Menu will automatically scroll that
								element to the middle of the Inline XBRL viewer window</li>
						</ul>
						<p class="reboot m-2">
							<strong>Highlight Colors</strong> (Use the save and reset buttons
							to save the selected setting or reset to default)
						</p>
						<ul class="reboot">
							<li class="reboot">Tagged Data - Change the highlight color
								of the tagged fact border</li>
							<li class="reboot">Search Results - Change the background
								color of tagged items matching the Search results</li>
							<li class="reboot">Selected Fact - Change the color of
								highlight border used to identify the currently selected fact</li>
							<li class="reboot">Tag Shading (hover) - Change the color of
								the shading applied to tagged data on hover</li>
						</ul>
						<p class="reboot m-2">
							<strong>Search Options</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">Match Case - Matches the specific case of
								the entered Search keyword</li>
							<li class="reboot">Include Labels - Extends Search to
								include tag labels</li>
							<li class="reboot">Include Definitions - Extends Search to
								include tag definitions</li>
							<li class="reboot">Include Dimensions - Extends Search to
								include dimensional detail</li>
							<li class="reboot">Include References - Extends Search to
								include authoritative reference information. Optionally specify
								the reference parts to include in the search (e.g., topic,
								subtopic, section)</li>
						</ul>
						<p class="reboot m-2">
							<strong>Help</strong>(this content)
						</p>
						<p class="reboot m-2">
							<strong>Version</strong>
						</p>
						<p class="reboot m-2">Indicates the current build of the Inline XBRL viewer
							application.</p>
					</div>
				</div>

			</div>
		</div>



		<div data-test="taxonomies-menu" id="taxonomies-menu" class="reboot right-sidenav col-sm-3 bg-light invisible">
			<div class="reboot d-flex flex-column flex-fill h-100">
				<div class="reboot mb-2">
					<span class="reboot lead">Facts</span>
					<a id="taxonomy-menu-secondary-toggle" data-test="taxonomy-secondary-toggle" class="reboot float-right click">
						<i class="reboot fas fa-times-circle mt-2"></i>
					</a>
				</div>
				<div id="taxonomies-menu-list-pagination" class="reboot d-flex flex-column flex-fill h-100 w-100">
					<div class="reboot pagination"></div>
					<div class="reboot form-group">
						<select id="taxonomies-menu-page-select" class="reboot form-control" aria-label="Quickly jump to a page in the Fact Menu." tabindex="13">
							<option class="reboot">Select Page</option>
						</select>
					</div>
					<div class="reboot list-group list-group-flush overflow-x-auto w-100"><span class="text-center py-5">Loading.</span></div>
				</div>
			</div>
		</div>
		<div id="back-to-top" class="reboot d-none">
			<button id="back-to-top-btn" type="button" class="btn btn-sm btn-primary">
				<i class="reboot fas fa-arrow-up"></i>
			</button>
		</div>

		<div id="dynamic-xbrl-form" class="position-relative"><!--?xml version="1.0" encoding="UTF-8"?-->
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:C5208C88729152B1A84627C41BACF85B,x:e3760e79439c4952bd129da79c1dc797-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->

	
		<meta http-equiv="Content-Type" content="text/html">
		<title>Document</title>
	
	<div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="FD2020Q1YTD" name="dei:AmendmentFlag" id="Fact-26807CE653435658B1276AE83523678B-wk-Fact-26807CE653435658B1276AE83523678B" format="ixt:booleanfalse">false</ix:nonnumeric><ix:nonnumeric contextref="FD2020Q1YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-C9C734EFB5BB568794BA81BC008BAEAE-wk-Fact-C9C734EFB5BB568794BA81BC008BAEAE">--12-31</ix:nonnumeric><ix:nonnumeric contextref="FD2020Q1YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-A8FB6FB1B78E51109DD2D1C6C8E100A4-wk-Fact-A8FB6FB1B78E51109DD2D1C6C8E100A4">Q1</ix:nonnumeric><ix:nonnumeric contextref="FD2020Q1YTD" name="dei:DocumentFiscalYearFocus" id="Fact-51F7D521036F564FACFEBEDB319B8CFB-wk-Fact-51F7D521036F564FACFEBEDB319B8CFB">2020</ix:nonnumeric><ix:nonnumeric contextref="FD2020Q1YTD" name="dei:EntityCentralIndexKey" id="Fact-CDE2FF0493AA5709B311D7B166C4D820-wk-Fact-CDE2FF0493AA5709B311D7B166C4D820">0000310158</ix:nonnumeric><ix:nonfraction decimals="-6" unitref="usd" contextref="FI2019Q4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-442FEAF85029500487DA1138E6E5D25C-wk-Fact-442FEAF85029500487DA1138E6E5D25C">17686000000</ix:nonfraction><ix:nonfraction decimals="-6" unitref="usd" contextref="FI2020Q1" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-9E403B36041C5FE89AD2C5F1E67C9CFB-wk-Fact-9E403B36041C5FE89AD2C5F1E67C9CFB">17706000000</ix:nonfraction><ix:nonfraction decimals="-6" unitref="usd" contextref="FI2019Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-450DE4CF29D158A7BE74AE6A3A37AB85-wk-Fact-450DE4CF29D158A7BE74AE6A3A37AB85">86000000</ix:nonfraction><ix:nonfraction decimals="-6" unitref="usd" contextref="FI2020Q1" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-A5A6BF1CB810588ABFB71107DF067977-wk-Fact-A5A6BF1CB810588ABFB71107DF067977">89000000</ix:nonfraction><ix:nonfraction decimals="-6" unitref="shares" contextref="FD2020Q1YTD" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-ADFFE2B2A8735B299F87FDCABCDE691F-wk-Fact-ADFFE2B2A8735B299F87FDCABCDE691F">2000000</ix:nonfraction><ix:nonfraction decimals="INF" unitref="usdPerShare" contextref="FD2019Q1QTD" name="us-gaap:CommonStockDividendsPerShareDeclared" id="Fact-031778C0690953B4BF9936E5011E7D2B-wk-Fact-031778C0690953B4BF9936E5011E7D2B">0.55</ix:nonfraction><ix:nonfraction decimals="INF" unitref="usdPerShare" contextref="FD2020Q1YTD" name="us-gaap:CommonStockDividendsPerShareDeclared" id="Fact-A00B0BBD024E526E9659E4E5EED57957-wk-Fact-A00B0BBD024E526E9659E4E5EED57957">0.61</ix:nonfraction><ix:nonfraction decimals="INF" unitref="usdPerShare" contextref="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-8AD5C01F3AD45BDA9626F56F4F9F1D93-wk-Fact-8AD5C01F3AD45BDA9626F56F4F9F1D93">0.50</ix:nonfraction><ix:nonfraction decimals="INF" unitref="usdPerShare" contextref="FI2020Q1" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-5518D3F590A25B2D93B53B5CBA01A913-wk-Fact-5518D3F590A25B2D93B53B5CBA01A913">0.50</ix:nonfraction><ix:nonfraction decimals="INF" unitref="shares" contextref="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-E9E1259639245B60A4B581B50EABF4D6-wk-Fact-E9E1259639245B60A4B581B50EABF4D6">6500000000</ix:nonfraction><ix:nonfraction decimals="INF" unitref="shares" contextref="FI2020Q1" name="us-gaap:CommonStockSharesAuthorized" id="Fact-2027214DE25957F4987D9460A3B28F28-wk-Fact-2027214DE25957F4987D9460A3B28F28">6500000000</ix:nonfraction><ix:nonfraction decimals="INF" unitref="shares" contextref="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-B65ABD0C36375F8F9524D376924432E3-wk-Fact-B65ABD0C36375F8F9524D376924432E3">3577103522</ix:nonfraction><ix:nonfraction decimals="INF" unitref="shares" contextref="FI2020Q1" name="us-gaap:CommonStockSharesIssued" id="Fact-BF459A74E6BA555B8F3E5F944881605D-wk-Fact-BF459A74E6BA555B8F3E5F944881605D">3577103522</ix:nonfraction><ix:nonfraction decimals="INF" unitref="number" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-334D4AC113E555A8A9CAEB88A6CB1E06-wk-Fact-334D4AC113E555A8A9CAEB88A6CB1E06">0.02350</ix:nonfraction><ix:nonfraction decimals="INF" unitref="number" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-2AF5391AC7425523B1AD9CCB1375C13B-wk-Fact-2AF5391AC7425523B1AD9CCB1375C13B">0.0240</ix:nonfraction><ix:nonfraction decimals="INF" unitref="number" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-EC1B750476215527A0F3B7D5728C5A13-wk-Fact-EC1B750476215527A0F3B7D5728C5A13">0.03875</ix:nonfraction><ix:nonfraction decimals="INF" unitref="usd" contextref="FI2019Q4" name="us-gaap:DerivativeCollateralRightToReclaimCash" id="Fact-C3B7B2EC178F5046BDEF79A7252026F6-wk-Fact-C3B7B2EC178F5046BDEF79A7252026F6">0</ix:nonfraction><ix:nonfraction decimals="-6" unitref="usd" contextref="FI2019Q4" name="us-gaap:RestrictedCashAndCashEquivalents" id="Fact-DEFACD0CFB7A54ACBCA7C356ED73D721-wk-Fact-DEFACD0CFB7A54ACBCA7C356ED73D721">258000000</ix:nonfraction><ix:nonfraction decimals="-6" unitref="usd" contextref="FI2020Q1" name="us-gaap:RestrictedCashAndCashEquivalents" id="Fact-7A65B67B9BF859B9A253840E908CD757-wk-Fact-7A65B67B9BF859B9A253840E908CD757">35000000</ix:nonfraction><ix:nonfraction decimals="INF" unitref="shares" contextref="FI2019Q4" name="us-gaap:TreasuryStockShares" id="Fact-2A2A74ABF2E753FEBDEC3E34F7B04D0B-wk-Fact-2A2A74ABF2E753FEBDEC3E34F7B04D0B">1038087496</ix:nonfraction><ix:nonfraction decimals="INF" unitref="shares" contextref="FI2020Q1" name="us-gaap:TreasuryStockShares" id="Fact-A3FECC5FAAA0591D8ADDE6EACF4BB8BB-wk-Fact-A3FECC5FAAA0591D8ADDE6EACF4BB8BB">1053090194</ix:nonfraction></ix:hidden><ix:references><link:schemaref xlink:href="mrk-20200331.xsd" xlink:type="simple"></link:schemaref></ix:references><ix:resources><xbrli:context id="FD2020Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2April30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.875Notesdue2026Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.375Notesdue2036Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A0.500Notesdue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A2.500Notesdue2034Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.125Notesdue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.125Notesdue2021Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_mrk_IPRDMK1026Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mrk:IPRDMK1026Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_mrk_IPRDMK7075Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mrk:IPRDMK7075Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-16</xbrli:startdate>
			<xbrli:enddate>2020-01-16</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1March2020_srt_CounterpartyNameAxis_mrk_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-03-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1March_srt_CounterpartyNameAxis_mrk_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-03-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1March_srt_CounterpartyNameAxis_mrk_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2018-03-01</xbrli:startdate>
			<xbrli:enddate>2018-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2021Q1March2021_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2021-03-01</xbrli:startdate>
			<xbrli:enddate>2021-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2018-01-01</xbrli:startdate>
			<xbrli:enddate>2018-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3July_srt_CounterpartyNameAxis_mrk_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2017-07-01</xbrli:startdate>
			<xbrli:enddate>2017-07-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2018-01-01</xbrli:startdate>
			<xbrli:enddate>2018-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1mar2018mar2021_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2018-03-01</xbrli:startdate>
			<xbrli:enddate>2021-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2018-01-01</xbrli:startdate>
			<xbrli:enddate>2018-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Prior2020_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2017-08-01</xbrli:startdate>
			<xbrli:enddate>2019-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Jan01-Jan31_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-01-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Priorto2020_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2018-04-01</xbrli:startdate>
			<xbrli:enddate>2019-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2018-01-01</xbrli:startdate>
			<xbrli:enddate>2018-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q4_srt_StatementScenarioAxis_srt_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Feb29_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Feb29_us-gaap_DebtInstrumentAxis_mrk_A1.85NotesDue2020Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.85NotesDue2020Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_mrk_SanofiPasteurMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_mrk_SanofiPasteurMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-10-01</xbrli:startdate>
			<xbrli:enddate>2019-12-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_mrk_SanofiPasteurMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_mrk_EurodominatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_mrk_EurodominatedNotesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_mrk_EurodominatedNotesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_mrk_EurodominatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeFutureMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeFutureMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoriesProducedinPreparationforProductLaunchesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoriesProducedinPreparationforProductLaunchesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_LitigationCaseAxis_mrk_NewJerseyStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:NewJerseyStateCourtMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_mrk_FosamaxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Mar_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2014-03-01</xbrli:startdate>
			<xbrli:enddate>2014-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_LitigationCaseAxis_mrk_CaliforniaStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:CaliforniaStateCourtMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_JanuviaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_mrk_JanuviaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementBusinessSegmentsAxis_mrk_HealthcareServicesSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_country_CN">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_country_CN">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_mrk_InternationalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_mrk_InternationalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2019-01-01</xbrli:startdate>
			<xbrli:enddate>2019-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember>
				<xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startdate>2020-01-01</xbrli:startdate>
			<xbrli:enddate>2020-03-31</xbrli:enddate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitnumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitnumerator>
			<xbrli:unitdenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitdenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="interest_rate_swap">
		<xbrli:measure>mrk:interest_rate_swap</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>mrk:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Claim">
		<xbrli:measure>mrk:Claim</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Case">
		<xbrli:measure>mrk:Case</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s036835464A9354FB91A1FA40A5649550"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:293px;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="1"></td></tr><tr><td style="width:293px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM </span><span><ix:nonnumeric id="d15726740e452-wk-Fact-81E1EEE45EC05DD197179ACAE1412A23" name="dei:DocumentType" contextref="FD2020Q1YTD"><span style="font-size:12pt;font-weight:bold;">10-Q</span></ix:nonnumeric></span><span style="font-family:inherit;font-size:12pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:293px;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="1"></td></tr><tr><td style="width:293px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Mark One)</span></div><div style="line-height:120%;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;color:#333333;font-weight:bold;"><span><ix:nonnumeric id="d15726740e490-wk-Fact-B6F0BDD42DA25805A2D4C27B6C796C87" name="dei:DocumentQuarterlyReport" contextref="FD2020Q1YTD" format="ixt-sec:boolballotbox">☒</ix:nonnumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the quarterly period ended </span><span style="font-family:inherit;font-size:8pt;"><span><span style="white-space:nowrap"><ix:nonnumeric id="d15726740e500-wk-Fact-663ADE5D5A9E5C07B8F7FE1177E1B74E" name="dei:DocumentPeriodEndDate" contextref="FD2020Q1YTD" format="ixt:datemonthdayyearen">March 31, 2020</ix:nonnumeric></span></span></span><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">OR</span></div><div style="line-height:120%;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;color:#333333;font-weight:bold;"><span><ix:nonnumeric id="d15726740e522-wk-Fact-B56D672579D25306A9E96F0241A392CB" name="dei:DocumentTransitionReport" contextref="FD2020Q1YTD" format="ixt-sec:boolballotbox">☐</ix:nonnumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For the transition period from ______ to ______</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Commission File No.&nbsp;</span><span><ix:nonnumeric id="d15726740e535-wk-Fact-ACEA94DD204A5332B55426FAC4DBB4AA" name="dei:EntityFileNumber" contextref="FD2020Q1YTD"><span style="font-size:9pt;font-weight:bold;">1-6571</span></ix:nonnumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:16pt;"><span><ix:nonnumeric id="d15726740e541-wk-Fact-002BFC8137625E9993E982BB1B50A12A" name="dei:EntityRegistrantName" contextref="FD2020Q1YTD"><span style="font-size:16pt;font-weight:bold;">Merck&nbsp;&amp; Co., Inc.</span></ix:nonnumeric></span><span style="font-family:inherit;font-size:16pt;font-weight:bold;"> </span></div><div style="line-height:174%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.59386973180077%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="3"></td></tr><tr><td style="width:43%;"></td><td style="width:13%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonnumeric id="d15726740e564-wk-Fact-59606D859AC758C1AA1184B91DA3C234" name="dei:EntityIncorporationStateCountryCode" contextref="FD2020Q1YTD" format="ixt-sec:stateprovnameen">New Jersey</ix:nonnumeric></span></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonnumeric id="d15726740e569-wk-Fact-D677F941EF5E54FFAF64ED6B29AF2174" name="dei:EntityTaxIdentificationNumber" contextref="FD2020Q1YTD">22-1918501</ix:nonnumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(State or other jurisdiction of incorporation)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(I.R.S Employer Identification No.)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonnumeric id="d15726740e612-wk-Fact-A154B70A1A995DAFA5B67C16BB081092" name="dei:EntityAddressAddressLine1" contextref="FD2020Q1YTD">2000 Galloping Hill Road</ix:nonnumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonnumeric id="d15726740e628-wk-Fact-7E16597819D55BCAB016257296411E49" name="dei:EntityAddressCityOrTown" contextref="FD2020Q1YTD">Kenilworth</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonnumeric id="d15726740e633-wk-Fact-843CF490475552D98DF31406E76D052B" name="dei:EntityAddressStateOrProvince" contextref="FD2020Q1YTD" format="ixt-sec:stateprovnameen">New Jersey</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonnumeric id="d15726740e638-wk-Fact-634344F36DB6580C9CF402026847379C" name="dei:EntityAddressPostalZipCode" contextref="FD2020Q1YTD">07033</ix:nonnumeric></span></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Address of principal executive offices) (zip code)</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Registrant’s telephone number, including area code)</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span><span><ix:nonnumeric id="d15726740e661-wk-Fact-7EFA2D037DBE5C0A9D8BF9978F9D29A5" name="dei:CityAreaCode" contextref="FD2020Q1YTD"><span style="font-size:9pt;font-weight:bold;">(908)</span></ix:nonnumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&nbsp;</span><span><ix:nonnumeric id="d15726740e666-wk-Fact-DC94F6433911509991CAF2B7650BA61B" name="dei:LocalPhoneNumber" contextref="FD2020Q1YTD"><span style="font-size:9pt;font-weight:bold;">740-4000</span></ix:nonnumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="3"></td></tr><tr><td style="width:21%;"></td><td style="width:57%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Not Applicable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Former name, former address and former fiscal year, if changed since last report.)</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;</span><span><ix:nonnumeric id="d15726740e716-wk-Fact-178CF104F1CE54F1B5544D66638C8D3C" name="dei:EntityCurrentReportingStatus" contextref="FD2020Q1YTD"><span style="font-size:9pt;">Yes</span></ix:nonnumeric></span><span style="font-family:inherit;font-size:9pt;">&nbsp;&nbsp;</span><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">☒</span><span style="font-family:inherit;font-size:9pt;">&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">☐</span></div><div style="line-height:120%;padding-top:9px;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required&nbsp;to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;</span><span><ix:nonnumeric id="d15726740e730-wk-Fact-1B2DB1A2F8075DEE9AB932F7D3B13FCD" name="dei:EntityInteractiveDataCurrent" contextref="FD2020Q1YTD"><span style="font-size:9pt;">Yes</span></ix:nonnumeric></span><span style="font-family:inherit;font-size:9pt;">&nbsp;&nbsp;</span><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">☒</span><span style="font-family:inherit;font-size:9pt;">&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">☐</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”  “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:29%;"></td><td style="width:27%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e760-wk-Fact-C6966959B6BC5985B6AF43BBDDA8ED40" name="dei:EntityFilerCategory" contextref="FD2020Q1YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">☒</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">☐</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">☐ </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Smaller reporting company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;"><span><ix:nonnumeric id="d15726740e817-wk-Fact-471F861EA2C652CCAA1EDA6A6822CCFB" name="dei:EntitySmallBusiness" contextref="FD2020Q1YTD" format="ixt-sec:boolballotbox">☐</ix:nonnumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;"><span><ix:nonnumeric id="d15726740e859-wk-Fact-06A34C020E1150C1AB1A7C4FD0591774" name="dei:EntityEmergingGrowthCompany" contextref="FD2020Q1YTD" format="ixt-sec:boolballotbox">☐</ix:nonnumeric></span></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;</span><span><ix:nonnumeric id="d15726740e867-wk-Fact-B4974E9C7E6E5C4C882D3BD10EC0F954" name="dei:EntityShellCompany" contextref="FD2020Q1YTD" format="ixt-sec:boolballotbox"><span style="color:#333333;font-size:9pt;">☐</span></ix:nonnumeric></span><span style="font-family:inherit;font-size:9pt;">&nbsp;&nbsp;No&nbsp;</span><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">☒</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.70114942528735%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="3"></td></tr><tr><td style="width:37%;"></td><td style="width:28%;"></td><td style="width:35%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Securities Registered pursuant to Section&nbsp;12(b) of the Act:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e919-wk-Fact-00E8AFE66A2D516284EA385B41D221F5" name="dei:Security12bTitle" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">Common Stock ($0.50&nbsp;par value)</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e924-wk-Fact-094138A691CA5D069F1F0EE96195E3B3" name="dei:TradingSymbol" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">MRK</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e929-wk-Fact-40D1BB6767955D2CB3D1437E887A9286" name="dei:SecurityExchangeName" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonnumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e935-wk-Fact-096D3E5F425A5851BCD112ADB1CE45E3" name="dei:Security12bTitle" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.125Notesdue2021Member">1.125% Notes due 2021</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e940-wk-Fact-28AACAF2162E5236BC5A162EEF46D945" name="dei:TradingSymbol" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.125Notesdue2021Member">MRK/21</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e945-wk-Fact-D3C500074B3E5B6D9949DAC10C88C6F3" name="dei:SecurityExchangeName" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.125Notesdue2021Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonnumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e951-wk-Fact-7CE2CDF887CE532A9714C2709AA9B990" name="dei:Security12bTitle" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A0.500Notesdue2024Member">0.500% Notes due 2024</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e956-wk-Fact-A893C0164A8D50E8AD52D58295DF97B6" name="dei:TradingSymbol" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A0.500Notesdue2024Member">MRK 24</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e961-wk-Fact-642E11071FBE59D6BFFCBD8983C338A7" name="dei:SecurityExchangeName" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A0.500Notesdue2024Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonnumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e967-wk-Fact-742AEFCEFF1651AC99ECE598FC9576D7" name="dei:Security12bTitle" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.875Notesdue2026Member">1.875% Notes due 2026</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e972-wk-Fact-1E951B296CE95271BF1C1C6AEC02677E" name="dei:TradingSymbol" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.875Notesdue2026Member">MRK/26</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e977-wk-Fact-56B6910CDD32581EBF2F4FB8488577B8" name="dei:SecurityExchangeName" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.875Notesdue2026Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonnumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e983-wk-Fact-A1E464681A335E48B65209D8C4D8242E" name="dei:Security12bTitle" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A2.500Notesdue2034Member">2.500% Notes due 2034</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e988-wk-Fact-A22C3778D9105FF59ACE6B7A0CBF976D" name="dei:TradingSymbol" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A2.500Notesdue2034Member">MRK/34</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e993-wk-Fact-845E9AB005AA5CAA9A34ADE4021DF2AB" name="dei:SecurityExchangeName" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A2.500Notesdue2034Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonnumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e999-wk-Fact-48F3888E6AF755EA969E01AEB957A006" name="dei:Security12bTitle" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.375Notesdue2036Member">1.375% Notes due 2036</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e1004-wk-Fact-157CC7BD8C365B04BA36223F7D36691B" name="dei:TradingSymbol" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.375Notesdue2036Member">MRK 36A</ix:nonnumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonnumeric id="d15726740e1009-wk-Fact-5D9F26DA0371526C97A0052475F1A898" name="dei:SecurityExchangeName" contextref="FD2020Q1YTD_us-gaap_StatementClassOfStockAxis_mrk_A1.375Notesdue2036Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonnumeric></span></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">The number of shares of common stock outstanding as of the close of business on </span><span style="font-family:inherit;font-size:9pt;">April&nbsp;30, 2020</span><span style="font-family:inherit;font-size:9pt;">: </span><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15726740e1018-wk-Fact-99084017824D5AD4B5CE599D93B68D9D" name="dei:EntityCommonStockSharesOutstanding" contextref="I2020Q2April30" unitref="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,524,101,191</ix:nonfraction></span></span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr></tbody></table></div></div><div><br></div><hr style="page-break-after:always"><div><a id="sB209AA0DA78B5E47B91CD145736E58D5"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Table of Contents</span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.9453125%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="5"></td></tr><tr><td style="width:14%;"></td><td style="width:21%;"></td><td style="width:21%;"></td><td style="width:30%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Page No.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s31B854976E005B3FA959F50D7E84194F"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s31B854976E005B3FA959F50D7E84194F">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6257E350AA505B1C9324EB665ABC933B"><span style="font-family:inherit;font-size:10pt;">Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6257E350AA505B1C9324EB665ABC933B">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s53C5DC56994356F7984858E5C878FD53"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statement of Income</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s53C5DC56994356F7984858E5C878FD53">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s266A8525304958D5BB474F9C0ABF0F63"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statement of Comprehensive Income</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s266A8525304958D5BB474F9C0ABF0F63">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFBBCC639B28E503193C1CD0168E9455C"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheet</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFBBCC639B28E503193C1CD0168E9455C">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s05ABAEBB3B3158E08FF7D0FD9CD623CA"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statement of Cash Flows</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s05ABAEBB3B3158E08FF7D0FD9CD623CA">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBD2822ADA8AD568285F5C7E531527143"><span style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBD2822ADA8AD568285F5C7E531527143">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s878C1D5D824054C3B3B404D96866C243"><span style="font-family:inherit;font-size:10pt;">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s878C1D5D824054C3B3B404D96866C243">28</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s870A5853D92353CD901AA6532B52E6A4"><span style="font-family:inherit;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s870A5853D92353CD901AA6532B52E6A4">41</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8284B946225E566E97C9D92D590D9673"><span style="font-family:inherit;font-size:10pt;">Cautionary Factors That May Affect Future Results</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8284B946225E566E97C9D92D590D9673">41</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD03B8D230CD7569A82634929FB37129D"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION </span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD03B8D230CD7569A82634929FB37129D">42</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7620D0D35468544F9A3ABD013CF5C58A"><span style="font-family:inherit;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7620D0D35468544F9A3ABD013CF5C58A">42</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1A.</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68902b065e894c3988d7853410d3b0ba"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68902b065e894c3988d7853410d3b0ba">42</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9875514127B5BE4AE6AC38BEA1017EB"><span style="font-family:inherit;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9875514127B5BE4AE6AC38BEA1017EB">44</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 6.</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s794F07382BF8513C97BEE390E6FFCFE8"><span style="font-family:inherit;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s794F07382BF8513C97BEE390E6FFCFE8">44</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s01E7433B40975D74839862292B66024D"><span style="font-family:inherit;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s01E7433B40975D74839862292B66024D">45</a></div></td></tr></tbody></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><br></div><hr style="page-break-after:always"><div><a id="s31B854976E005B3FA959F50D7E84194F"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Part I - Financial Information</span></div><div><a id="s6257E350AA505B1C9324EB665ABC933B"></a></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item&nbsp;1. Financial Statements</span></div><div><a id="s53C5DC56994356F7984858E5C878FD53"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENT OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, $ in millions except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e535-wk-Fact-C7D37DB85BC556E9852BBCC58A9EEE17" name="us-gaap:Revenues" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,057</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e554-wk-Fact-F10A548F31825340A653E3FF20E0EA91" name="us-gaap:Revenues" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,816</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs, Expenses and Other</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e610-wk-Fact-7F2196A545775DAFA0CA65CCE9E4340F" name="us-gaap:CostOfGoodsAndServicesSold" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,312</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e629-wk-Fact-AF12CF053EFA50C5A50CE605924511B4" name="us-gaap:CostOfGoodsAndServicesSold" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,052</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e649-wk-Fact-B6B1D98B303E5E6E853C1BBB0492C77C" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,555</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e668-wk-Fact-26B2FFB348D558B580BC78252D64D232" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,425</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e688-wk-Fact-B9D2B8AFCF0054058BE8E9AFA3C04906" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,209</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e707-wk-Fact-CB97956D88125756A685FA3F97C7027F" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,931</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e727-wk-Fact-DE7E57136CB85A7092C55CC822E7DC67" name="us-gaap:RestructuringCharges" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e746-wk-Fact-DF75872AE4F8527CB336E4F77ADF0DFB" name="us-gaap:RestructuringCharges" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e766-wk-Fact-BF3F141D6DBB50E6868729F8668306DA" name="us-gaap:OtherNonoperatingIncomeExpense" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">71</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e785-wk-Fact-666DAA4ADD06583890FC628151F9D47F" name="us-gaap:OtherNonoperatingIncomeExpense" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">188</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e805-wk-Fact-6FFC2EA4E7915E8EAD45F39B3B7B39FB" name="mrk:CostsExpensesAndOther" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e824-wk-Fact-BC555ACCCD5550E498409E2A765CDDA6" name="mrk:CostsExpensesAndOther" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,749</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income Before Taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e844-wk-Fact-D3CCBE4A2AE854BF8A94C4143491EE09" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,838</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e863-wk-Fact-9979E9259B3A516894C0D77BA7209E5C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,067</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes on Income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e884-wk-Fact-9DC4FE49197351EE8163DD6795A83B25" name="us-gaap:IncomeTaxExpenseBenefit" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">619</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e903-wk-Fact-AA8717D1B88B5CB99EF7C0C9012615BA" name="us-gaap:IncomeTaxExpenseBenefit" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e923-wk-Fact-04A0B49FB6515A48BFEB29E286C58509" name="us-gaap:ProfitLoss" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e942-wk-Fact-F2DD15DA647E55D7AB924274EF9BAE76" name="us-gaap:ProfitLoss" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,862</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net Loss Attributable to Noncontrolling Interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e962-wk-Fact-48BFD274D8F759B586EB5410F51070FA" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15728526e981-wk-Fact-58CCAAA7F575509AAA16BEEA0BCB273C" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e1007-wk-Fact-9DE27B9844CD5D60A33395D3FD63C368" name="us-gaap:NetIncomeLoss" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e1026-wk-Fact-7B12A10282AB516C82FAAF50CA9DD77C" name="us-gaap:NetIncomeLoss" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,915</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic Earnings per Common Share Attributable to Merck&nbsp;&amp; Co., Inc. Common Shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e1046-wk-Fact-E9B2BAB59E005621ABF759FA7DE6CB80" name="us-gaap:EarningsPerShareBasic" contextref="FD2020Q1YTD" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.27</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e1065-wk-Fact-AD8F01DE48D653EB85908354120B977D" name="us-gaap:EarningsPerShareBasic" contextref="FD2019Q1QTD" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.13</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings per Common Share Assuming Dilution Attributable to Merck&nbsp;&amp; Co., Inc. Common Shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e1085-wk-Fact-9A79A20D9C695260BF1EF2B9C3AB5DCB" name="us-gaap:EarningsPerShareDiluted" contextref="FD2020Q1YTD" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.26</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15728526e1104-wk-Fact-79862A7BB20B5295BA119BCE55E1DA4A" name="us-gaap:EarningsPerShareDiluted" contextref="FD2019Q1QTD" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.12</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&nbsp;</span></div><div><a id="s266A8525304958D5BB474F9C0ABF0F63"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, $ in millions)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e534-wk-Fact-9DE27B9844CD5D60A33395D3FD63C368" name="us-gaap:NetIncomeLoss" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e553-wk-Fact-7B12A10282AB516C82FAAF50CA9DD77C" name="us-gaap:NetIncomeLoss" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,915</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Comprehensive (Loss) Income Net of Taxes:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on derivatives, net of reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e609-wk-Fact-052D71227A2051ACBC274D861A355893" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15729057e628-wk-Fact-AA4ED9CE4122567D9EFD60E10A0A94DE" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">48</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized (loss) gain on investments, net of reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15729057e649-wk-Fact-5205360CD8AA5BD183F77454E282F101" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">18</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e669-wk-Fact-7E656D0F34C6576BB3FBD03A6BDB7440" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit plan net gain and prior service credit, net of amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e689-wk-Fact-9F0E43917BA5587FA2720F40FB4EF688" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e708-wk-Fact-5F7C67C1E4755D4CADAE390F72C8EA9D" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">15</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cumulative translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15729057e728-wk-Fact-6AE14640DCA954E08B1C8C64694E782F" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">344</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e748-wk-Fact-45F7C354949C5DD4A1AEE7A421280142" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15729057e768-wk-Fact-FB7B73E1583257B08FF24DB183829375" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">198</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e788-wk-Fact-7EDF15BDBDBF51B482D56AFFC86D8A55" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e813-wk-Fact-2FEC9234468F5CD89AA23C6AAD53FE00" name="us-gaap:ComprehensiveIncomeNetOfTax" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,021</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15729057e832-wk-Fact-637CEE5BD79D5CBBA5836FB4A1782935" name="us-gaap:ComprehensiveIncomeNetOfTax" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,114</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">&nbsp;</span><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">3</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><a id="sFBBCC639B28E503193C1CD0168E9455C"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEET</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, $ in millions except per share amounts)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">&nbsp;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current Assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e575-wk-Fact-9D09959D659B570696A10A7F73FC63B0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,425</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e594-wk-Fact-DC09666258EF5FCEA8B419B522AFBDE7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,676</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e609-wk-Fact-0ABB183A853050FEB9995C2529245A4E" name="us-gaap:MarketableSecuritiesCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e628-wk-Fact-286E0FDA9A3E5D2CAD92033E3163D579" name="us-gaap:MarketableSecuritiesCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">774</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable (net of allowance for doubtful accounts of $89 in 2020</span></div><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and $86 in 2019) </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e651-wk-Fact-8E9D3212C4A459D1BAC8CB377ECC821D" name="us-gaap:AccountsReceivableNetCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,182</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e670-wk-Fact-AFEB9C43C8405EDB9FFE5772060FB219" name="us-gaap:AccountsReceivableNetCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,778</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories (excludes inventories of $1,630 in 2020 and $1,480 in 2019</span></div><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">classified in Other assets - see Note&nbsp;6)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e693-wk-Fact-91377BBF40D05BD6B9F3FF82427A7C37" name="us-gaap:InventoryNet" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,846</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e712-wk-Fact-4F981ABF5D425F9CAC720E56BF97A2DE" name="us-gaap:InventoryNet" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,978</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e732-wk-Fact-BCDA7D230DEF55D8A55CD53A3E32C139" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,714</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e751-wk-Fact-F69CF4DFDCF85FEEB603A920367867C5" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,277</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e771-wk-Fact-40D1A52AA9885025AA1F3FBDC9D6F11E" name="us-gaap:AssetsCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,174</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e790-wk-Fact-0787C4BE7D06568986C6A21C5DD856BB" name="us-gaap:AssetsCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27,483</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e810-wk-Fact-FB61CE3910785901810428DE1BA1CCBB" name="us-gaap:MarketableSecuritiesNoncurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">555</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e829-wk-Fact-5F94D3EF231C5B70BB7DEFD84D1FB55C" name="us-gaap:MarketableSecuritiesNoncurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,469</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,706</span></div><div style="padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">in 2020 and $17,686 in 2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e852-wk-Fact-B023D1C78A785CDFBAA5690BAA509C44" name="us-gaap:PropertyPlantAndEquipmentNet" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,269</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e871-wk-Fact-F565ADA775A95F67809143ACF6A94949" name="us-gaap:PropertyPlantAndEquipmentNet" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,053</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e892-wk-Fact-A5B38DA5A6695F6EBB7459608A98FF41" name="us-gaap:Goodwill" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,767</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e911-wk-Fact-64FDBFA498D05107A4E02391B1BD41FC" name="us-gaap:Goodwill" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,425</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Intangibles, Net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e931-wk-Fact-4A3A70DD5A2255E983BCBE41EBD02E8F" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,096</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e950-wk-Fact-128B5D4FD9195D55BCEABFF1E130673E" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,196</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e970-wk-Fact-E15D4B6CF93C59888033CF3400E0CCCF" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,052</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e989-wk-Fact-5EA5132C18945F56B8694A2493941ABC" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,771</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1014-wk-Fact-1F36BA3234DB58648B552AC2358257F3" name="us-gaap:Assets" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84,913</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1033-wk-Fact-21BAE4756077551FA5ADCA8C99D2CBF9" name="us-gaap:Assets" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84,397</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and Equity</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loans payable and current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1135-wk-Fact-0E822033B63A56DC8566AA4ABB4A45AF" name="us-gaap:DebtCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,361</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1154-wk-Fact-002D626665D8582B89AC500A8B9DE29E" name="us-gaap:DebtCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,610</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1169-wk-Fact-E09A6EDC20B55EEA9DF258FEB91CB2EA" name="us-gaap:AccountsPayableCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,572</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1188-wk-Fact-0546DB47CA2E55FFBF8F3D1673C935ED" name="us-gaap:AccountsPayableCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,738</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1208-wk-Fact-58117D1517125140A11B77C1891F0F0F" name="us-gaap:OtherLiabilitiesCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,932</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1227-wk-Fact-EF0EA7097A785F55B42DD67D056AD3D2" name="us-gaap:OtherLiabilitiesCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,549</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1247-wk-Fact-46782C9E6F8152B7AB1169A7D382A016" name="us-gaap:AccruedIncomeTaxesCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,033</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1266-wk-Fact-BB17FF97981D559D8CD296F7D46EE42F" name="us-gaap:AccruedIncomeTaxesCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">736</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividends payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1286-wk-Fact-4BD640DF784E5A85B0737A518E6786DC" name="us-gaap:DividendsPayableCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,585</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1305-wk-Fact-734A457B2E865BCC8C9F9122DD3FCFD7" name="us-gaap:DividendsPayableCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,587</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1326-wk-Fact-633E0B91DB795E1C9B973E8C0CA33E97" name="us-gaap:LiabilitiesCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,483</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1345-wk-Fact-AF3B430B221A57D2B2C8ECC27AEB87E0" name="us-gaap:LiabilitiesCurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,220</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-Term Debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1365-wk-Fact-4C5A620CFEBB5335A0DD0609EFB77939" name="us-gaap:LongTermDebtNoncurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,637</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1384-wk-Fact-617714724DC755649D8E52E874C659C0" name="us-gaap:LongTermDebtNoncurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,736</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Income Taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1404-wk-Fact-B064EF583A39558888A10D2FF8D4AE8A" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,943</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1423-wk-Fact-755BC1F947215B4FBD4CA72D8C74D6F6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,470</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Noncurrent Liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1443-wk-Fact-562EFB34647B57D88AC54D44F33AB19A" name="us-gaap:OtherLiabilitiesNoncurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,550</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1462-wk-Fact-85C0FF1E0D395B08B0367AC975A7BF24" name="us-gaap:OtherLiabilitiesNoncurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,970</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck&nbsp;&amp; Co., Inc. Stockholders’ Equity</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, $0.50 par value</span></div><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Authorized - 6,500,000,000 shares</span></div><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issued - 3,577,103,522 shares in 2020 and 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1529-wk-Fact-2F735540D0D05AF89B87C0B4ED3FE2C3" name="us-gaap:CommonStockValue" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,788</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1548-wk-Fact-BA155D5B8C01549A9EB4D589A565CDE8" name="us-gaap:CommonStockValue" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,788</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1568-wk-Fact-8D2E2035F243552F97F17487A7C993EF" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,697</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1587-wk-Fact-16B166A15B49513BB9F13F48C26AF4D3" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,660</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1607-wk-Fact-371DF831D7CC52DA8D6C35ED7CBE7DFD" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48,272</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1626-wk-Fact-61001640491057829E344151390AA236" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46,602</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15730901e1646-wk-Fact-AC187D2A046B53B08452A04CCE5559B8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,391</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15730901e1666-wk-Fact-BF27A2C582305A4F9786A7152A605D7A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,193</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1687-wk-Fact-0EE20F78D97354ADA7A58230B69EEBF7" name="us-gaap:StockholdersEquityBeforeTreasuryStock" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83,366</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1706-wk-Fact-334CC850130551C4B859565911045391" name="us-gaap:StockholdersEquityBeforeTreasuryStock" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81,857</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less treasury stock, at cost:</span></div><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,053,090,194 shares in 2020 and 1,038,087,496 shares in 2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1729-wk-Fact-9E232BFCDBB25DD48DE06B5825850D92" name="us-gaap:TreasuryStockValue" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57,161</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1748-wk-Fact-4772D125AD4C50E3857D20C0EC85D366" name="us-gaap:TreasuryStockValue" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55,950</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Merck&nbsp;&amp; Co., Inc. stockholders’ equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1769-wk-Fact-430B412278995D81ADD1232F0066D666" name="us-gaap:StockholdersEquity" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,205</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1788-wk-Fact-C0EF1E3F4D015D9BACF315E27AAAA2A2" name="us-gaap:StockholdersEquity" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25,907</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncontrolling Interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1808-wk-Fact-679EAFFF975A5D71B43C6C831C7A9CFF" name="us-gaap:MinorityInterest" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1827-wk-Fact-3FA6FA8DC99B508CAB26CA005410D2AE" name="us-gaap:MinorityInterest" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1847-wk-Fact-DCA80302EE4456349004593316814A69" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,300</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1866-wk-Fact-5C82559F23195F7B847A42E82C4148CE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,001</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1891-wk-Fact-4C8F40CE01C1556D908559D0730F49B1" name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84,913</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15730901e1910-wk-Fact-9BE13F377E1750CC90B358C8B47CBFD6" name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84,397</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">4</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><a id="s05ABAEBB3B3158E08FF7D0FD9CD623CA"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, $ in millions)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flows from Operating Activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e575-wk-Fact-04A0B49FB6515A48BFEB29E286C58509" name="us-gaap:ProfitLoss" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e594-wk-Fact-F2DD15DA647E55D7AB924274EF9BAE76" name="us-gaap:ProfitLoss" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,862</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e650-wk-Fact-6136A10BD30A52E29216B489D4695DAB" name="us-gaap:DepreciationDepletionAndAmortization" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">821</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e669-wk-Fact-5911DFB38A8E589796CED6AF4C0671AB" name="us-gaap:DepreciationDepletionAndAmortization" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">898</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset impairment charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e689-wk-Fact-6088F7E24E0B5D0B967EB9F1ABEE746A" name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e708-wk-Fact-7589D4727E4A5247909671D65499AAD3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e728-wk-Fact-0AC48122314E515CBE3AC2563D65615D" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e747-wk-Fact-96B4566EAF5C5D2E89A250524A1F256E" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e767-wk-Fact-CA2DBAF14F4B519AA559EC786715BFED" name="us-gaap:ShareBasedCompensation" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e786-wk-Fact-DF860C036A7E58A69A4D560BB1906DB5" name="us-gaap:ShareBasedCompensation" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e806-wk-Fact-3DEA6C674E1C5C29A17345DA3F55C9E9" name="us-gaap:OtherNoncashIncomeExpense" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">143</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e825-wk-Fact-694F9515525E5252ADC3AF31280DE419" name="us-gaap:OtherNoncashIncomeExpense" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">120</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net changes in assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e845-wk-Fact-AE80C6263A4257C7BA994D51E1AC903B" name="us-gaap:IncreaseDecreaseInOperatingCapital" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,666</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e865-wk-Fact-A1FB4ACCDD805E128CA0E4B042FF2C45" name="us-gaap:IncreaseDecreaseInOperatingCapital" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,935</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Cash Provided by Operating Activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e887-wk-Fact-5A62F73CC6E150DBA668D5AE7A454A0A" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">707</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e906-wk-Fact-7E6A6FB463AB537DB85B51BD3073BEDC" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,336</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flows from Investing Activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital expenditures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e967-wk-Fact-26ABB90E6456538D86C396B168A52764" name="us-gaap:PaymentsToAcquireProductiveAssets" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">986</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e987-wk-Fact-834176F257C9525085F3685AFE884AC5" name="us-gaap:PaymentsToAcquireProductiveAssets" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">595</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of securities and other investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1008-wk-Fact-CDF415FA4EBC5E5B822145E1C3941B03" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1028-wk-Fact-DD18937CB9C65455889842F7B4AC8192" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">974</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from sales of securities and other investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1049-wk-Fact-9EAD200ED52B5F98A144DFEBD2571CE5" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,816</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1068-wk-Fact-64F3F0EE7AF95C29A8C2C8B69B9E4569" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,899</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition of ArQule, Inc., net of cash acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1088-wk-Fact-FACBFDE1FD2975C7FF06A5EFEC7B8D11" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,545</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1108-wk-Fact-516A4800811D0D73E6B8A5EFEC715386" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1128-wk-Fact-6EF5183040AC51438836C49D64A92251" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">136</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1147-wk-Fact-10875805AF1D550C83541E63B5FABFFA" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">38</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Cash (Used in) Provided by Investing Activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1167-wk-Fact-4EB54A4743EE58499792B28890C7C9BE" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,628</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1187-wk-Fact-08F0C3E1A4C85007A1F368F640B1C929" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">368</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flows from Financing Activities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net change in short-term borrowings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1248-wk-Fact-BB4A9200A8BC5A60AC5447C48EAB922C" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,583</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1267-wk-Fact-49AF089D7AEC5CE483AFB3F2E22E74FA" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,135</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments on debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1288-wk-Fact-6DAA8394164B5F2CAF4B9EE39E2E01A5" name="us-gaap:RepaymentsOfLongTermDebt" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,951</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1308-wk-Fact-5DBEB85F427C5D79A827AD23729ABEF8" name="us-gaap:RepaymentsOfLongTermDebt" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1329-wk-Fact-F9084C8CC7085785944FA0EC3EAFF12B" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1348-wk-Fact-78258717886458BD8DA8AA683741F4F7" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,958</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1368-wk-Fact-FF0DB78F368953AE9735777880773627" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,281</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1388-wk-Fact-89C5BB3BFBAE5C0BA8891371C272C987" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,090</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividends paid to stockholders</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1409-wk-Fact-C07E002C60FA5A4DA82905FDC7DB9624" name="us-gaap:PaymentsOfDividendsCommonStock" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,551</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1429-wk-Fact-93DD5CC6F9C45319A2CAE976B1A02058" name="us-gaap:PaymentsOfDividendsCommonStock" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,428</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1450-wk-Fact-EF559B900C725996A7AB439856331374" name="us-gaap:ProceedsFromStockOptionsExercised" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1469-wk-Fact-4AB76283C27D5AE5909108CCD4F79F11" name="us-gaap:ProceedsFromStockOptionsExercised" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1489-wk-Fact-00A8F4ACE3365958830788D5B8E7F3AA" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">316</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1509-wk-Fact-715294FD15B757CBA000FFE3B1E1824D" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">92</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Cash Used in Financing Activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1530-wk-Fact-C5B7D1CBF18F52919A155ADA8C7DABE8" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,490</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1550-wk-Fact-09B3A82EAF92551D8B226AA8AF55BBEB" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,614</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1571-wk-Fact-E5CDE99AFE965D83946008BFE6BBB14C" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">63</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1591-wk-Fact-D86D5C0973935123A8A5D4923A000369" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732406e1611-wk-Fact-056024D92AC4597296CDFF2E0EE0763F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,474</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1631-wk-Fact-C0DB71E8A1AB5804B88C1BB303C2E7A8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted </span></div><div style="padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cash of $258 million at January 1, 2020 included in Other Assets)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1654-wk-Fact-332E644CA1FA53E08BC6AE4561EED2D1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,934</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1673-wk-Fact-02A7DEACA0D95446821E571B6BA8295B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="FI2018Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,967</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash </span></div><div style="padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of $35 million at March 31, 2020 included in Other Assets)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1701-wk-Fact-4FFD75926BE25D2D8ACC1B464298DD35" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,460</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732406e1720-wk-Fact-F501BEDCA65F5D15B490C6EB7191D5F7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="FI2019Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,077</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">5</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><a id="s04e69ab2232a4a3b9ecf209e7ab9e612"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><a id="sBD2822ADA8AD568285F5C7E531527143"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-8C42D9BC997C566EB6C18AE7B6BCCB73-0-wk-Fact-52F42D1762F75F23843251CD374E01C2" continuedat="TextSelection-8C42D9BC997C566EB6C18AE7B6BCCB73-1" escape="true"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="TextSelection-ABDFFE80F0D9555696BE5E480DBDB950-0-wk-Fact-7B4FF0295E7B58E99AFDBF15E07C863E" continuedat="TextSelection-ABDFFE80F0D9555696BE5E480DBDB950-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</span></div></ix:nonnumeric></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-ABDFFE80F0D9555696BE5E480DBDB950-1"><ix:continuation id="TextSelection-8C42D9BC997C566EB6C18AE7B6BCCB73-1"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements of Merck&nbsp;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February&nbsp;26, 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. </span></div></ix:continuation><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Planned Spin-Off of Women’s Health, Legacy Brands and Biosimilars into New Company </span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, Merck announced its intention to spin-off products from its women’s health, trusted legacy brands and biosimilars businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The legacy brands included in the transaction consist of dermatology, non-opioid pain, respiratory, and select cardiovascular products including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia</span><span style="font-family:inherit;font-size:10pt;"> (ezetimibe) and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vytorin </span><span style="font-family:inherit;font-size:10pt;">(ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the first half of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, legacy brands and biosimilars businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-06A96DC94C445767858CA3D53758F69F-0-wk-Fact-A03F6DCBB2AF5AEBA27265D646FAC293" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&nbsp;The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div></ix:nonnumeric></ix:continuation><div><a id="sA6DD89663E8C5754A3BC8913E00568A3"></a></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">6</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="mrk:AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" id="TextSelection-E5B15697F0C450658472340252DE671C-0-wk-Fact-926E88E2B8C25EDF89FDD0A2C4405000" continuedat="TextSelection-E5B15697F0C450658472340252DE671C-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisitions, Research Collaborations and License Agreements</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-E5B15697F0C450658472340252DE671C-1"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15732969e436-wk-Fact-B537E5234FD162F16E26C49E2B9F1DBF" name="us-gaap:PaymentsToAcquireBusinessesGross" contextref="D2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.7</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> included </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15732969e440-wk-Fact-1D5DE00654828BB44331C33D32394D3B" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15732969e444-wk-Fact-B0890A32265B57B45043C26D10F141EE" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative</span><span style="font-family:inherit;font-size:10pt;"> expenses in the first quarter of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-0297AC8CF3C6C1A8459584E45787F9F7-0-wk-Fact-02300E86CD4F45B9027084E58F85BBDB" continuedat="TextSelection-0297AC8CF3C6C1A8459584E45787F9F7-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 16, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732969e523-wk-Fact-4BC32DF298E8E79E5ABB84C35471071F" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732969e540-wk-Fact-060FAEE995EF5A5738E384C35490E846" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_mrk_IPRDMK1026Member" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,280</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D MK-7075 (formerly ARQ 092) </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732969e562-wk-Fact-BCA88CBC02AA7D9FE8ED84C3547E0F93" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_mrk_IPRDMK7075Member" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangement for ARQ 087</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732969e582-wk-Fact-8C0BA0522BFD2D75579A84D763B3A939" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15732969e602-wk-Fact-C0CD03B74CC3182F618684C35466A27B" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">434</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets and liabilities, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732969e623-wk-Fact-1A4CEACB0413CF480B8A84C354783BD7" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total identifiable net assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732969e643-wk-Fact-87B0C68E5CA711A6195084D20F9B50D1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,276</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732969e665-wk-Fact-67EC58EBF63C4075C1E584C35484358F" name="us-gaap:Goodwill" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">414</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consideration transferred</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15732969e690-wk-Fact-16809598FCF6CD4E5B4984D2F49BAC6E" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,690</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:1px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The fair values of the identifiable intangible assets related to in-process research and development (IPR&amp;D) were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span><ix:nonfraction id="d15732969e703-wk-Fact-5904322A4A297EBF5A35CCEC4210CE6E" name="mrk:IntangibleAssetMeasurementInput" contextref="I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitref="number" decimals="3" scale="-2" format="ixt:numdotdecimal">12.5</ix:nonfraction>%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Actual cash flows are likely to be different than those assumed. </span></div></td></tr></tbody></table></ix:nonnumeric><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-0297AC8CF3C6C1A8459584E45787F9F7-1" continuedat="TextSelection-0297AC8CF3C6C1A8459584E45787F9F7-2"><div style="line-height:120%;font-size:8pt;padding-left:1px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&nbsp;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-0297AC8CF3C6C1A8459584E45787F9F7-2"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div></ix:continuation></td></tr></tbody></table><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:0.78125%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:continuation><div><a id="s6826753262B751A6837B3E9F2F7088C1"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-A679BAD265C35C0D91694E423CC13665-0-wk-Fact-4F4791EE538D5BAE861D34828308A226" continuedat="TextSelection-A679BAD265C35C0D91694E423CC13665-1" escape="true">Collaborative Arrangements</ix:nonnumeric></span></div><ix:continuation id="TextSelection-A679BAD265C35C0D91694E423CC13665-1" continuedat="TextSelection-A679BAD265C35C0D91694E423CC13665-2"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AstraZeneca</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase&nbsp;(PARP) inhibitor currently approved for certain types of advanced ovarian, breast and pancreatic cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> (pembrolizumab) and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca’s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">was approved for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&nbsp;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Profits from Lynparza and Koselugo&nbsp;product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> in combination with Lynparza or </span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">7</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-A679BAD265C35C0D91694E423CC13665-2" continuedat="TextSelection-A679BAD265C35C0D91694E423CC13665-3"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> costs.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the agreement, Merck made an upfront payment to AstraZeneca of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e458-wk-Fact-7DD62FB570F05854BD30265EDDA222E5" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextref="D2017Q3July_srt_CounterpartyNameAxis_mrk_AstraZenecaMember" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.6</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in 2017 and made payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e462-wk-Fact-4B80193FDE745CBA9BFEB70E1BE18529" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" contextref="D2017Q3July_srt_CounterpartyNameAxis_mrk_AstraZenecaMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to 2020, Merck accrued sales-based milestone payments aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e469-wk-Fact-7C313B74CB5C533B81BB098CB3B4134E" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" contextref="D2019Q4Prior2020_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> related to Lynparza, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e473-wk-Fact-BC7F10C9163F528AB36982830D529983" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="FD2019Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&nbsp;and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e477-wk-Fact-F2A3F7FA4685EAEE29E42CDAFA3D5CDB" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid to AstraZeneca in 2019 and 2018, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e481-wk-Fact-3119D1469493AED0D2E12CDBC0EFA3AB" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="D2020Q1Jan01-Jan31_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in the first quarter of 2020. Potential future sales-based milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e485-wk-Fact-4AA6ED7FBDD95775A20EACE977F38994" name="mrk:ContingentPaymentsCollaborativeArrangement" contextref="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.1</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e492-wk-Fact-B2EC5191BA3EA36D1B742CE270D316D0" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="FD2019Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e496-wk-Fact-1E25A95E3B58553DA9B8AADC0FE76E51" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e500-wk-Fact-4AAA9CAC3D3C5967A0C270DBAF4D08C8" name="mrk:ContingentPaymentsCollaborativeArrangement" contextref="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> remain under the agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e507-wk-Fact-2E90DBCE48E95E7CA76AEF3B5E9E9BF8" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="FI2020Q1_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">928</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangibles, Net</span><span style="font-family:inherit;font-size:10pt;"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-917083C7A0655AD99AA7D3FF4CB79E45-0-wk-Fact-C3C6CBB26E945CE693663457F80802E3" continuedat="TextSelection-917083C7A0655AD99AA7D3FF4CB79E45-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e638-wk-Fact-8CE377E9D68258FFBA7D48B2BE1EC4A9" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e657-wk-Fact-3272D316CF21552891F9D0EDC68A150D" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&nbsp;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e715-wk-Fact-75FA27F519665D5185D9670112C37BCE" name="us-gaap:CostOfGoodsAndServicesSold" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e734-wk-Fact-7859FB28F4BC576897E0010A77C6F5F0" name="us-gaap:CostOfGoodsAndServicesSold" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e754-wk-Fact-F9DA94F8E70A588FBFD8789DF4C9D700" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e773-wk-Fact-E738C3D379C75377A9A847E3E9BB549C" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e793-wk-Fact-479985CB190D513589D339931B75A237" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e812-wk-Fact-9D3CC161986158438099CBAD69C6F8D2" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from AstraZeneca included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e921-wk-Fact-A28D05DA9D0A5B0BA2ED7350A9B1CDF0" name="us-gaap:ReceivablesNetCurrent" contextref="FI2020Q1_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e940-wk-Fact-ECADCAF94EEF57AFB77F88B5E9616DAA" name="us-gaap:ReceivablesNetCurrent" contextref="FI2019Q4_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to AstraZeneca included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued and other current liabilities</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&nbsp;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e959-wk-Fact-91DA09231BA25F1AAD8A56B72B021791" name="us-gaap:LiabilitiesCurrent" contextref="FI2020Q1_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e978-wk-Fact-E84194B2541D5194926669082ACCD826" name="us-gaap:LiabilitiesCurrent" contextref="FI2019Q4_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">577</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents amortization of capitalized milestone payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone payments.</span></div></ix:nonnumeric><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><ix:continuation id="TextSelection-917083C7A0655AD99AA7D3FF4CB79E45-1" continuedat="TextSelection-CB808E954BD85AABB83839A0BF088243-0"></ix:continuation>Eisai</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development </span><span style="font-family:inherit;font-size:10pt;">expenses. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the agreement, Merck made an upfront payment to Eisai of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1024-wk-Fact-C68121C66E5B52098FBF1F6864E71007" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextref="D2018Q1March_srt_CounterpartyNameAxis_mrk_EisaiMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and agreed to make payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1028-wk-Fact-249AC4A8CFA6588CB331CF021F2C0158" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" contextref="D2018Q1mar2018mar2021_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">650</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for certain option rights through 2021 (of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1032-wk-Fact-32E3EE5AE23F5F94BE11E4C536F7C208" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" contextref="D2019Q1March_srt_CounterpartyNameAxis_mrk_EisaiMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in March 2019, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1036-wk-Fact-05473D3961B451B99EEE099A911C70DD" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" contextref="D2020Q1March2020_srt_CounterpartyNameAxis_mrk_EisaiMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in March 2020 and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1040-wk-Fact-1332F499F49F5A4BB160CA3036F51411" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" contextref="D2021Q1March2021_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to 2020, Merck accrued sales-based milestone payments aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1047-wk-Fact-982A0CFAC37450C290D54F0091EA744A" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" contextref="D2019Q4Priorto2020_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">950</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to Lenvima. Of these amounts, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1051-wk-Fact-5C8E5605A05450DD924A019A034D92CE" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="FD2019Q4YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&nbsp;was paid to Eisai in 2019 and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1055-wk-Fact-E04D8256375D6EB78D9D31682066E065" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in the first quarter of 2020. Potential future sales-based milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1059-wk-Fact-A666827D260C5A3FAAAA5930A7A53A59" name="mrk:ContingentPaymentsCollaborativeArrangement" contextref="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.0</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">8</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-A679BAD265C35C0D91694E423CC13665-3" continuedat="TextSelection-A679BAD265C35C0D91694E423CC13665-4"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1066-wk-Fact-AFC0DC1E2337508B991BA4F1ADEEAE76" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1070-wk-Fact-C797D4310F705AAFA2BF7C988CB68081" name="mrk:ContingentPaymentsCollaborativeArrangement" contextref="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_TypeOfArrangementAxis_mrk_RegulatoryMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">135</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> remain under the agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1077-wk-Fact-C034E047EEB059718BD6CA4588CD594F" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="FI2020Q1_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">921</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangibles, Net</span><span style="font-family:inherit;font-size:10pt;"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><ix:continuation id="TextSelection-CB808E954BD85AABB83839A0BF088243-0" continuedat="TextSelection-62173206116E565EA7F319F41E4C3083-0"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1206-wk-Fact-1FAC76265F565371BB37A83C8D473252" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1225-wk-Fact-83251D6AD6385124B8AD3BA615701C8E" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&nbsp;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1283-wk-Fact-864A2B43B2455A7D970D3BFAF70D4DD6" name="us-gaap:CostOfGoodsAndServicesSold" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1302-wk-Fact-554A06B91DDC5252A8777CFE4699AE6B" name="us-gaap:CostOfGoodsAndServicesSold" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1322-wk-Fact-36431E4EAA345B0D9A6D351EBBFD8873" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1341-wk-Fact-1ACE6E12628A59FCB67E56167E8BE842" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1361-wk-Fact-11E8D27AD75E5633A3098D0998DF616A" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1380-wk-Fact-6E0E4A84F1305A0ABFB9554FEEAE4565" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1489-wk-Fact-DC3425CC36775D3890DC55EF90134682" name="us-gaap:ReceivablesNetCurrent" contextref="FI2020Q1_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1508-wk-Fact-54DA36D49A5A558992D80350C33ED6FA" name="us-gaap:ReceivablesNetCurrent" contextref="FI2019Q4_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued and other current liabilities</span><span style="font-family:inherit;font-size:10pt;">&nbsp;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1529-wk-Fact-858EABEC1F235C5BBE798BB3C66895C2" name="us-gaap:LiabilitiesCurrent" contextref="FI2020Q1_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">425</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1548-wk-Fact-F28FC49BB1D65D27BD9A68E56D53945A" name="us-gaap:LiabilitiesCurrent" contextref="FI2019Q4_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">700</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Noncurrent Liabilities</span><span style="font-family:inherit;font-size:10pt;">&nbsp;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1575-wk-Fact-455463FC0DA254029B5E703D9339BB34" name="us-gaap:LiabilitiesNoncurrent" contextref="FI2020Q1_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1594-wk-Fact-2F4644F3F9255636AB67A34E30673FB8" name="us-gaap:LiabilitiesNoncurrent" contextref="FI2019Q4_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">525</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents amortization of capitalized milestone payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone and future option payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone payments.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bayer AG</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer’s vericiguat, which is in development for the potential treatment of worsening heart failure. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories. In addition, the agreement provides for additional contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to 2020, Merck accrued&nbsp;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1633-wk-Fact-8D4377BEB177578DBA0E5EB7DB41F9D1" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" contextref="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">725</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&nbsp;of sales-based milestone payments for this collaboration, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1637-wk-Fact-74BC72A71F19517091C4F8B9FB56AD41" name="mrk:MilestonePaymentsMadetoCollaborativePartner" contextref="FD2018Q4YTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid to Bayer in 2018. There is an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1641-wk-Fact-BC9FAD0041845D97A1DC6A486986D2E3" name="mrk:ContingentPaymentsCollaborativeArrangement" contextref="FD2020Q1YTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> potential future sales-based milestone payment that&nbsp;has not yet been accrued as it is not deemed by the Company to be probable at this time.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15734829e1648-wk-Fact-35B8E6A32FD85E3C9D6663383495294B" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="FI2020Q1_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherIntangibleAssetsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">844</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangibles, Net </span><span style="font-family:inherit;font-size:10pt;">on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-62173206116E565EA7F319F41E4C3083-0"><ix:continuation id="TextSelection-A679BAD265C35C0D91694E423CC13665-4"><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales of Adempas recorded by Merck</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1778-wk-Fact-9DADAEB4119F5F96A377F5306FC72FD0" name="mrk:CollaborativeArrangementSalesNet" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1797-wk-Fact-9FA01C54D1F7584A873A86F6F70BEB05" name="mrk:CollaborativeArrangementSalesNet" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1812-wk-Fact-80B34E70BED55E2EA3D1B05444B477A2" name="mrk:CollaborativeArrangementProfitSharing" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1831-wk-Fact-DA2744EB5A10527FA9B20E5BD0924593" name="mrk:CollaborativeArrangementProfitSharing" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1851-wk-Fact-EDD51C71A4355E3B9E35C7DEB8918473" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1870-wk-Fact-F9D323F2825158659E4B32517DA11D55" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&nbsp;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1933-wk-Fact-4E4EEC13B6CA52498057291AB126F10D" name="us-gaap:CostOfGoodsAndServicesSold" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1952-wk-Fact-3B7652317944561592EDA02539A05EB2" name="us-gaap:CostOfGoodsAndServicesSold" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1972-wk-Fact-F1539190FD3D519F870181DA15FCC15A" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e1991-wk-Fact-EC63F794ADF75DEBA58AFAEBBBDCD0A7" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e2011-wk-Fact-BF657C9312CF5BD08AA8DB4E17758E74" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2020Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e2030-wk-Fact-21F68BB25E91529A989B1BD0F30DE2F9" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2019Q1QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from Bayer included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e2140-wk-Fact-35FC682FBFE35CE1883C077074A0F8F5" name="us-gaap:ReceivablesNetCurrent" contextref="FI2020Q1_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e2159-wk-Fact-F9A6D2A79443573C97A3ABA06E6068B4" name="us-gaap:ReceivablesNetCurrent" contextref="FI2019Q4_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Bayer included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Noncurrent Liabilities</span><span style="font-family:inherit;font-size:10pt;">&nbsp;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e2180-wk-Fact-D661511502115BEF9D452D5966A48E28" name="us-gaap:LiabilitiesNoncurrent" contextref="FI2020Q1_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">375</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15734829e2199-wk-Fact-944944026DD85574948AA677B32D4592" name="us-gaap:LiabilitiesNoncurrent" contextref="FI2019Q4_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">375</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes amortization of intangible assets.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents accrued milestone payment.</span></div></ix:continuation></ix:continuation><div><a id="sF82FB7EE81A052A2AC6B5A2D20E1A401"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="TextSelection-8C7608873E1253659FBB51A7474DD345-0-wk-Fact-1D15E5215ABE541EAAF828DC5A2A50BF" continuedat="TextSelection-8C7608873E1253659FBB51A7474DD345-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-8C7608873E1253659FBB51A7474DD345-1" continuedat="TextSelection-8C7608873E1253659FBB51A7474DD345-2"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In early 2019, Merck&nbsp;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint.&nbsp;This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15736639e431-wk-Fact-A62B2ACDFD655653B3CE8E3AC0704747" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextref="FI2020Q1" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.5</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. The Company estimates that approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15736639e435-wk-Fact-312EF1EE2E0A5AC5A7E0581A0DEE7251" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" contextref="FD2020Q1YTD" unitref="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonfraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15736639e439-wk-Fact-70F4CA6CB5465150B82AA53BBA7C7271" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" contextref="FD2020Q1YTD" unitref="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonfraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15736639e443-wk-Fact-810ABA1559B657D3B7EA820CE43F6628" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextref="FI2020Q4_srt_StatementScenarioAxis_srt_ScenarioForecastMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">800</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded total pretax costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15736639e454-wk-Fact-F719C2F300D259C48234181B75D501FA" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15736639e458-wk-Fact-295474BC8A895D4F9D4710D2B7BDC27A" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">187</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, related to restructuring program activities. Since inception of the Restructuring Program through </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, Merck has recorded total pretax accumulated costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15736639e479-wk-Fact-AAF4AF02621206EF0D015217D8B9C693" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextref="FI2020Q1" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. For segment reporting, restructuring charges are unallocated expenses.</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="TextSelection-32039B82850E57DFA559EBDBAA2E5CC9-0-wk-Fact-6B31A4029255597CB7B2BBF5001738D5" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="16"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e704-wk-Fact-A6C85DFAD96458BDABD2A770B34F668E" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e723-wk-Fact-98B3523B426852AFB7C8C3403C50FC47" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e742-wk-Fact-C03643532EEC51AF8C93A244E8BB1B8D" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e762-wk-Fact-04E1D1F0930654C0BC525D655FCC0CEF" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e777-wk-Fact-51E04AE3D520581E9222BB058A007293" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e796-wk-Fact-2E7D0497E67054F185BA82034F97003C" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e815-wk-Fact-A081CB1A5C41527289EE4C629536FC1C" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e835-wk-Fact-B0B6950297B25140B609D338ACD2C348" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e855-wk-Fact-21220CE6AC1A5F89B3D0CFD1830E8F70" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e874-wk-Fact-77C1FBF8B58654D6BA76D3555EB31FB1" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e893-wk-Fact-3100F974662C5772A834F8119C726A40" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e913-wk-Fact-9CA023E6D5975B83952E529208143181" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e933-wk-Fact-9CEFA97083B95B01A23F5F58922E750E" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e952-wk-Fact-E208F9031D3D58B1916520619DFEF653" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e971-wk-Fact-3E29B795A0FA56BC97B45264E979DFC3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e991-wk-Fact-8C47D23F45F95AF59DC764A821F6AA23" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1016-wk-Fact-CDD14454D7455984803AEBC52B258601" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1035-wk-Fact-E65578F8BE07571F9DF50267955161DB" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1054-wk-Fact-DFF93645715754709F7917BB3ADE02C7" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1074-wk-Fact-F719C2F300D259C48234181B75D501FA" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="16"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1287-wk-Fact-DD009A465213569EB3B9AF85846DBD3D" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1306-wk-Fact-26130F4A2A925CC3BDD190B1B8F8A061" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1325-wk-Fact-A775ABA322575E8BB205D73558EF3DE4" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1345-wk-Fact-1F0CDC2F8CC3527B8ABB50FAAA6D4A4D" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1360-wk-Fact-E26D0980FEC15635A55706B56D58593C" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1379-wk-Fact-7AF81A59CB0F5AF98009A9A0897FDA23" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1398-wk-Fact-DB4B4E68267A50039278190F771FAEEC" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1418-wk-Fact-8C415BA8984E58BC873B780F8CF809CC" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1443-wk-Fact-3301357ACA0C5291A595A19F6A228229" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1462-wk-Fact-F3F539DD866754749B917A3B3E1FF7D4" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1481-wk-Fact-05B42A5A7A6B5C3EB72807C7668E98E1" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1501-wk-Fact-295474BC8A895D4F9D4710D2B7BDC27A" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">187</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-8C7608873E1253659FBB51A7474DD345-2" continuedat="TextSelection-8C7608873E1253659FBB51A7474DD345-3"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other activity in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="TextSelection-4A10ED83FE0655D49B3DB3532E1657A2-0-wk-Fact-7DE25AB002AE5F5BA2303E1EA74B22AA" continuedat="TextSelection-4A10ED83FE0655D49B3DB3532E1657A2-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the charges and spending relating to restructuring program activities for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring reserves January&nbsp;1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1684-wk-Fact-45D6C15F759156428BA77891F3FC54A4" name="us-gaap:RestructuringReserve" contextref="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">690</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1703-wk-Fact-AC3F79DBE80D586FA181714D5E88794F" name="us-gaap:RestructuringReserve" contextref="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1722-wk-Fact-30F86C72FBFC542087309A033C75198B" name="us-gaap:RestructuringReserve" contextref="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1742-wk-Fact-3158EF36C8E95692912A3FF2EE4EE329" name="us-gaap:RestructuringReserve" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">759</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1757-wk-Fact-CDD14454D7455984803AEBC52B258601" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1776-wk-Fact-E65578F8BE07571F9DF50267955161DB" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1795-wk-Fact-DFF93645715754709F7917BB3ADE02C7" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1815-wk-Fact-F719C2F300D259C48234181B75D501FA" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Payments) receipts, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15736639e1835-wk-Fact-C9BABAC641335DDDBD4CFB7EC4CC77F4" name="us-gaap:PaymentsForRestructuring" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1855-wk-Fact-D8D7D72928A95ABB999971D820397400" name="us-gaap:PaymentsForRestructuring" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15736639e1874-wk-Fact-5E507AC55351575EAAA3B83170E7C3CC" name="us-gaap:PaymentsForRestructuring" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15736639e1895-wk-Fact-B9CD335C99725E12BCC98B84AEFBDB0A" name="us-gaap:PaymentsForRestructuring" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">290</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash activity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1916-wk-Fact-2D6B297070225CABB8BB95DF3C476909" name="mrk:RestructuringReserveNoncashActivity" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15736639e1935-wk-Fact-AF34D1F9006351FC82DA01892C6128A1" name="mrk:RestructuringReserveNoncashActivity" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e1955-wk-Fact-B208C197EE445DA49F8EBB2EAEB5FF4B" name="mrk:RestructuringReserveNoncashActivity" contextref="FD2020Q1QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">42</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15736639e1975-wk-Fact-3E50DB9B63D953EDBD7D2C6536CDA389" name="mrk:RestructuringReserveNoncashActivity" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring reserves March 31, 2020 </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e2003-wk-Fact-00EBD1ACC3C45C81B623D87881A311FF" name="us-gaap:RestructuringReserve" contextref="FI2020Q1_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">569</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e2022-wk-Fact-83C2E7D6C8445FED8DA0875D6C9773C4" name="us-gaap:RestructuringReserve" contextref="FI2020Q1_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e2041-wk-Fact-4F82BBE876B156C7BF30C7C4B3A6EAB5" name="us-gaap:RestructuringReserve" contextref="FI2020Q1_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15736639e2061-wk-Fact-AC2526615243582F8AA412B1F08993FD" name="us-gaap:RestructuringReserve" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">626</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div></ix:nonnumeric></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-4A10ED83FE0655D49B3DB3532E1657A2-1" continuedat="TextSelection-4A10ED83FE0655D49B3DB3532E1657A2-2"><ix:continuation id="TextSelection-8C7608873E1253659FBB51A7474DD345-3" continuedat="TextSelection-8C7608873E1253659FBB51A7474DD345-4"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><ix:continuation id="TextSelection-4A10ED83FE0655D49B3DB3532E1657A2-2"><ix:continuation id="TextSelection-8C7608873E1253659FBB51A7474DD345-4">The remaining cash outlays are expected to be substantially completed by the end of 2023.</ix:continuation></ix:continuation> </span></div></td></tr></tbody></table><div><a id="s176786006AEB5F1DA374DA9CCA1EE4A1"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-0-wk-Fact-9952EF4B66EB5ABAB0516A4B90AEA319" continuedat="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-1" continuedat="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-2"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Risk Management</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonnumeric id="d15752037e446-wk-Fact-4CBA131025F75C67B43FEDAEFCC27225" name="us-gaap:DerivativeAverageRemainingMaturity1" contextref="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" format="ixt-sec:durwordsen">two years</ix:nonnumeric></span></span><span style="font-family:inherit;font-size:10pt;"> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;">) and reclassified into </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:10pt;"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:10pt;"> each period. The cash&nbsp;flows from both designated and non-designated contracts are reported as operating activities&nbsp;in the Condensed Consolidated Statement of&nbsp;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">11</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-2" continuedat="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-3"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;">. The forward contracts are not designated as hedges and are marked to market through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonnumeric id="d15752037e492-wk-Fact-876EADED70DB5300A9C5F5C315201DEF" name="us-gaap:DerivativeAverageRemainingMaturity1" contextref="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" format="ixt-sec:durwordsen">one year</ix:nonnumeric></span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> and remain in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded component). Changes in fair value of the excluded components are recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">. The Company recognizes in earnings the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-B63C471D0AE75C58B7F00EC2F069DB21-0-wk-Fact-4C091FF8F6CA5E3590CC42C4EDC46FE3" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effects of the Company’s net investment hedges on </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> and the Consolidated Statement of Income are shown below:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="16"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&nbsp;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Pretax (Gain) Loss Recognized in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;">&nbsp;for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Net Investment Hedging Relationships</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e898-wk-Fact-EC0568E96897599F8BCCFCCB855F2C9A" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e918-wk-Fact-F67B5648600B5142A342F7EBFB702955" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e938-wk-Fact-3F58C21704C55EA584DF164FC3D2E988" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e959-wk-Fact-2A01BCFB79BB5390AD0FD40A036E678C" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Euro-denominated notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e975-wk-Fact-B0B91E48B52E5FE58973E871F8B17503" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_mrk_EurodominatedNotesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e995-wk-Fact-4A1BB1DF1D985C66A4D0C2A7B122420D" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_mrk_EurodominatedNotesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1015-wk-Fact-D67EEC5EA1415366BC25FA75B80E2648" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_mrk_EurodominatedNotesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1035-wk-Fact-4C115763688E5507883A3795428C9656" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_mrk_EurodominatedNotesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div></ix:nonnumeric><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Risk Management</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020,&nbsp;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752037e1064-wk-Fact-0672AAA40072CA593D79C2953933E972" name="us-gaap:NumberOfInterestRateDerivativesHeld" contextref="I2020Q1Feb29_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitref="number" decimals="0" scale="0" format="ixt-sec:numwordsen">five</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;">&nbsp;interest rate swaps with notional amounts of&nbsp;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e1068-wk-Fact-18E7624E0135E0DE08FFC2974A0DB10B" name="us-gaap:DerivativeNotionalAmount" contextref="I2020Q1Feb29_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&nbsp;each matured. These swaps effectively converted the Company’s&nbsp;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e1072-wk-Fact-F88B88B5D9C4592A5337C298C89BFB60" name="us-gaap:DebtInstrumentFaceAmount" contextref="I2020Q1Feb29_us-gaap_DebtInstrumentAxis_mrk_A1.85NotesDue2020Member" unitref="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">1.25</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">,&nbsp;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752037e1076-wk-Fact-62035A40A66FFE4B8131C29A6FE9574C" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="I2020Q1Feb29_us-gaap_DebtInstrumentAxis_mrk_A1.85NotesDue2020Member" unitref="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.85</ix:nonfraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&nbsp;fixed-rate notes due 2020 to variable rate debt.&nbsp;<ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="TextSelection-27F9582C88415F569FFD80E660847C85-0-wk-Fact-CF329F66036E5168A91DBF7DD9F79F9D" continuedat="TextSelection-27F9582C88415F569FFD80E660847C85-1" escape="true">At </ix:nonnumeric></span><ix:continuation id="TextSelection-27F9582C88415F569FFD80E660847C85-1" continuedat="TextSelection-27F9582C88415F569FFD80E660847C85-2"><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company was a party to </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752037e1094-wk-Fact-ECE27AB920AD560BBAAAEA02492B6CCA" name="us-gaap:NumberOfInterestRateDerivativesHeld" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitref="interest_rate_swap" decimals="INF" scale="0" format="ixt:numdotdecimal">14</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.</span></ix:continuation></div><ix:continuation id="TextSelection-27F9582C88415F569FFD80E660847C85-2" continuedat="TextSelection-27F9582C88415F569FFD80E660847C85-3"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March&nbsp;31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Par Value of Debt</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Number of Interest Rate Swaps Held</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total Swap Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3.875% notes due 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1241-wk-Fact-A250ABEB393F536F9DE31C2C01D49A4D" name="us-gaap:DebtInstrumentFaceAmount" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member" unitref="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">1,150</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1255-wk-Fact-08B6434153525C929CC7B4AAB4655869" name="us-gaap:NumberOfInterestRateDerivativesHeld" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member" unitref="interest_rate_swap" decimals="INF" scale="0" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1274-wk-Fact-D46DDDAD9BAC5726943C67CD2C397B0B" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,150</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2.40% notes due 2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1289-wk-Fact-7A589E4B5E1057858442CCAA2EFA36D7" name="us-gaap:DebtInstrumentFaceAmount" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member" unitref="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">1,000</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1308-wk-Fact-58D403431E7558899F2B1B9F08EC2444" name="us-gaap:NumberOfInterestRateDerivativesHeld" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member" unitref="interest_rate_swap" decimals="INF" scale="0" format="ixt:numdotdecimal">4</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1322-wk-Fact-11D5E0EB84B355F3AA9566B04A6B1384" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2.35% notes due 2022</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1342-wk-Fact-D9E0F570FC3553D0B5CDE247D3F276AB" name="us-gaap:DebtInstrumentFaceAmount" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member" unitref="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">1,250</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1361-wk-Fact-D027BF8FCE3254DEACC003F507125E44" name="us-gaap:NumberOfInterestRateDerivativesHeld" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member" unitref="interest_rate_swap" decimals="INF" scale="0" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1375-wk-Fact-A0E447CFB3DF5CD9B316CEF447E6DFF7" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div></ix:continuation></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">12</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-3" continuedat="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-4"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-27F9582C88415F569FFD80E660847C85-3"></ix:continuation>The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="TextSelection-6D2CA0D0FE3B5378A83B170A77CDF099-0-wk-Fact-2409D1D2100257B3A99B416DF20170BB" continuedat="TextSelection-6D2CA0D0FE3B5378A83B170A77CDF099-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Carrying Amount of Hedged Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Balance Sheet Line Item in which Hedged Item is Included</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loans payable and current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1685-wk-Fact-94AA9B4629A15F8A80B7D553A3E135AA" name="us-gaap:HedgedLiabilityFairValueHedge" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,160</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1704-wk-Fact-853FB6755D39558CB7FDC700426E17EE" name="us-gaap:HedgedLiabilityFairValueHedge" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,249</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1723-wk-Fact-BF235A3503605407ACFC61EDD29ADFB5" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e1743-wk-Fact-31BDCA31A3715239A8DBCEF48632816B" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Long-Term Debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1759-wk-Fact-C1FBF0E2D52C5879B16BFE88734EDE63" name="us-gaap:HedgedLiabilityFairValueHedge" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,315</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1778-wk-Fact-A5D3FD26B81D54C1B399828F54623ACF" name="us-gaap:HedgedLiabilityFairValueHedge" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,409</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1797-wk-Fact-51370FA9B6675EDF801E022E32807EBE" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e1817-wk-Fact-803AFB5B926E5E03802840E4C46757B3" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div></ix:nonnumeric><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="TextSelection-1E6C514ECE245B22B9B2CDF1C06E4E48-0-wk-Fact-D5C32D49F1B156CABC054AC70C64A4C7" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-6D2CA0D0FE3B5378A83B170A77CDF099-1"></ix:continuation>Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="25"></td></tr><tr><td style="width:22%;"></td><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair&nbsp;Value&nbsp;of&nbsp;Derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S.&nbsp;Dollar</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Notional</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair&nbsp;Value&nbsp;of&nbsp;Derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S.&nbsp;Dollar</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance Sheet Caption</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Designated as Hedging Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2413-wk-Fact-76E992AC00371592CD527B62D77C7253" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2452-wk-Fact-17F80A315095A96BE2C27B62DE39F569" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,150</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2471-wk-Fact-7A25A6937C80A9FB36D77B62E157B266" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2510-wk-Fact-3129EF9C60E9BBB01B977B62E68D4D81" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2530-wk-Fact-105DF41BD91E5846979BDE20ACE38780" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2568-wk-Fact-A2DDA0AD1FA253ABB09CC8C031D2B036" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,250</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2588-wk-Fact-2FC1E6EC46B251C58011277FD1D35F0A" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2627-wk-Fact-0C2AFBB708E45827AEE3CAC30FFECB89" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,400</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2671-wk-Fact-917BB0BF319F5847A4754A2352DBB6BA" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2690-wk-Fact-DA612BBF15E75DA0831F697CDB88630D" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2729-wk-Fact-0038FFDB96AE544286193CDE560E04F8" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2749-wk-Fact-4AE4BE0E129D596FAB59670F9D7B175F" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2774-wk-Fact-8F4D9A0759F65093AD2BBA8A87460F6D" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2812-wk-Fact-4568E87296FB5C7698301ABF7CF10B90" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,546</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2832-wk-Fact-45C3D99E90B951CF88D21E3C20A40EA3" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2871-wk-Fact-E5C3FD3145D358B4AB080E0B08151495" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,117</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2896-wk-Fact-0D979D7041BE5AB1AAF884E70098500D" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2934-wk-Fact-64EF76505211546C8DDCB80F8CE4CF94" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,064</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2954-wk-Fact-C2CB15BC8F0C5D0B8E78740B59E167A2" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e2993-wk-Fact-B1646942A1405D038323A4A6CF136D4F" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,160</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3037-wk-Fact-17C9C08FF7855977A56EA154EB8D3FCB" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3056-wk-Fact-EA74E4C394FA5D6A85F32CC2144E5303" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">734</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3095-wk-Fact-53B2D5F9844B51F78DBF8AAE1DAD5C55" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3115-wk-Fact-A3A331FA5ED2589792E50FA6506E4F4D" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,748</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Noncurrent Liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3159-wk-Fact-A169C0381F5353738B62D5DE3E98D778" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3178-wk-Fact-7B6E63CDAEB9573BA4DDD3876639F654" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3217-wk-Fact-F33F33D61B22560F873E6E6BD5A6A879" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3237-wk-Fact-0148F59EF37D5F83AF8FB7048A4CFAE7" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3268-wk-Fact-CB3DB7607BAC5AFEAED2DB0E1DD77C2B" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">363</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3286-wk-Fact-68D66B5B57635C9B9DD3248E00E544F7" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3305-wk-Fact-067E12F189425DC6B814169944BA7E00" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,749</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3323-wk-Fact-19A47E1E7FAA5F4B9CD177A8873C61DD" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3341-wk-Fact-DC0DFD2412EA5CCF90145F1B919933CE" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3360-wk-Fact-AB3C79D7987857049A0F2DC7ADE4E281" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,728</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Not Designated as Hedging Instruments</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3513-wk-Fact-33B609F837FF56778ECB722D4C85DC34" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">347</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3552-wk-Fact-5EBF0337572450D2BDAB9F37EA427B66" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,039</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3571-wk-Fact-4A85B1BEA30F5C50B90BB67545F3A9E8" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3610-wk-Fact-3D8BE2769F865EEEB9EC4134FCC193A1" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,245</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3649-wk-Fact-98F5DE9787C354539BCF75F52B467464" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3668-wk-Fact-1FE0932F2F0C5E78B3DF8CAF9E94AA48" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,665</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3707-wk-Fact-29F3435195265CCE9D64B1985C4C3284" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3727-wk-Fact-DC2E6BB73CA8564CBA704355CBA44467" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,693</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3757-wk-Fact-558A5CB6BAEC5CC3B4DCF1CE87201D66" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">347</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3776-wk-Fact-3A140ECB9CE45203BC170F4CDBFBF4CF" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3796-wk-Fact-1CEC625BD30558BD96F399ADF343223B" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,704</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3815-wk-Fact-A5AA9E6EAF805A3D84F9A7A1A8081AD6" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3834-wk-Fact-6CE2A0A385BF58359951D2CDD53D0C50" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3854-wk-Fact-1836368C989E5884B6D7809385EE5EFE" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,938</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3879-wk-Fact-32111C8BA2525BE69EED9580C62BD3BD" name="us-gaap:DerivativeAssets" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3897-wk-Fact-E8B7B3144C7A511DAB5B65C2CF46968D" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3916-wk-Fact-278940469840524D9229D77A8B102CE7" name="us-gaap:DerivativeNotionalAmount" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27,453</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3934-wk-Fact-EF649D6059E65979B99622260DB856BC" name="us-gaap:DerivativeAssets" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">288</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3952-wk-Fact-E112A659372E55B69C6836A694A0B241" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e3971-wk-Fact-078D2187E37B521E9AFAC38E86C704F9" name="us-gaap:DerivativeNotionalAmount" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30,666</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</span><span style="font-family:inherit;font-size:10pt;"> below). <ix:nonnumeric contextref="FD2020Q1YTD" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="TextSelection-9FCCBFB0B39B5795986CC0896F0B8D81-0-wk-Fact-F4AC8DB351ED5F778DD758D346CE5C0E" continuedat="TextSelection-9FCCBFB0B39B5795986CC0896F0B8D81-1" escape="true">The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</ix:nonnumeric></span></div><ix:continuation id="TextSelection-9FCCBFB0B39B5795986CC0896F0B8D81-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="16"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross amounts recognized in the condensed consolidated balance sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4204-wk-Fact-32111C8BA2525BE69EED9580C62BD3BD" name="us-gaap:DerivativeAssets" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4223-wk-Fact-E8B7B3144C7A511DAB5B65C2CF46968D" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4242-wk-Fact-EF649D6059E65979B99622260DB856BC" name="us-gaap:DerivativeAssets" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">288</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4262-wk-Fact-E112A659372E55B69C6836A694A0B241" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e4277-wk-Fact-7B9251A8242F5AD6B2B788B3C43C777E" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e4297-wk-Fact-1CC86571022E50978BF13260F4F9E4C5" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e4317-wk-Fact-F74028D79AF35F2E8B352DD68D0618D4" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e4338-wk-Fact-C1B00D4FE92D51EA9C6ED895C30289E6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash collateral received</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e4359-wk-Fact-917DE601B26C5ECB882C75AE54B94C86" name="us-gaap:DerivativeCollateralObligationToReturnCash" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4379-wk-Fact-2B81BE4CE7BF5413943190F6420B9D62" name="us-gaap:DerivativeCollateralRightToReclaimCash" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e4398-wk-Fact-7603DCCB21315E67B52FD93D787AA35C" name="us-gaap:DerivativeCollateralObligationToReturnCash" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4419-wk-Fact-9082E966749E50849EB10774BB3A77AE" name="us-gaap:DerivativeCollateralRightToReclaimCash" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net amounts</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4444-wk-Fact-622F556B79CF52DDA41251175BA4171A" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">405</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4463-wk-Fact-92D005A12DA951B6A5F1F094A22F83C4" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4482-wk-Fact-C715872520A65D1BA5A11F12BB1DFA14" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e4502-wk-Fact-2B72ED4F9DD4590AAA4258ADA3C84EAF" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:continuation></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">13</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-4" continuedat="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-5"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-26CDD540DE705DBCBD9BCDDEB6C89572-0-wk-Fact-02A446A66D9A5E85AC216D45111AC4B0" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="24"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other (income) expense, net </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive income (loss)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e4937-wk-Fact-C7D37DB85BC556E9852BBCC58A9EEE17" name="us-gaap:Revenues" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,057</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e4956-wk-Fact-F10A548F31825340A653E3FF20E0EA91" name="us-gaap:Revenues" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,816</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e4975-wk-Fact-BF3F141D6DBB50E6868729F8668306DA" name="us-gaap:OtherNonoperatingIncomeExpense" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">71</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e4995-wk-Fact-666DAA4ADD06583890FC628151F9D47F" name="us-gaap:OtherNonoperatingIncomeExpense" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">188</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e5014-wk-Fact-FB7B73E1583257B08FF24DB183829375" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">198</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e5035-wk-Fact-7EDF15BDBDBF51B482D56AFFC86D8A55" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(Gain) loss on fair value hedging relationships</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Interest rate swap contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hedged items</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e5334-wk-Fact-6D9458C82A32537B80A8B3A67BF5E006" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">67</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e5354-wk-Fact-6D8AEB0BA77F5E9792F12105F6B1C9AC" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">33</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e5451-wk-Fact-DAFB6BF8B4A95001869EB080DB27EBC8" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e5472-wk-Fact-4016BE6973D0542DAC25ACFB25004E6A" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Impact of cash flow hedging relationships</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Foreign exchange contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of gain (loss) recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e5859-wk-Fact-B3EFD2CA134A58ACB842CCBC9C4D7A9C" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">178</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e5878-wk-Fact-D41C957CB0445A1FB7FFBB398A7BB077" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Increase (decrease) in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;as a result of </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e5909-wk-Fact-B0977B99EDEF597FAF8E98485F0E16AF" name="us-gaap:Revenues" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonfraction id="d15752037e5928-wk-Fact-5B195AB57B1650D289AF9A6542DF7356" name="us-gaap:Revenues" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e5986-wk-Fact-1FA8208C033450C8B5D67B9EB1D86970" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">46</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e6006-wk-Fact-C5B0F43E5B815A30B05A192A05C0734E" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">44</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Interest rate contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of gain recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e6193-wk-Fact-51D7F85F568F518EB13B23A045A8D038" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e6214-wk-Fact-105C2BF02E865509ACBE2EAE15992F19" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of loss recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e6355-wk-Fact-820A829ECA755ECA8AC301B5E640479D" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(<ix:nonfraction id="d15752037e6375-wk-Fact-90457190ED335C6E93463115F176A63A" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Interest expense is a component of </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net.</span></div></ix:nonnumeric><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="TextSelection-8199AF23395A5F8A88E8A339753B2641-0-wk-Fact-7BC3168A70165943B64E23D976591676" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="10"></td></tr><tr><td style="width:58%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income Statement Caption</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Not Designated as Hedging Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&nbsp;</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e6653-wk-Fact-6F2AB127A67255AD98ED7D95CFE95090" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e6673-wk-Fact-FD851756BA4D5BFA81343E94715FDB34" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">118</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sales</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15752037e6700-wk-Fact-42C8F64921E05D30ACCCEA5ECE472E06" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextref="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeFutureMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e6720-wk-Fact-CDCAACE298D75055AD06E1F67389BD73" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextref="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeFutureMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company estimates </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752037e6770-wk-Fact-32663F396F965871AECFF53E44B88589" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:10pt;">. The amount ultimately reclassified to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:10pt;"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">14</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-5" continuedat="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-6"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Investments in Debt and Equity Securities</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="TextSelection-CF40A123D4C65546A539F593558E69E7-0-wk-Fact-1FD2CBD5AA7A5BB18E18C14AF7C3D72D" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information on investments in debt and equity securities is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="32"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross&nbsp;Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Value</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross&nbsp;Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7355-wk-Fact-0DBCBB426458581BA665D8C761FB1D22" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7374-wk-Fact-53CF8535C45856A9BB508F114849888C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7393-wk-Fact-E6F714C0297E59D4A693DB99384F5A4A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7413-wk-Fact-7520A5CEBC905624A0F738DD55EF7BB7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7432-wk-Fact-2FBC414B737F53D88CB59E9532883A51" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7452-wk-Fact-0F7154DE449A5D8086242C20DF2134B6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7471-wk-Fact-0F67037AB4C5573CB37923E6023FFEED" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7490-wk-Fact-276B67EA00C75D5297E7A7C8D473F137" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">269</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign government bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7505-wk-Fact-58A5D632A8B3561389E62B3D12577E8F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7524-wk-Fact-0200B7B670AA59288E8DE00694D71D1D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7543-wk-Fact-5979263BB62E53809B669D59B14F1933" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7563-wk-Fact-138B4C18747559D382FBCFE875FC4382" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7582-wk-Fact-F0CC0B69D7D951B09A2408471FC55A4C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7601-wk-Fact-8A7F8B7FE3945B9BBCD4000B17A6A286" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7621-wk-Fact-4AD5EABD6DDE5354A856F8D73636E06B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7640-wk-Fact-64ECF6997744530C84D6D9400CB6B3A3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7660-wk-Fact-08848946AE7005769FAD2BAEDF057297" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7679-wk-Fact-3025F9DDEEC7D0F072402BAEE1A106C0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7698-wk-Fact-7F2462524A28EC8255972BAEE4068CAD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7718-wk-Fact-7188A0C6F73E7791B79C520C64BF8301" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7737-wk-Fact-850F85AC3CD6615EE4842BAE96B84601" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">668</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7756-wk-Fact-DD7D390715A63B6788282BAE9941DFED" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7776-wk-Fact-92F40E1BBD0A42F328252BAE9BB29D4A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7795-wk-Fact-13640870208938B15687520C64CCC363" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">668</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate notes and bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7815-wk-Fact-C9F6B14F7B5F5AD9919ECEB7B20E6BB9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7834-wk-Fact-60C5B2F85714546BA15BA97E90ADC8AC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7853-wk-Fact-AF58706CFFD656CC9D8583432523862A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7873-wk-Fact-F75A6E159FCF517584ED1C85BF784344" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7892-wk-Fact-0FC0067968C75F908461E29FD8CC2139" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">608</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7911-wk-Fact-6FAE2463F9B95789BD48EE6834C7DA51" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7931-wk-Fact-13D5A28FAEDD557BAC0FACAB2CAFBAD0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7950-wk-Fact-05A0BCC7D5E755E69843FC11F47DB59A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">621</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7970-wk-Fact-5C1DA99528125565A0B895EDD7F064AE" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e7989-wk-Fact-E313B4D55289559C8196FA1EE5BCF21B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8008-wk-Fact-CFCCC81940FB59568FE49A9276742F86" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8028-wk-Fact-288C738134C850EEA80E6151C183C9E5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8047-wk-Fact-2872CFA6D99E532FB5FBA20296FDB039" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">226</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8066-wk-Fact-A595D9C50862556DBF384F7ABD50B21A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8086-wk-Fact-2F3581E5AE0E5C6EB98FFD9C0BEA6656" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8105-wk-Fact-D8E10C9496555B4DB49E30BE4AB1FC47" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8130-wk-Fact-E9F7B2FD30F95DFB8302FE2E6F226D18" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8148-wk-Fact-7B1C6AD89DA65DF6906210C7C8394BDD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8166-wk-Fact-949187D11A0E5CF1BA644A82E3A582C5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8185-wk-Fact-248F95949EB15F5F984C6BEEEA40C4F8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8203-wk-Fact-A48D693F043F521FB4E853D6C946CD5A" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,768</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8222-wk-Fact-8257D07B76C95F459D96AB69E3BFBC3C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8240-wk-Fact-89C3223B3F235C049047C95CD86D1541" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8258-wk-Fact-35EAAE1B1BA55300974C6CF4CD469D2F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,785</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8336-wk-Fact-B5D476808F97529E92C0BDBA3D9DB5BE" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">779</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8410-wk-Fact-FD366FEB4E0F59EFB0DD85E8DF2F6AE8" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">838</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total debt and publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8488-wk-Fact-718A8FFC03D35B4590F170BC376274DF" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">843</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e8560-wk-Fact-E46D353E2FE054E7982CB2F28440C610" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,623</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)  </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Unrealized net losses recognized in </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on equity securities still held at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> were </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$<ix:nonfraction id="d15752037e8585-wk-Fact-8196805E3015554ABEBFE50FC56BB84E" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> in the </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">first</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> quarter of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Unrealized net gains recognized in </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on equity securities still held at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March&nbsp;31, 2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> were </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$<ix:nonfraction id="d15752037e8606-wk-Fact-1CDEE3BD00BE5925BEB8121E9104C363" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> in the </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">first</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> quarter of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company also had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e8633-wk-Fact-CCAB7796771F5B5284C0F8734EF34DE8" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">450</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e8637-wk-Fact-401E9783E9809EC9D320C28F98119E3A" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextref="FI2019Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">542</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of equity investments without readily determinable fair values included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Assets</span><span style="font-family:inherit;font-size:10pt;">. During the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized unrealized losses of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e8654-wk-Fact-355B6C72701829FE8E9AC28F98221993" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;"> related to certain of these investments held at </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> based on unfavorable observable price changes. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e8671-wk-Fact-26518A750B75556DB0ABC54FD6C8ECDF" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e8675-wk-Fact-00B7EA528E6954FDBD12470FE9E55D71" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&nbsp;1 having the highest priority and Level 3 having the lowest: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1</span><span style="font-family:inherit;font-size:10pt;"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2</span><span style="font-family:inherit;font-size:10pt;"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3</span><span style="font-family:inherit;font-size:10pt;"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">15</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-6" continuedat="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-7"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-20D35FB5ED585C37AC6F958C356145B6-0-wk-Fact-25A4819A0B6558C5AC9B2C11E6BDC4FF" continuedat="TextSelection-20D35FB5ED585C37AC6F958C356145B6-1" escape="true"><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="32"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">($ in millions)</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign government bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9580-wk-Fact-A797710B4C165F57AF3938F4C8E7930F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9599-wk-Fact-8950572487445A09B1DB8EF491C943BD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9618-wk-Fact-11ACEB9FB3E3546E98A1ADECB6C353CA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9638-wk-Fact-A92463CD0040FA7A0486933D2AEB664E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9657-wk-Fact-45E14FDBDAEA5FE883BE1048CFAE533E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9677-wk-Fact-D18792EED24854C69CE03A05EA88C13C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9696-wk-Fact-FE442A4345EA5FD8B1D0096FA2C89FB9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9715-wk-Fact-91292BCAC12C000525AD933DA5CFFF96" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9730-wk-Fact-2A8B6FED4583E2222B8B7B85E7C9C0A7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9749-wk-Fact-939629D149EA3B1FB3A57B85EAD97F91" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9768-wk-Fact-8890E863A1BEC91912247B85EF9F495C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9788-wk-Fact-2FB9AB4914077EBDD1227B85F380A2A4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9807-wk-Fact-5ABC9E306EA588DF534F7B85F6033F13" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9826-wk-Fact-B0501B95DD40605AF3957B85F9076408" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">668</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9846-wk-Fact-33CCDD3702953F706BA07B85FBA8CF01" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9865-wk-Fact-B37DAEFEA8AAD8FD21037B85FE3DFE9E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">668</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate notes and bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9885-wk-Fact-71FED71406565344B9CFD309ECD0BD6B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9904-wk-Fact-7F59E76DE0B25AB888B9F3885F2FEE98" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9923-wk-Fact-12E90B5CC3345179B90EDCEC92402D7B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9943-wk-Fact-302AD4E682425F6BB5C650FA61D8A29E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9962-wk-Fact-4EB40BAC1803521BB2F1C16EFE222A2F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e9981-wk-Fact-7DAD14A7C2625606AB6F13931FA64548" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">621</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10001-wk-Fact-4BF270E3E4DB5DC2969FA16561BF4887" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10020-wk-Fact-B7920215D96C5226A4708900EE6CB771" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">621</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset-backed securities</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&nbsp;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10042-wk-Fact-248CE7DED296565CABED4C6368FF48AE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10061-wk-Fact-39EBE1238B6D51F4BAB8186A205DF5A4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10080-wk-Fact-18EDEC38248C546F898356D831F55AB7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10100-wk-Fact-2B6557EAD33B5CDD9C71F615B7D1C295" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10119-wk-Fact-6087A0B1AD8A58B2B2212E53D07D983F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10138-wk-Fact-F4644E55DE0550848F77CF39B8F34B0A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10158-wk-Fact-7802EF6138CC50B59640AA518DAC88CE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10177-wk-Fact-82EF9E0AEF485E4D8CD47B5905AA9F63" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10197-wk-Fact-4B813072F4D9589EB4A344A292A32C15" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10216-wk-Fact-482D058F9F3D56AFB3F939FA444902DF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10235-wk-Fact-8EE42F10C9F550C5A9C0A2FB3A05CD7C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10255-wk-Fact-3C9A5125F8FA5A528833883C8AC99C7F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10274-wk-Fact-26244B43C3CE522D90DDF610EC13572B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10293-wk-Fact-677B7039F3C15443A377356C4AF43122" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10313-wk-Fact-1ECBA12C8903506693DADA9C20885E45" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10332-wk-Fact-791DF06849A8510690F18A94C6192E34" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10352-wk-Fact-2DF17B79BF0B5968BCC9C67283664961" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10371-wk-Fact-6DAA815CBFED52F198B20B0E82B75D16" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10390-wk-Fact-E1CA36E969AA5483A8AAD568A3956B55" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10410-wk-Fact-68C820DB2FD15AA5AAA72DE5A076CF80" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10429-wk-Fact-9A41ED3311B45C4CA3CE847ED313E720" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10448-wk-Fact-64DC079168435D51A0122B221A0D6BDC" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10468-wk-Fact-C3F55D3A1113531396FF8A4EAE47D2A6" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10487-wk-Fact-E5EBC0F1373551A38A4B136A2DB025DE" name="us-gaap:EquitySecuritiesFvNi" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10508-wk-Fact-7B849F67E2C05DB0B16C1354142DCA11" name="us-gaap:TradingSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10526-wk-Fact-64800AC4D6E5578FBF3864F606CE17DA" name="us-gaap:TradingSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10544-wk-Fact-CAE44590B61152D08779CD006F308A69" name="us-gaap:TradingSecurities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10563-wk-Fact-145B74029A155201BDEB7A05DAEA7BF7" name="us-gaap:TradingSecurities" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">562</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10581-wk-Fact-37E016513BDA53D4B4A40A47C6160BCD" name="us-gaap:TradingSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10599-wk-Fact-8D73512626465C39A23C29656D0C0F0F" name="us-gaap:TradingSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,725</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10618-wk-Fact-85F0D375E474554683270BE2A8C0A6A6" name="us-gaap:TradingSecurities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10636-wk-Fact-831D0D7AFCC45E548C6C8F392CB448BB" name="us-gaap:TradingSecurities" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,243</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other assets </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10821-wk-Fact-4FD8FDC3C759514CA2C6C11F7BCC23F9" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10840-wk-Fact-0626BCEF10075AC4A31A25CE807AF9E9" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10859-wk-Fact-574B1C5131E25BD195FE53D33441C90A" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10879-wk-Fact-FBA4195B059A549AAE4E08B01D8257FB" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10898-wk-Fact-51F69850BC77571D8A89B8D88BB9448C" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10917-wk-Fact-45E9F9E5850C5DDA953BF5D4FF083749" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10937-wk-Fact-2BE025D800955369B58E616F2275DD09" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10956-wk-Fact-0AF3A0A329E95059BA3687FE30E25BA4" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10976-wk-Fact-D05D6722229B543BB66A520FEE03AF44" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e10995-wk-Fact-610075C8C0985CB197E1DA587363D233" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11014-wk-Fact-A8232F49123B575EBAB9C6592C82109F" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11034-wk-Fact-0E5A9EE3E3AE5DA29385A38DE18883DC" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11053-wk-Fact-827FB64F2FB5509D8C31F02129A9FCE1" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">320</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11072-wk-Fact-5931591D627A547583904AD4BC6DD195" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11092-wk-Fact-54E3E31F5ECC5FECB82C50145A83E985" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11111-wk-Fact-216DBCB673FF5E9180BED16AE69C6462" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">320</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11131-wk-Fact-069D0701532A5BA1B3FB5F0987812A2A" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11149-wk-Fact-6E6CEE2A42CE55C284B74C68FCBAD089" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11167-wk-Fact-F7C21105CA37507B937254DFAA1D9543" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11186-wk-Fact-50D887A9785D596E9667F79F85D135B2" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11204-wk-Fact-84F7FF7143D45884B666479B50A1F099" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11222-wk-Fact-1ED9928DDAF152F28F5F967F53F17C30" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11241-wk-Fact-F61B525089575384A4BCE859B59D55C4" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11259-wk-Fact-E6FD3BD6BFF1598E92964FF55002DE98" name="us-gaap:OtherAssetsNoncurrent" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivative assets </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Forward exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11444-wk-Fact-9E0D2E47D6EC55EA86BB35B75215DEBC" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11463-wk-Fact-32871F1C7A385577A538585B681DDFA3" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">455</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11482-wk-Fact-82EF61B8828458398C0850D63C5D1B4B" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11502-wk-Fact-59C000F46DE650618704CF4B915D22D8" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">455</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11521-wk-Fact-E6F3734F89AB58FAB8BA31DFB9070367" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11540-wk-Fact-D778737B1EEC5CD784C1DDB0D06B6528" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">169</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11560-wk-Fact-844FAA5FD50E5D2095793879F42BB626" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11579-wk-Fact-63F623954A505D0A8682CA1C702C74CD" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">169</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Purchased currency options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11599-wk-Fact-0C8E1400C98053C5A56438376EAB7FDF" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11618-wk-Fact-B0659991E8BB55099A1F5A1BACD662EA" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11637-wk-Fact-F2AA88CEB4FB55CBAED297DDB3F53C96" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11657-wk-Fact-0C4FA8BB5E435ED5A186ADF299373F71" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11676-wk-Fact-6397CD80B6185B538DEEC85F2CCC0163" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11695-wk-Fact-7B7A33BD478259B7995DD040C3196F03" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11715-wk-Fact-3E5F3E4B467B5DD9954DE4E4F0D03EBF" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11734-wk-Fact-F1FD3015FC5D56EABF38B2907CF497FB" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11754-wk-Fact-B74D79FE17EA564B896CCBC137AF8E69" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11773-wk-Fact-46F0528E88215A32BBAF8117ED686478" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11792-wk-Fact-A05D7FD8E9E65751A2CAE3C7A6F73765" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11812-wk-Fact-A091DACB4A1F51B18552A7790744E4BC" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11831-wk-Fact-369B454923105155A916F9EA04025C85" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11850-wk-Fact-653AA93D164E515A943BA4F37D76C6AD" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11870-wk-Fact-7FBF1BB712DF54C686C64B9E416904F4" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11889-wk-Fact-89994A64B28F56878E81B2856F2DA478" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11909-wk-Fact-B513E91DB68F57C4B694218987F697F7" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11927-wk-Fact-E1855AFF4CD05108AA18CB0AB45CCC48" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11945-wk-Fact-4793C636A3195968B67724C13597183B" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11964-wk-Fact-407B7FB862D25A5E8E4D73B3938165A5" name="us-gaap:DerivativeAssets" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e11982-wk-Fact-FBDBBF48ADDD58BCBA9F05D0B1ADE2F1" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12000-wk-Fact-42172B91934F5DFBB7C9177D243C862C" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">288</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12019-wk-Fact-4232364216DD5DBC88698836D7D3E74D" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12037-wk-Fact-F13CD54946315F199DA58E16F602DB19" name="us-gaap:DerivativeAssets" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">288</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12062-wk-Fact-317EDF911AC65DB6AD521D241E40A0A7" name="us-gaap:AssetsFairValueDisclosure" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">841</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12080-wk-Fact-8D3E65BC5AAB5144BC4EA57355F1E506" name="us-gaap:AssetsFairValueDisclosure" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">712</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12098-wk-Fact-6B82131345AE56758C2FF9405790C32F" name="us-gaap:AssetsFairValueDisclosure" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12117-wk-Fact-BD3BC2DE087C592A82BE6F7D36648C18" name="us-gaap:AssetsFairValueDisclosure" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,553</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12135-wk-Fact-A85E3A965BB550CE975DE37ADD897641" name="us-gaap:AssetsFairValueDisclosure" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">898</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12154-wk-Fact-DDB787C9BB6E54AB8E25F722B9F668A9" name="us-gaap:AssetsFairValueDisclosure" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,013</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12172-wk-Fact-8B51F80FF1245DB4B229F5F6353D7EF8" name="us-gaap:AssetsFairValueDisclosure" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12190-wk-Fact-DF0353A9541A53FDB9A6ADC5DC7674FD" name="us-gaap:AssetsFairValueDisclosure" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,911</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12537-wk-Fact-A17EA68B6B305323AB77F3E0B7E51E74" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12556-wk-Fact-682BFCFEBEF757E59671D0296B54B3EA" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12575-wk-Fact-9D7E2C74D702597387939D655EFC9DA0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">694</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12595-wk-Fact-B3FC1DAC9AB356008B1F2DF487874FF8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">694</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12614-wk-Fact-00D3C30602005E41B8AE7FC3D3FC9EDE" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12634-wk-Fact-92DCF74E07565AEE9A0256CBC78EA51F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12653-wk-Fact-1C3EBAD6E9F253E19E2A1829160B4417" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12672-wk-Fact-8BA2C1803A595E0089113C2FD15C13E6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivative liabilities </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Forward exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12852-wk-Fact-7AEE4E098999576B90A451FE6FDE7447" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12871-wk-Fact-B36EEC2379455D2EB36CBE2CEC3E1CC4" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12890-wk-Fact-D2CE5912D5FF58259F11A0CC147FDEDA" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12910-wk-Fact-19CDC46465575D0DBE6852960E17FA22" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12929-wk-Fact-74E3E5B52DA65587984CD8521AEE53F9" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12948-wk-Fact-2B831C403E6A5AD4B4EBE1B37335A8AA" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12968-wk-Fact-F4B8CC36C0985D8BB44C122B300D8B6B" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e12987-wk-Fact-2CB7D1B0E0ED5AFE82771C192C0437EE" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Written currency options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13007-wk-Fact-86384D78FEC250FA906CF08D8F27A5BB" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13026-wk-Fact-73F36F10DAF85BC5B1EB7D12F5F88306" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13045-wk-Fact-BE84F934484151A6B155C526BCBAA606" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13065-wk-Fact-758240BD2030506B94CB57492268E5D8" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13084-wk-Fact-89EBCE91695A568DAAA3F4836FAA9E40" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13103-wk-Fact-620FC0E42B695CBAA6EDFBC1EA4523C5" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13123-wk-Fact-98D3D618F38D563C89B661C01309A81F" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13142-wk-Fact-851643ADC8C556BF84B401ED5B403BE7" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13162-wk-Fact-82157C55BFBC54128BACF3CEDA0F4A51" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13181-wk-Fact-D1B71E190D4158B4A5B7903DDB7A7CDC" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13200-wk-Fact-70A5718225415912841AA75271C71971" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13220-wk-Fact-C89749E69D0657A3995F70EEB47F56EE" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13239-wk-Fact-2F2DA19C1D2054E0B84FDD86BF9179C0" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13258-wk-Fact-B3CF8DA47B70577F95FB0B3408D8FD31" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13278-wk-Fact-94070477CA1A58AA933F85431FFAF75E" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13297-wk-Fact-D5C1C004D529525EA0101CAB53344416" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13317-wk-Fact-8AA3FDABA0D3558094CA85DB7B53FEAC" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13336-wk-Fact-541587CB67005BBBA1FDDEB4C78C1385" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13355-wk-Fact-52AF6930D07F58FE96929909AED8E19B" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13375-wk-Fact-15AD5A62A84F5D5CBC5EBD2E627679A3" name="us-gaap:DerivativeLiabilities" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13394-wk-Fact-74B7F416CB1456A0A6807E84A1A2684E" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13413-wk-Fact-1ACB47ED025959E594D8EBEE1E3A7172" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13433-wk-Fact-21EF0B92FCFE5909AE9D9D6455CCF920" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13452-wk-Fact-8501BB9BB93C5DADAFE8EF889A1FD200" name="us-gaap:DerivativeLiabilities" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13477-wk-Fact-B39830735AB35762914BC0C5FA6E506D" name="us-gaap:LiabilitiesFairValueDisclosure" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13495-wk-Fact-C60F5873EF2857348E3DFCF5BB27D279" name="us-gaap:LiabilitiesFairValueDisclosure" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13513-wk-Fact-08BCA807B2CA52B0ABF576F6771F4EB8" name="us-gaap:LiabilitiesFairValueDisclosure" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">694</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13532-wk-Fact-67F88835FE12501B9DB7BAF70DDED699" name="us-gaap:LiabilitiesFairValueDisclosure" contextref="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">787</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13550-wk-Fact-8DF9244E73F05A01999A0961390FE5E9" name="us-gaap:LiabilitiesFairValueDisclosure" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13569-wk-Fact-AA3E6115A4DA5641B6985E4DFC035FDE" name="us-gaap:LiabilitiesFairValueDisclosure" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13587-wk-Fact-DCB3AD17E87057CA88C48A48C39B49A2" name="us-gaap:LiabilitiesFairValueDisclosure" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15752037e13605-wk-Fact-3A0C776964E65C0F998AA3DB2A404711" name="us-gaap:LiabilitiesFairValueDisclosure" contextref="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">864</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Primarily all of the asset-backed securities were highly-rated (Standard&nbsp;&amp; Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span><ix:nonnumeric id="d15752037e13619-wk-Fact-6E2AC2C2C4F851A5B736F89C11137083" name="mrk:InvestmentsPrimaryWeightedAverageLifeofCollateral" contextref="FD2020Q1YTD_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" format="ixt-sec:duryear">5</ix:nonnumeric></span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> years or less. </span></div></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div></td></tr></tbody></table></ix:nonnumeric><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-20D35FB5ED585C37AC6F958C356145B6-1" continuedat="TextSelection-20D35FB5ED585C37AC6F958C356145B6-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup>&nbsp;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-20D35FB5ED585C37AC6F958C356145B6-2"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div></ix:continuation></td></tr></tbody></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span><span style="font-family:inherit;font-size:10pt;"> included </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e13665-wk-Fact-019537C42FBB5EA4A219FB9C78140207" name="us-gaap:CashEquivalentsAtCarryingValue" contextref="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">6.8</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e13669-wk-Fact-462FD2AE61B177FC2A27BE208D211B82" name="us-gaap:CashEquivalentsAtCarryingValue" contextref="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.9</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">16</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-7" continuedat="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-8"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Consideration</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-712816E0EFD4505E83832082736F6CA1-0-wk-Fact-89D97A4DE5555569841FCB660968B64F" escape="true"><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752037e13799-wk-Fact-419F56AA7F8951BB9F21AD865B46F29C" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752037e13818-wk-Fact-37AA4D531DD55598A181004D0BE23D19" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2018Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">788</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in estimated fair value</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&nbsp;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752037e13835-wk-Fact-B00EBA88F26C5B3394D55D053A637466" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15752037e13854-wk-Fact-806EB3B628175E2ABE70373D6666874A" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">36</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15752037e13875-wk-Fact-264FB0EE3E2759A8826CCE4E022D610E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15752037e13895-wk-Fact-03C6478D5A5A5CE985CAD93000063139" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value March 31 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(3)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752037e13923-wk-Fact-AE7A40289FBC533DB393947B2697FA77" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">694</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752037e13942-wk-Fact-1B5555D5B0A958CF83B5374A26F6D4FD" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2019Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">667</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Recorded in </span><span style="font-family:inherit;font-size:8pt;">Cost of sales, Research and development</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> expenses, and </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Includes cumulative translation adjustments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Balance at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> includes </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$<ix:nonfraction id="d15752037e13972-wk-Fact-4E97EFA5A364506B847F19772CE9226E" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">  At </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$<ix:nonfraction id="d15752037e13993-wk-Fact-B426522A46A98E8F7CB731B56D9E73AE" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2020Q1_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_mrk_SanofiPasteurMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">520</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$<ix:nonfraction id="d15752037e13997-wk-Fact-92E43DEE8210139C4E9131B5C59CD97A" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="FI2019Q4_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_mrk_SanofiPasteurMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">625</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span><ix:nonfraction id="d15752037e14001-wk-Fact-DFDFA318C908FC4E666131B614543329" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextref="FI2019Q4_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_mrk_SanofiPasteurMember" unitref="number" decimals="3" scale="-2" format="ixt:numdotdecimal">11.5</ix:nonfraction>%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span><ix:nonfraction id="d15752037e14006-wk-Fact-62C81A74FD2B8283A3AE31B660E87E82" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextref="FI2019Q4_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_mrk_SanofiPasteurMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitref="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonfraction>%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> to present value the cash flows.</span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increase in the estimated fair value of liabilities for contingent consideration in the first quarter of 2020 primarily relates to MK-7264 (gefapixant), a program obtained in connection with the acquisition of Afferent Pharmaceuticals, following the conclusion of Phase 3 studies evaluating gefapixant for the treatment of chronic cough. The decline in the estimated fair value of liabilities for contingent consideration in the first quarter of 2019 primarily relates to a decision not to pursue an acute cough indication for gefapixant. The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of loans payable and long-term debt (including current portion) at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752037e14028-wk-Fact-11044CA815C7527280AA055D5B90C248" name="us-gaap:DebtInstrumentFairValue" contextref="FI2020Q1" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">30.6</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> compared with a carrying value of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752037e14032-wk-Fact-911CE4607B305F9AA06EA31E1276F9BF" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" contextref="FI2020Q1" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">28.0</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> and at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752037e14040-wk-Fact-F22D553F3C9159B7A38A59B3949C4C0C" name="us-gaap:DebtInstrumentFairValue" contextref="FI2019Q4" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">28.8</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> compared with a carrying value of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752037e14045-wk-Fact-9875DDDE87A05BC08FA05853FB78C2F6" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" contextref="FI2019Q4" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">26.3</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company’s accounts receivable arise from product sales in the United&nbsp;States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&nbsp;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e14061-wk-Fact-09E28B0CB340ABEBA5ADC28FD3245A38" name="us-gaap:AccountsReceivableSale" contextref="FD2020Q1YTD" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.9</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e14065-wk-Fact-66F9F9397B5B3A76687AC28FD30C1AB6" name="us-gaap:AccountsReceivableSale" contextref="FD2019Q4QTD" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.7</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and the fourth quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">de minimis</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e14089-wk-Fact-917DE601B26C5ECB882C75AE54B94C86" name="us-gaap:DerivativeCollateralObligationToReturnCash" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752037e14093-wk-Fact-7603DCCB21315E67B52FD93D787AA35C" name="us-gaap:DerivativeCollateralObligationToReturnCash" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The </span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">17</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-5B709A662DF05BC5A06EB658334DC2CF-8"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obligation to return such collateral is recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued and other current liabilities</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752037e14112-wk-Fact-42EB80473FEB558E8EE2172DB76574BA" name="us-gaap:DerivativeCollateralRightToReclaimCash" contextref="FI2020Q1" unitref="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> cash collateral was advanced by the Company to counterparties as of </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="s188F21C773FA5EE29DBD3E650914777B"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-F7E2B0EB90FF55898AB24E5921024CBA-0-wk-Fact-BB0489BD254A516BA4DF8423361A3FDC" continuedat="TextSelection-F7E2B0EB90FF55898AB24E5921024CBA-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-F7E2B0EB90FF55898AB24E5921024CBA-1"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-ABAC0A62184754708EA5E035D7064908-0-wk-Fact-C68DEA0F9D2754429E74A35A49F7F253" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e510-wk-Fact-A514A8ACBA105B6AA238637B31D8DA9B" name="us-gaap:InventoryFinishedGoods" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,753</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e529-wk-Fact-F70288401A0B50E6815514AD20120D35" name="us-gaap:InventoryFinishedGoods" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,772</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e544-wk-Fact-56CC5E321FDE5D4D8BD98C5FE958F8D0" name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,629</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e563-wk-Fact-E1951DA9F54F50378A7512B5FF574667" name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,650</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e583-wk-Fact-AC99BD812B6D51FB9C7960A9D0E00B58" name="us-gaap:OtherInventorySupplies" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e602-wk-Fact-D1F4ED23DB625D2DBECE65CED94347BD" name="us-gaap:OtherInventorySupplies" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">207</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total (approximates current cost)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e622-wk-Fact-5BCFDD06868F5284B8835A1D642F4C43" name="us-gaap:InventoryGross" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,614</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e641-wk-Fact-18E53E9056E05C44B3F2AD9C19639B85" name="us-gaap:InventoryGross" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,629</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decrease to LIFO cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15741909e661-wk-Fact-7EE9C45184C754D098B4BEE564E068FE" name="us-gaap:InventoryLIFOReserve" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15741909e681-wk-Fact-5105653C3B54511CADBD9AFB519A9F9D" name="us-gaap:InventoryLIFOReserve" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e707-wk-Fact-6AAFE6282A5757288734ED096F6199C6" name="mrk:InventoryNetAndInventoryNoncurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,476</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e726-wk-Fact-99CC7262AEE051218013EB4997F0363F" name="mrk:InventoryNetAndInventoryNoncurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,458</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognized as:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e787-wk-Fact-91377BBF40D05BD6B9F3FF82427A7C37" name="us-gaap:InventoryNet" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,846</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e806-wk-Fact-4F981ABF5D425F9CAC720E56BF97A2DE" name="us-gaap:InventoryNet" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,978</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e821-wk-Fact-EBC0A7C86CEC5A908420E2771EE4B5D8" name="us-gaap:InventoryNoncurrent" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,630</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15741909e840-wk-Fact-6A3260C196A05B68B50387099FCFAAD7" name="us-gaap:InventoryNoncurrent" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,480</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recognized as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Assets</span><span style="font-family:inherit;font-size:10pt;"> are comprised almost entirely of raw materials and work in process inventories. At </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, these amounts included </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15741909e876-wk-Fact-EC5BC571DEBF5301BB27DB2D4CC92A73" name="us-gaap:InventoryNoncurrent" contextref="FI2020Q1_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15741909e880-wk-Fact-A88870D1A06F5377992D27299D8ABFA8" name="us-gaap:InventoryNoncurrent" contextref="FI2019Q4_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of inventories not expected to be sold within one year. In addition, these amounts included </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15741909e885-wk-Fact-431AB10CA6B65A0C945F21F921E47B5E" name="us-gaap:InventoryNoncurrent" contextref="FI2020Q1_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoriesProducedinPreparationforProductLaunchesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">258</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15741909e889-wk-Fact-8F23DA031ED05AB7BB80B137A1E208C5" name="us-gaap:InventoryNoncurrent" contextref="FI2019Q4_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoriesProducedinPreparationforProductLaunchesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, of inventories produced in preparation for product launches.</span></div></ix:continuation><div><a id="s0B18214A61675D709F35CD2D74DB650A"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-0-wk-Fact-36557F3C424E5E8FAF4EFB5364117F70" continuedat="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-1" continuedat="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-2"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&nbsp;what claims, if any, will survive dispositive motion practice, (ii)&nbsp;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&nbsp;how the discovery process will affect the litigation, (iv)&nbsp;the settlement posture of the other parties to the litigation and (v)&nbsp;any other factors that may have a material effect on the litigation.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. <ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:LegalCostsPolicyTextBlock" id="TextSelection-FB121E6BE182553F94861151810ACD19-0-wk-Fact-7D647FCD159450F6B60B48F2CC4E2BD1" escape="true">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</ix:nonnumeric></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Liability Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span><span style="font-family:inherit;font-size:10pt;"> Litigation). As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752302e481-wk-Fact-86E8BCEDF0B2532E89B940DDE237242F" name="us-gaap:LossContingencyPendingClaimsNumber" contextref="FI2020Q1_srt_ProductOrServiceAxis_mrk_FosamaxMember" unitref="Case" decimals="0" scale="0" format="ixt:numdotdecimal">3,590</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Glynn v. Merck</span><span style="font-family:inherit;font-size:10pt;">, the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s </span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">18</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-2" continuedat="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-3"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">motion for judgment as a matter of law in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Glynn</span><span style="font-family:inherit;font-size:10pt;"> case and held that the plaintiff’s failure to warn claim was preempted by federal law.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Glynn</span><span style="font-family:inherit;font-size:10pt;"> case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752302e510-wk-Fact-B9C8387551885796829522057710D21D" name="us-gaap:LossContingencyClaimsDismissedNumber" contextref="D2014Q1Mar_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember" unitref="Case" decimals="0" scale="0" format="ixt:numdotdecimal">650</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> cases on preemption grounds. Plaintiffs in approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752302e514-wk-Fact-0CADAD3F39375F1A8E6E212035174F1C" name="mrk:LossContingencyClaimsonAppealNumber" contextref="D2014Q1Mar_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember" unitref="Case" decimals="0" scale="0" format="ixt:numdotdecimal">515</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Merck filed its initial brief on February 21, 2020, as required by the District Court.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, as of </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752302e526-wk-Fact-8B81F310AE1153C087F9C3CF514CE474" name="us-gaap:LossContingencyPendingClaimsNumber" contextref="FI2020Q1_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember" unitref="Case" decimals="0" scale="0" format="ixt:numdotdecimal">970</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> cases were actively pending in the Femur Fracture MDL.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752302e537-wk-Fact-5445EC9E50EF509585B66A36E517AF2A" name="us-gaap:LossContingencyPendingClaimsNumber" contextref="FI2020Q1_srt_LitigationCaseAxis_mrk_NewJerseyStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember" unitref="Case" decimals="0" scale="0" format="ixt:numdotdecimal">2,345</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752302e548-wk-Fact-D741BEE0C8695F939080F819B6E91C4A" name="us-gaap:LossContingencyPendingClaimsNumber" contextref="FI2020Q1_srt_LitigationCaseAxis_mrk_CaliforniaStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember" unitref="Case" decimals="0" scale="0" format="ixt:numdotdecimal">275</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, there are </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752302e555-wk-Fact-2897999A4D2F5E18A17EFBD27EB34C88" name="us-gaap:LossContingencyPendingClaimsNumber" contextref="FI2020Q1_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember" unitref="Case" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> Femur Fracture cases pending in other state courts.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits. </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia/Janumet</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;"> and/or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, Merck is aware of approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752302e580-wk-Fact-20AFDC12531B5297AE4ECE8665E5C46B" name="us-gaap:LossContingencyPendingClaimsNumber" contextref="FI2020Q1_srt_ProductOrServiceAxis_mrk_JanuviaMember" unitref="Claim" decimals="0" scale="0" format="ixt:numdotdecimal">1,410</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> product users alleging that </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;"> and/or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> caused the development of pancreatic cancer and other injuries. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2015, the MDL and California State Court–in separate opinions–granted summary judgment to defendants on grounds of federal preemption.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceeding agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Daubert </span><span style="font-family:inherit;font-size:10pt;">motions. Under the stipulated case management schedule, the hearings for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Daubert</span><span style="font-family:inherit;font-size:10pt;"> and summary judgment motions are expected to take place in the second half of 2020.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752302e617-wk-Fact-CDB4D99D97AD581B9D47D336D902D986" name="us-gaap:LossContingencyPendingClaimsNumber" contextref="FI2020Q1_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_JanuviaMember" unitref="Claim" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="font-family:inherit;font-size:10pt;">(relating to the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span><span style="font-family:inherit;font-size:10pt;"> matter discussed above). Merck filed the opinion in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Albrecht</span><span style="font-family:inherit;font-size:10pt;"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Albrecht</span><span style="font-family:inherit;font-size:10pt;">, that preemption presents a legal question to be resolved by the court.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752302e642-wk-Fact-9B0172599A0D507BB9A4580A1BD04D6A" name="us-gaap:LossContingencyPendingClaimsNumber" contextref="FI2020Q1_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" unitref="Claim" decimals="0" scale="0" format="ixt:numdotdecimal">50</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional claims. The Company intends to continue defending against these lawsuits.</span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">19</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-3" continuedat="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-4"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vioxx</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vioxx</span><span style="font-family:inherit;font-size:10pt;">. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Governmental Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. In February 2020, Merck received a subpoena for documents. Merck is cooperating with the California Attorney General’s investigation.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commercial and Other Litigation</span></div><div style="line-height:174%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Litigation</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia</span><span style="font-family:inherit;font-size:10pt;"> alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants’ motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. Trial in this matter has been rescheduled to begin on February 23, 2021.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto Litigation</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the Company was served with a complaint in the United States District Court for the District of New Jersey, seeking to certify a nationwide class action of purchasers or users of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto</span><span style="font-family:inherit;font-size:10pt;"> (fluralaner) products in the United States or its territories between May 1, 2014 and December 27, 2019.&nbsp;The complaint contends&nbsp;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto</span><span style="font-family:inherit;font-size:10pt;"> causes neurological events and&nbsp;alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. A similar case was filed in Quebec, Canada in May 2019.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, </span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">20</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-7CC87AB4B9725ED09DE63A47BA5CCE7C-4"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion </span><span style="font-family:inherit;font-size:10pt;">—</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion</span><span style="font-family:inherit;font-size:10pt;"> (sugammadex) Injection.&nbsp;In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&nbsp;These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. No schedule for the cases has been set by the courts.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia, Janumet, Janumet XR</span><span style="font-family:inherit;font-size:10pt;"> — In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet XR</span><span style="font-family:inherit;font-size:10pt;"> following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026, and a later granted patent owned by the Company covering the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan) in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single 3-day trial on invalidity issues in October 2021. The Court will schedule separate 1-day trials on infringement issues if necessary. In the Company’s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has settled with three generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2019, Mylan filed a petition for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inter Partes</span><span style="font-family:inherit;font-size:10pt;"> Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of the 2026 patent. The Company filed a Patent Owner Preliminary Response in the IPR proceeding in February 2020. The Company expects the USPTO to determine whether it will institute the IPR proceeding in May 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In Germany, a generic company has sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;">. If the generic company is successful, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> could lose market exclusivity in Germany as early as July 2022. It is possible that challenges to the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet </span><span style="font-family:inherit;font-size:10pt;">SPC could occur in other European countries.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Defense Reserves</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> of approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752302e789-wk-Fact-DDD85CB77A7859C985AB43F213ECDCA7" name="us-gaap:LitigationReserve" contextref="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752302e793-wk-Fact-570F680DB14257B083701E20011EFD2A" name="us-gaap:LitigationReserve" contextref="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div></ix:continuation><div><a id="sDBADF3F742D3503881089BE717A9D9AA"></a></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">21</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-8FA08DC0CA83517F966B73EC98D6D7BC-0-wk-Fact-12632236850C5D4A88968D1E7B9A2000" continuedat="TextSelection-8FA08DC0CA83517F966B73EC98D6D7BC-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</span></div></ix:nonnumeric></td></tr></tbody></table><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="TextSelection-756DD8ADAD3E5910AB3FF4A954DAE5FA-0-wk-Fact-2A3DEEF4DE6658378D7492A848D166D3" escape="true"><ix:continuation id="TextSelection-8FA08DC0CA83517F966B73EC98D6D7BC-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="26"></td></tr><tr><td style="width:31%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="vertical-align:middle;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;vertical-align:middle;">&nbsp;&nbsp;</span></div><div style="text-align:center;vertical-align:middle;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;vertical-align:middle;">Common Stock</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Paid-In</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Capital</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Earnings</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">controlling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interests</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ and shares in millions except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Par&nbsp;Value</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e904-wk-Fact-2C83E898CD7F5DC0AEC67F24653071A5" name="us-gaap:CommonStockSharesIssued" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,577</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e918-wk-Fact-D33724388C17582EB6C1819CD717AA6E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,788</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e932-wk-Fact-B7874C517BFC5F069E8BF8A59FED8F45" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,808</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e946-wk-Fact-A1CF7ABB918E5368A35D711E753418C0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42,579</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e961-wk-Fact-537F1009EB0D5ED1875BDB8335B13271" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,545</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e971-wk-Fact-369C9124331053EA83718F74FF8EDDD0" name="us-gaap:CommonStockSharesIssued" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">985</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e985-wk-Fact-8EB7DCE64B2A50D3956916C2E57F3605" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">50,929</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1000-wk-Fact-A13D95FED43A50F7A15D4C022831E727" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1015-wk-Fact-59072768C77F53FEA120F877E5EF5294" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,882</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income attributable to Merck&nbsp;&amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1067-wk-Fact-42E87301AEF25ACDB9424E9B782B243D" name="us-gaap:NetIncomeLoss" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,915</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1134-wk-Fact-7B12A10282AB516C82FAAF50CA9DD77C" name="us-gaap:NetIncomeLoss" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,915</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other comprehensive income, net of taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1206-wk-Fact-22D1F097FB425FDD805B2E679B5FF0A0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1258-wk-Fact-5DDA604723695D8DA0AEA7B451DECC03" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash dividends declared on common stock ($0.55 per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1315-wk-Fact-16BD45712E945F4BADDA1DC1FF972656" name="us-gaap:DividendsCommonStockCash" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,429</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1383-wk-Fact-73D8FE994F1356F7965010B24FD37A2E" name="us-gaap:DividendsCommonStockCash" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,429</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury stock shares purchased</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1470-wk-Fact-52DC4922FF935B108ED8DAFF21B36A48" name="us-gaap:TreasuryStockSharesAcquired" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1479-wk-Fact-8363627428F35436A91FEB5A7D6BDFC4" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,090</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1509-wk-Fact-153B934B48675F35BFA7DDA9A4BFED11" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,090</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation plans and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1553-wk-Fact-3A121F469F7D54C5BAC47BDACCB54EB4" name="us-gaap:StockholdersEquityOther" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1597-wk-Fact-6E4ABD6BD6C452589A3F7310037AA875" name="us-gaap:StockholdersEquityOtherShares" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1607-wk-Fact-07D456B46D0B52AFA74BE6AB29F6ECFC" name="us-gaap:StockholdersEquityOther" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">283</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1636-wk-Fact-1BF0BB94CEC8549FA40F862527C3A50C" name="us-gaap:StockholdersEquityOther" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">243</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1745-wk-Fact-6BA9F3972117552EAFFB839DCB9DE7C9" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1761-wk-Fact-58CCAAA7F575509AAA16BEEA0BCB273C" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other changes in noncontrolling ownership interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1871-wk-Fact-D217EF620CC85DE1A15DAEF324F7D727" name="mrk:Noncontrollinginterestchangesinownershipinterestother" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1886-wk-Fact-6C4F737D83D15111BB91EA66153DFD77" name="mrk:Noncontrollinginterestchangesinownershipinterestother" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1907-wk-Fact-CA7479C71DCB53019990179F133E37C0" name="us-gaap:CommonStockSharesIssued" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,577</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1921-wk-Fact-1CAEE0E0148655019AC7E37048527DB8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,788</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1935-wk-Fact-CB00C006944258B792399BBF494A2A52" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,768</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1949-wk-Fact-2AEC0CEEB7A153F38686D5CAA2EE5A8E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">44,065</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1964-wk-Fact-55EC21C3647E5974916A7C2945AD7F31" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,346</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e1974-wk-Fact-736D4A5A5DCB54BBB076ED8D0019F6F2" name="us-gaap:CommonStockSharesIssued" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">994</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e1988-wk-Fact-BC8B3AFE97165131B2BE13344414D81E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">51,736</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2003-wk-Fact-670BF34C4AEF5D27AF5E5BC16A46CEBF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2018-wk-Fact-F19002459DC85BB8B4214449C2944D6A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27,670</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2033-wk-Fact-9AD49BAC8DB05D9EAE71D5B0CF62AE10" name="us-gaap:CommonStockSharesIssued" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,577</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2047-wk-Fact-C2F6C97AB0A15D75AF19FE4C671AEFA2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,788</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2061-wk-Fact-312A20C088705EB486789F93B55FF7CB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,660</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2075-wk-Fact-24422443A8AC5A9593A430B4AD51C79A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46,602</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2090-wk-Fact-5C581E0AC9E558A79233D67DF948B826" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,193</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2100-wk-Fact-67DB3BB187D25A82996E1B9B32DB44DC" name="us-gaap:CommonStockSharesIssued" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,038</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2114-wk-Fact-D50D7EAE8B155FD489761A41CAC78B72" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55,950</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2129-wk-Fact-00A94B0AFC6A564690E9FC9930EA24D6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2144-wk-Fact-5C82559F23195F7B847A42E82C4148CE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,001</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income attributable to Merck&nbsp;&amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2196-wk-Fact-8680F6DBF0AC5A0EA3E1AF60FF4F0D58" name="us-gaap:NetIncomeLoss" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2263-wk-Fact-9DE27B9844CD5D60A33395D3FD63C368" name="us-gaap:NetIncomeLoss" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other comprehensive loss, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2335-wk-Fact-AA7F3FDB85055F4F8DD9CC79D0FA3E84" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">198</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2388-wk-Fact-7085DCD4612F51A7AE6CF1F8B9639395" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">198</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash dividends declared on common stock ($0.61 per share)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2446-wk-Fact-77FFE23AAB805FE6B706EEC6878327C4" name="us-gaap:DividendsCommonStockCash" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,549</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2514-wk-Fact-0066C399AE96560CB21BE30CD15FD58E" name="us-gaap:DividendsCommonStockCash" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,549</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury stock shares purchased</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2601-wk-Fact-3D553454E0845348AE849F419953B376" name="us-gaap:TreasuryStockSharesAcquired" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2610-wk-Fact-63ECDD0284905384AE694FDFC32E2E7D" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,281</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2640-wk-Fact-228C94D6E17D5626B754754AC2557982" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,281</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation plans and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2684-wk-Fact-176F7D575BF85B23BA739523DC3F14B6" name="us-gaap:StockholdersEquityOther" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">37</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2727-wk-Fact-3A720F607DF25CEBA0307FBCC22F7DCC" name="us-gaap:StockholdersEquityOtherShares" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2737-wk-Fact-D17FD05BA20655AFA60779261BBB49E2" name="us-gaap:StockholdersEquityOther" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">70</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2766-wk-Fact-2F863770DFFE537BAB5798D44CE38A82" name="us-gaap:StockholdersEquityOther" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">107</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other changes in noncontrolling ownership interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2875-wk-Fact-74D8377564955135BD14C3D3DE6008A1" name="mrk:Noncontrollinginterestchangesinownershipinterestother" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2890-wk-Fact-CAE6E1D9A7955F8DB521C827D42F6F75" name="mrk:Noncontrollinginterestchangesinownershipinterestother" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2910-wk-Fact-1BD9745C931553888B0406845D9A5894" name="us-gaap:CommonStockSharesIssued" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,577</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2924-wk-Fact-69E2C58A2155559E9F82E385B493D042" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,788</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2938-wk-Fact-FB7EDFF30ADE570BAE5C7510E818CF7C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,697</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2952-wk-Fact-C35E92687DA15B0C889AF518BA4B15C9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48,272</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2967-wk-Fact-1E8A3B9FD5EE587BB72FDCCB76D1ED09" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,391</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e2977-wk-Fact-C9E58D005E19562DA50A2477AEBC42AC" name="us-gaap:CommonStockSharesIssued" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,053</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonfraction id="d15755686e2991-wk-Fact-0E4C2892910A5944961B0B3FDDB6C163" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">57,161</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e3006-wk-Fact-180DD81BD1E05EF2AAC9D0F7B255DECA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonfraction id="d15755686e3021-wk-Fact-DCA80302EE4456349004593316814A69" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,300</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.6640625%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:continuation></ix:nonnumeric><div><a id="sCE213381CFCB581282692ED4E44A7B4D"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-AC29E7ABF8A65F2ABFBCD395EA9DEC6F-0-wk-Fact-D00D236E49E857F1B1232355BCCD69C7" continuedat="TextSelection-AC29E7ABF8A65F2ABFBCD395EA9DEC6F-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Compensation Plans</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-AC29E7ABF8A65F2ABFBCD395EA9DEC6F-1"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.</span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-E24842ED80B7536997529E67EF1BDF51-0-wk-Fact-75CC61941AFB542AB5546D62B1429D34" escape="true"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pretax share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752708e553-wk-Fact-CA2DBAF14F4B519AA559EC786715BFED" name="us-gaap:ShareBasedCompensation" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752708e572-wk-Fact-DF860C036A7E58A69A4D560BB1906DB5" name="us-gaap:ShareBasedCompensation" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15752708e587-wk-Fact-2299D12EEA4E5C5AB43BD603BC940ABE" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15752708e607-wk-Fact-B198BDBB829E5D898A4478751D5C03A7" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total share-based compensation expense, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752708e633-wk-Fact-1BAD46D70B9258BF9C71E5A00D1B3784" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752708e652-wk-Fact-77DE8581645A55679B8155575ABF0CAE" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, the Company granted </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752708e679-wk-Fact-A96A3CA0E34057BFB5BA2B56A03E8E85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextref="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitref="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonfraction> thousand</span></span><span style="font-family:inherit;font-size:10pt;"> RSUs with a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752708e683-wk-Fact-A321932CB6AB50539FE5F081DDC1DCA9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">85.66</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> per RSU and during the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> granted </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15752708e698-wk-Fact-CB463DC6793F52A78145F745F37CF980" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextref="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitref="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">70</ix:nonfraction> thousand</span></span><span style="font-family:inherit;font-size:10pt;">&nbsp;RSUs with a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15752708e702-wk-Fact-8CB91172C9F8574C8FCC1B2E4D2E1927" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">77.39</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> per RSU. During the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752708e715-wk-Fact-42F790CCE50D59F19673FCBD5AD60D9A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextref="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitref="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">770</ix:nonfraction> thousand</span></span><span style="font-family:inherit;font-size:10pt;"> PSUs with a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752708e719-wk-Fact-CD9805A86A8159E0A4B9282E41A654EE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">75.65</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> per PSU and during the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> granted </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15752708e733-wk-Fact-EB34ED6BE3F85E2890E7F77106CCB0B3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextref="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitref="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">609</ix:nonfraction> thousand</span></span><span style="font-family:inherit;font-size:10pt;">&nbsp;PSUs with a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752708e738-wk-Fact-3A97201BC21D5050984A97901A4CBDD1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">90.50</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> per PSU. <ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-B770A0DEDF15581BB1E4AC2B4E89C8B0-0-wk-Fact-CEA4977504A15C52A3FAA56FF3B78916" continuedat="TextSelection-B770A0DEDF15581BB1E4AC2B4E89C8B0-1" escape="true">The Company did not grant any stock options during the first three months of 2020 or 2019. </ix:nonnumeric></span></div><ix:continuation id="TextSelection-B770A0DEDF15581BB1E4AC2B4E89C8B0-1"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15752708e759-wk-Fact-A91D32408FBB5E7AB269E2B40E2F3C50" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextref="FI2020Q1" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonnumeric id="d15752708e763-wk-Fact-55C54836689F50868A11F121D1A91434" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextref="FD2020Q1YTD" format="ixt-sec:duryear">2.4</ix:nonnumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. The Company typically communicates the value of annual share-based compensation awards to employees during the first quarter, but the related share amounts are not established and communicated until early May. Therefore, while the number of RSU, PSU and stock option grants disclosed above do not reflect any amounts relating to the annual grants, share-based compensation costs for the first quarter of 2020 and 2019 and unrecognized compensation expense at March 31, 2020 reflect an impact relating to the awards communicated to employees. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.84375%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;&nbsp;</span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:continuation></ix:continuation><div><a id="s8EB4D309C46C57DC9CC99ED57216A848"></a></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">22</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-766DEC69049D5DE883BA8E22936E924A-0-wk-Fact-F49015721F5C5E48B2887A16668DC20B" continuedat="TextSelection-766DEC69049D5DE883BA8E22936E924A-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pension and Other Postretirement Benefit Plans</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-766DEC69049D5DE883BA8E22936E924A-1"><ix:nonnumeric contextref="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="TextSelection-F71642FC6CA05BA8B535CF55BF842AEC-0-wk-Fact-98B93223AC575C8CB53637C9AD5966EA" continuedat="TextSelection-F71642FC6CA05BA8B535CF55BF842AEC-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:</span><span style="font-family:inherit;font-size:9pt;">&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="16"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;&nbsp;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">International</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e726-wk-Fact-87421417B06D55C6AA9BF5920A274945" name="us-gaap:DefinedBenefitPlanServiceCost" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e745-wk-Fact-067BF527934E587AACF6815B6FE93439" name="us-gaap:DefinedBenefitPlanServiceCost" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e764-wk-Fact-23F45EC0520458FCAD0FAC9AA2BFFE3F" name="us-gaap:DefinedBenefitPlanServiceCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e784-wk-Fact-880B744D7E75586AB6CEA249D4124881" name="us-gaap:DefinedBenefitPlanServiceCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e799-wk-Fact-54343103CD215B82A32697F2D1977EC4" name="us-gaap:DefinedBenefitPlanInterestCost" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e818-wk-Fact-4ACF00C3A2B753FF98A63FF0438B26AF" name="us-gaap:DefinedBenefitPlanInterestCost" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e837-wk-Fact-5ED5D3A52EE65C4E9201F177BD72644E" name="us-gaap:DefinedBenefitPlanInterestCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e857-wk-Fact-EBB7EF5841ED5C3A9D43E67377703F9E" name="us-gaap:DefinedBenefitPlanInterestCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e877-wk-Fact-73D7608D6D7C59C59AA06F231DDD80D1" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e897-wk-Fact-3FC986B4E3685AADA7BAB9D11BD2C6DD" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e917-wk-Fact-61BD99FE2ED5545CA3A5379C8FBD9D98" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">206</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e938-wk-Fact-444758EECCA3533796100409FE94EBA1" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e959-wk-Fact-081E228FF1B851A09E5B99AFAFCAEF70" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e979-wk-Fact-4446797FA6F350599B1DE8410B0225D2" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e999-wk-Fact-2EF61FFAFAE8579C888BC3DFC7CD61A7" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e1020-wk-Fact-0E110E4D29D1587F9BA83F6A09E24380" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1041-wk-Fact-5387EC8914405B448391D69E03A776FB" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">75</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1060-wk-Fact-ECFDA08E183658F99664A3FE28701A62" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1079-wk-Fact-FBC320C2C68E529382E3F063C6E9910C" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">35</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1099-wk-Fact-EA76EBC289E95D59941A79D43736689C" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1119-wk-Fact-20E64E314B7655119A3E553FD9E98F22" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1138-wk-Fact-9D41FB72168B5032A67B6E6589FDCB3D" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1157-wk-Fact-93A6257536035BF28CFC628F082EBE62" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1177-wk-Fact-746D8AD7B68957A9948FDE7C66D56929" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Curtailments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1197-wk-Fact-E11810C2B0C8596B9A5433C239EBEC80" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e1216-wk-Fact-4AF58112B7035160B7019862B48534FF" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1236-wk-Fact-DB7BDCFA92615D56891D39D6ED0D4224" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1256-wk-Fact-EE08E8B5EF425D08BF2BE7BB53513BFD" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1281-wk-Fact-076D5FA1AF035B63A466A1E1C7FE7F81" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1299-wk-Fact-8F3FC011F8F553AB84B2A741323EA18E" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextref="FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1317-wk-Fact-79A652D3C203508490598F2C4EF0441F" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1336-wk-Fact-50530FDA77385DC7BB1C83AA129B43FE" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div></ix:nonnumeric><ix:nonnumeric contextref="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="TextSelection-F029AEEDB04E50CC8EB2C0968FD838F1-0-wk-Fact-28CA2ED6CEB25494816DD4CBA7C7A4B4" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-F71642FC6CA05BA8B535CF55BF842AEC-1"></ix:continuation>The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="font-family:inherit;font-size:9pt;">&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1476-wk-Fact-AA32771A183E59C4BFBBC1DA026D9888" name="us-gaap:DefinedBenefitPlanServiceCost" contextref="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1495-wk-Fact-FBA25872DFBC5BA0A64F8EA806C356B1" name="us-gaap:DefinedBenefitPlanServiceCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1510-wk-Fact-0E769D55DDF7502EBFC3D1EFBB2DCD10" name="us-gaap:DefinedBenefitPlanInterestCost" contextref="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757186e1529-wk-Fact-8C878EE8663A599D8771E7249AC3DC5F" name="us-gaap:DefinedBenefitPlanInterestCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e1549-wk-Fact-50594E5FF2A85771BC1F2CEFDFB5B60B" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextref="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e1569-wk-Fact-62F03D2C4B0E50DD8AD0DAA79881F22C" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextref="FD2019Q1QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e1590-wk-Fact-FDB4D9CD67975C389A19D08F7E53158F" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextref="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">22</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e1610-wk-Fact-258FDDA6850A57619B0899F649C40725" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextref="FD2019Q1QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">21</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e1636-wk-Fact-B6FA2B00FC48522B95701F833D903A3D" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextref="FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757186e1656-wk-Fact-C167522BBE5D5480AECF68B51F624D79" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextref="FD2019Q1QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension plans as reflected in the tables above.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;"> (see Note 11), with the exception of certain amounts for termination benefits and curtailments, which are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring costs</span><span style="font-family:inherit;font-size:10pt;"> if the event giving rise to the termination benefits or curtailment is related to restructuring actions as noted above.</span></div></ix:continuation><div><a id="sFA1FC3E29FA9568295FD3A38375383B6"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">11.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="TextSelection-7732A7947A8153F9BD8679A5BD86E371-0-wk-Fact-DD109F5A42395E5898F1C927DC0CDE56" continuedat="TextSelection-7732A7947A8153F9BD8679A5BD86E371-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other (Income) Expense, Net</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-7732A7947A8153F9BD8679A5BD86E371-1" continuedat="TextSelection-7732A7947A8153F9BD8679A5BD86E371-2"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-1A380435B17352AC97722C0FD83C9002-0-wk-Fact-6AEA34D2DABA5060B1F3E9953B0209AE" continuedat="TextSelection-1A380435B17352AC97722C0FD83C9002-1" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net, consisted of:</span><span style="font-family:inherit;font-size:9pt;">&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757834e552-wk-Fact-11430EDFED9B5A91A4F12A821E40EF96" name="us-gaap:InvestmentIncomeInterest" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757834e572-wk-Fact-C8426FCF606B5FE884D37EF832DE5B24" name="us-gaap:InvestmentIncomeInterest" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757834e588-wk-Fact-D1083F10372357EAAD7143A055D172F0" name="us-gaap:InterestExpense" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">212</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757834e607-wk-Fact-52395EA31A575D26BF0D4D89EA7B7368" name="us-gaap:InterestExpense" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exchange losses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757834e627-wk-Fact-1EF67B57C689515F99F9A0BBF6B5E8BD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">54</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757834e646-wk-Fact-208BD5F024C554679297BB58163E5A09" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">101</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss from investments in equity securities, net </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757834e668-wk-Fact-DE7C9F5F0C0851A9A341D6833C9F6042" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757834e688-wk-Fact-97CA905C3FCA5B99A995D10B4AE616F4" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">25</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic defined benefit plan (credit) cost other than service cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757834e708-wk-Fact-A5D6895E5A275BAA9FF4570B5D427EA4" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">90</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757834e728-wk-Fact-8F96B08FBC6B5C679A667125B04DB50C" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">141</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15757834e749-wk-Fact-5F44AB2A2DE55D10A13545820452405C" name="mrk:OtherNonoperatingIncomeExpenseOther" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757834e769-wk-Fact-BB0689B580E15803B5C7BC815E945DC4" name="mrk:OtherNonoperatingIncomeExpenseOther" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">83</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757834e794-wk-Fact-BF3F141D6DBB50E6868729F8668306DA" name="us-gaap:OtherNonoperatingIncomeExpense" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">71</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757834e813-wk-Fact-666DAA4ADD06583890FC628151F9D47F" name="us-gaap:OtherNonoperatingIncomeExpense" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">188</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:nonnumeric><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-1A380435B17352AC97722C0FD83C9002-1" continuedat="TextSelection-1A380435B17352AC97722C0FD83C9002-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-1A380435B17352AC97722C0FD83C9002-2"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. </span></div></ix:continuation></td></tr></tbody></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The higher exchange losses in the first quarter of 2019 reflect losses on forward exchange contracts related to the acquisition of Antelliq Corporation.</span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">23</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-7732A7947A8153F9BD8679A5BD86E371-2"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net (as reflected in the table above) in the first quarter of 2019 includes </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15757834e842-wk-Fact-F2AEE9E274A054E1C863CDAB7C076891" name="us-gaap:GoodwillImpairmentLoss" contextref="FD2019Q1YTD_us-gaap_StatementBusinessSegmentsAxis_mrk_HealthcareServicesSegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of goodwill impairment charges related to certain businesses in the Healthcare Services segment. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest paid for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15757834e861-wk-Fact-A234A3552A65517EB8E163F9AC45008F" name="us-gaap:InterestPaid" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonfraction id="d15757834e865-wk-Fact-DBFDC74D122D556786BE91C0AD0A595B" name="us-gaap:InterestPaid" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">195</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><a id="sC59D5082483C555A8306E24F16CE268C"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-1CF46D06099F583AA8ED64E0CE6DC5E3-0-wk-Fact-2EE1A85D18B45761B9BFE5F1444AC114" continuedat="TextSelection-1CF46D06099F583AA8ED64E0CE6DC5E3-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Taxes on Income</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-1CF46D06099F583AA8ED64E0CE6DC5E3-1"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective income tax rates of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonfraction id="d15757938e431-wk-Fact-6E8573801BDA58C199AB81EC4802683A" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="FD2020Q1YTD" unitref="number" decimals="3" scale="-2" format="ixt:numdotdecimal">16.1</ix:nonfraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15757938e435-wk-Fact-5C56F11142185D08BEAD768C83EF4A89" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="FD2019Q1QTD" unitref="number" decimals="3" scale="-2" format="ixt:numdotdecimal">6.7</ix:nonfraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. In addition, the effective income tax rate for the first quarter of 2019 reflects the favorable impact of a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15757938e452-wk-Fact-9C45689055845BF09523E9C56E4B63BD" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextref="FD2019Q1QTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> net tax benefit related to the settlement of certain federal income tax matters. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15757938e459-wk-Fact-7738AF31D34D5D2F9F3C1E22939150BB" name="us-gaap:IncomeTaxesPaid" contextref="FD2019Q1QTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15757938e463-wk-Fact-9C45689055845BF09523E9C56E4B63BD" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextref="FD2019Q1QTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> net tax benefit in the first quarter of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div></ix:continuation><div><a id="sC35992097ECC58A8BD25B499B8DECC8F"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">13.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-BF9446C0E212548AAC4996B6136D4CCC-0-wk-Fact-689EB70077B65C68AA1C030C02E0E1CE" continuedat="TextSelection-BF9446C0E212548AAC4996B6136D4CCC-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings Per Share</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-BF9446C0E212548AAC4996B6136D4CCC-1" continuedat="TextSelection-BF9446C0E212548AAC4996B6136D4CCC-2"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-2C437227723452F9BE165F44EFE6D64D-0-wk-Fact-65C51E9BFA8B5DE89E2FA639B5F1E60C" continuedat="TextSelection-2C437227723452F9BE165F44EFE6D64D-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The calculations of earnings per share are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ and shares in millions except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Merck&nbsp;&amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e550-wk-Fact-9DE27B9844CD5D60A33395D3FD63C368" name="us-gaap:NetIncomeLoss" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e569-wk-Fact-7B12A10282AB516C82FAAF50CA9DD77C" name="us-gaap:NetIncomeLoss" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,915</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e584-wk-Fact-1D70B2EF67BE59BBA1A42DF38013B750" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextref="FD2020Q1YTD" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2,533</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e603-wk-Fact-32355C6F7EBA5F08934CE8EDA895CF7C" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextref="FD2019Q1QTD" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2,585</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common shares issuable </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e625-wk-Fact-D1A8C2DDA07552BC802327E348A3924A" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextref="FD2020Q1YTD" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e644-wk-Fact-C4F3868EA2DB5690A8ABA702B41A0FE1" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextref="FD2019Q1QTD" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common shares outstanding assuming dilution </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e664-wk-Fact-DF45925F880D57B6A855CB66922160F1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextref="FD2020Q1YTD" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2,547</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e683-wk-Fact-1ECD489EE5EB5C1F9E44EB696451FC3A" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextref="FD2019Q1QTD" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2,603</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e708-wk-Fact-E9B2BAB59E005621ABF759FA7DE6CB80" name="us-gaap:EarningsPerShareBasic" contextref="FD2020Q1YTD" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.27</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e727-wk-Fact-AD8F01DE48D653EB85908354120B977D" name="us-gaap:EarningsPerShareBasic" contextref="FD2019Q1QTD" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.13</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e747-wk-Fact-9A79A20D9C695260BF1EF2B9C3AB5DCB" name="us-gaap:EarningsPerShareDiluted" contextref="FD2020Q1YTD" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.26</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e766-wk-Fact-79862A7BB20B5295BA119BCE55E1DA4A" name="us-gaap:EarningsPerShareDiluted" contextref="FD2019Q1QTD" unitref="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.12</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div></ix:nonnumeric><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-2C437227723452F9BE165F44EFE6D64D-1" continuedat="TextSelection-2C437227723452F9BE165F44EFE6D64D-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-2C437227723452F9BE165F44EFE6D64D-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Issuable primarily under share-based compensation plans.</span></div></ix:continuation></td></tr></tbody></table></ix:continuation><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><ix:continuation id="TextSelection-BF9446C0E212548AAC4996B6136D4CCC-2" continuedat="TextSelection-BF9446C0E212548AAC4996B6136D4CCC-3"><span style="font-family:inherit;font-size:10pt;">For both the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15758419e806-wk-Fact-6FB5E9B335715215BBA32642226A42B3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="FD2019Q1QTD" unitref="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-BF9446C0E212548AAC4996B6136D4CCC-3"> of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</ix:continuation> </span></div><div><a id="s60795C9CE1995C63889143F6B90F59AC"></a></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">24</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">14.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="TextSelection-B95EB98C79905047BADDC6F5A1FB3DB6-0-wk-Fact-F090162EFABB5B11804AD5D3474AECD6" continuedat="TextSelection-B95EB98C79905047BADDC6F5A1FB3DB6-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Comprehensive Income (Loss)</span></div></ix:nonnumeric></td></tr></tbody></table><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-1ABE99F0A14E5BCEBD896C0B70EE10AE-0-wk-Fact-080E957F4C2E53D7BA0C226402CD8076" escape="true"><ix:continuation id="TextSelection-B95EB98C79905047BADDC6F5A1FB3DB6-1"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> by component are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="20"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivatives</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Investments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Employee</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Plans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cumulative</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Translation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjustment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income (Loss)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance January 1, 2019, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e710-wk-Fact-E27EFE0F82C1508C944A2DB736361FF4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">166</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e729-wk-Fact-A8D33C6C6B42540D8CFA4F44EFF72D6A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">78</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e749-wk-Fact-3B0099B2982D5311832C4DEDC1D8F339" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,556</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e770-wk-Fact-C3AB5A035F2E516B976D4F577CC3316B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,077</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e790-wk-Fact-537F1009EB0D5ED1875BDB8335B13271" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,545</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e806-wk-Fact-C7DDB9B4D7A756D8879622BB1E8DC9D8" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e826-wk-Fact-14F692424EBE56D7A23D9F3BD24558CB" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e845-wk-Fact-B10451018A6E5511B0F6E500B562E91B" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e866-wk-Fact-5B2A1C6A08A15EACA38E2A15F72D1CB8" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">156</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e885-wk-Fact-92AD4C8F412150CA81D3AFA20F9D89A6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e905-wk-Fact-C8389606BD22542A80CCA62C0F882595" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e924-wk-Fact-07160A3E1A8050C9A9F5EE2AA17CEC69" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e943-wk-Fact-6F5D74DBBE3252078B90CB358B0F5E29" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e963-wk-Fact-F114041FF2855513906068B60F79192C" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e983-wk-Fact-7804BB7A110B5B6099F54687C7E84840" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1003-wk-Fact-B4F8D5E89F6A593BAD0A94CD5AD22BA8" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1023-wk-Fact-E1E241C7945E58369879E909822D7C86" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1042-wk-Fact-33E710E19EA959F98F59F01D93064CCD" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1062-wk-Fact-7ABE1583713D59279A4E241A99BE244E" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1081-wk-Fact-5A8979F11EC558B2B513603CE0BF77F6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1101-wk-Fact-957F952313AB5E2F9FF66237914BFE4A" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1121-wk-Fact-735D342A439C59A498E777AE3B01D667" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup>&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1140-wk-Fact-07D152E4ACC95882BBB5BE17CBF8B794" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup>&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1160-wk-Fact-1E553EB7D8435218B4A4138E0D187FE6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1179-wk-Fact-889127B67D555311859AA682DA2F9A81" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1200-wk-Fact-AC3E14836DC959859D4E28158C16887F" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1219-wk-Fact-95F6645D622952C0829B4622737BDA7D" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1238-wk-Fact-45C09C294A495A45B4F34AF33D63B7AC" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1259-wk-Fact-BBAAB8F978745572B5A00CBD2E470141" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1278-wk-Fact-49D10CA83080529C990C3E528430F726" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1298-wk-Fact-10AD26CB95745E4EA9D408E6861701DD" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1317-wk-Fact-9751C69EC0515F4BB429FE70E798F999" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1335-wk-Fact-04CC1F3D5BEA52E7AEF26F3C2779B474" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1354-wk-Fact-31F3E672FCCD58F0B870915E57B396DC" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1373-wk-Fact-18CDACDA6E5E539EA0B480A901ED36BB" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss), net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1394-wk-Fact-56F9967913785696ABFAF881731E13DB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">48</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1414-wk-Fact-90527A28F7945B5C9C005DAF8C88DAC6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1433-wk-Fact-C6D74DF5450C58FF926B6398CB3014D9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1453-wk-Fact-CE9AA863AE595BFEB44AF944EC67B3CC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1472-wk-Fact-7EDF15BDBDBF51B482D56AFFC86D8A55" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance March 31, 2019, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1497-wk-Fact-4D6B467710E25051BA99B8FE4C08E056" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">118</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1516-wk-Fact-96FD9CF4230B57A2BE36FDBA8A346D65" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1535-wk-Fact-C75B43A1A8B053408EAFEE4B7F2075F7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,541</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1556-wk-Fact-53F67BA65149511CBC06EA0E1E6FD890" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,927</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1576-wk-Fact-55EC21C3647E5974916A7C2945AD7F31" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,346</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance January 1, 2020, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1598-wk-Fact-E695B0B26DDB5E4CABF71FCFB7C462AA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1617-wk-Fact-E9373FC10D4C5BA2B46A0DFD00E39234" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1636-wk-Fact-E102AE9291F35C6090A8C9D96F8DD9B6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,261</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1657-wk-Fact-0B2895248A23568BB9A34BDE58788B79" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,981</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1677-wk-Fact-5C581E0AC9E558A79233D67DF948B826" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,193</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1693-wk-Fact-7373E4C74C03538E8B94D1C36CDDC1EA" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">178</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1712-wk-Fact-E06BFA0D31D35084BF7A841D8AACB80F" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1731-wk-Fact-1465680289FC57C7AAD3920E9FE4C642" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1751-wk-Fact-12E3A55014A256CD8E718E3ED3668FA1" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">333</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1771-wk-Fact-5FEBC2F3500F58319FB4A6500802C743" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">152</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1792-wk-Fact-6F95075DB12257DBA7070BCBF60D4C43" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1812-wk-Fact-C592CEBB9A0B51B5B5703556369DF746" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1831-wk-Fact-4D52D7A6AEF95B809DFDA1A1BE709100" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1851-wk-Fact-2BBA7CA980955C3D855D99485A0CA768" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1871-wk-Fact-9A7127598549544CB63247B2215A1DB8" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1892-wk-Fact-2B349297A4875AEF8093E0B222EFD5CC" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1911-wk-Fact-23176BEB39B35E0BA6981612843D061A" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e1930-wk-Fact-ECBC11B12C7656D3B3C82F25A3CAFCE6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1950-wk-Fact-CEA7EC831A355E5886E20AFCC5A31A32" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">344</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1970-wk-Fact-CCFCF4BF880154DFBFE46345381281E3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">195</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e1991-wk-Fact-D2823F78763853BDB66D176839B9BCD8" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2011-wk-Fact-3CC59CEA8609501BB580F041DF3DA3FE" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup>&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2031-wk-Fact-9A88C7B5F3C250468158786182D3FF1E" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">69</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup>&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2051-wk-Fact-5869E197C01E5C49BB5A77C321267925" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2070-wk-Fact-A82EA7CCC06C596AB4C3429387AAEDC9" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2090-wk-Fact-8677A9650DB9577F8366B36808D15393" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2109-wk-Fact-45114DC5D3415260B3521E553EAB91C8" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2128-wk-Fact-57BBD51FDE1A5AD29104F3B96F5C3515" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2149-wk-Fact-64455A854D1B58BE907A3E47943ECA78" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2168-wk-Fact-67D8D4AA38C957B0A74516B4E4544EE7" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2189-wk-Fact-23E688003CC055B6BFFC87B44DB8DA83" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2208-wk-Fact-A26C0D56C0CB5B139CFBA699C994546F" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2227-wk-Fact-0EDF535921A45F439570F56B18AB2C72" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2246-wk-Fact-A4049825DC9656829F024994C136FA18" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2265-wk-Fact-B32438FB702956C7B780522AC85BC927" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss), net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2286-wk-Fact-D7EAF5F4246A5BB1BA7E2DE0248310F0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2305-wk-Fact-BFEB865876D8571DA144410888A77D8B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">18</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2325-wk-Fact-5DCDA4C6B8E35814B3166BCA5D008576" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2345-wk-Fact-3F1F5BF058505546B9FABCB2546BBDAC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">344</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2365-wk-Fact-FB7B73E1583257B08FF24DB183829375" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">198</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance March 31, 2020, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2391-wk-Fact-CEBF88BC657F5FD8906BB593EE498CCD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">135</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonfraction id="d15760837e2409-wk-Fact-941F3E8B509E5A84ABC9522398309774" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2427-wk-Fact-7C385A64293A5EB3B16E2747D6B8147E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,201</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2447-wk-Fact-9B770A0DC16C5679AF5DD68FD05FCB21" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,325</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonfraction id="d15760837e2466-wk-Fact-1E8A3B9FD5EE587BB72FDCCB76D1ED09" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextref="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,391</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></tbody></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Relates to foreign currency cash flow hedges that were reclassified from </span><span style="font-family:inherit;font-size:8pt;">AOCI</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> to </span><span style="font-family:inherit;font-size:8pt;">Sales</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></tbody></table><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)  </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from </span><span style="font-family:inherit;font-size:8pt;">AOCI </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">to</span><span style="font-family:inherit;font-size:8pt;"> Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. </span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)  </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 10).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:39.453125%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:continuation></ix:nonnumeric><div><a id="s58FB1429E6FF5555B6CEDC7597861FBC"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">15.</span></div></td><td style="vertical-align:top;"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:SegmentReportingDisclosureTextBlock" id="TextSelection-79643DC486A759929D9356592B7F019C-0-wk-Fact-1F1FE942C564535B9D31F6A955F6E9D9" continuedat="TextSelection-79643DC486A759929D9356592B7F019C-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Reporting</span></div></ix:nonnumeric></td></tr></tbody></table><ix:continuation id="TextSelection-79643DC486A759929D9356592B7F019C-1" continuedat="TextSelection-79643DC486A759929D9356592B7F019C-2"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s operations are principally managed on a products basis and include </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e431-wk-Fact-1C034D04A79F5A2F87046814577C6FC1" name="us-gaap:NumberOfOperatingSegments" contextref="FD2020Q1YTD" unitref="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonfraction></span></span><span style="font-family:inherit;font-size:10pt;"> operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&nbsp;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">25</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-79643DC486A759929D9356592B7F019C-2" continuedat="TextSelection-79643DC486A759929D9356592B7F019C-3"><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="TextSelection-0C96B5B0C00E5FFABAE09F4A85E9E442-0-wk-Fact-9D517359B539529787E35A0656EB15B6" continuedat="TextSelection-0C96B5B0C00E5FFABAE09F4A85E9E442-1" escape="true"><div style="line-height:120%;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of the Company’s products were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="24"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">&nbsp;($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Int’l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Int’l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pharmaceutical:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Oncology</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Keytruda</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1118-wk-Fact-12D5B615EA065B789F119AB276ED67DF" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,906</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1137-wk-Fact-217A3BBC568B565985A8AE620F88A265" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,378</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1156-wk-Fact-759128F54E5A5D768138ACDE33B8F29C" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,284</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1176-wk-Fact-6CC9255410A858C1B06DF5AE7B25D301" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,284</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1195-wk-Fact-088AEF8C16E757DEB848112214258CB4" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">985</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1215-wk-Fact-420D4FA1DDE05DC4818B469664CAA591" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,269</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Lynparza</span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&nbsp;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1232-wk-Fact-B3F717B722855F8AB7DD680E2D3DB3BE" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1251-wk-Fact-835135A6091F5913BE207872D58507D0" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1270-wk-Fact-556A5643E4A65EFDAF37ABD79496AD3C" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1290-wk-Fact-7A78F730341257E681254045AC4FFB81" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1309-wk-Fact-BE3520B58D445B86928A9E7FF2403B9C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1328-wk-Fact-0857839877805BA49590727CE4CF27FC" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Lenvima</span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&nbsp;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1351-wk-Fact-156375C0A50A5D288637033C42CC89B4" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1370-wk-Fact-A13F6AD5017657348CF702F8E3653635" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1389-wk-Fact-57D66ACA2F855236B4893C6CEADFAFEE" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1409-wk-Fact-0CCB9D8B0D405860913072F691362F69" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1428-wk-Fact-3EECACC577665996936561B50D80659A" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1447-wk-Fact-4304F67B87D8568BBD28294C2F78B8BC" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Emend</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1468-wk-Fact-9672129353345B2597E6A8CD68033828" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1487-wk-Fact-5A74D71CF83F5377AE3DCF6FBF6B32D4" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1506-wk-Fact-F328E44737785F1FB3A80B9CD9BDB59E" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1526-wk-Fact-DBD413C9F03E52CCA2CABECB65996346" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1545-wk-Fact-1D14F15031CC5043B63ABC9352102A8D" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1564-wk-Fact-4BE36A2ED7235635895B3A25E9ED71E5" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">117</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Vaccines</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Gardasil/Gardasil </span><span style="font-family:inherit;font-size:7pt;">9</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1710-wk-Fact-0B96DBA34BE35CCAA20DC3515F9D9569" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">461</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1729-wk-Fact-6F74FB57B323547BA52548B95FC550A7" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">636</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1748-wk-Fact-E5953BC985F25952985E8D9A7F26F8E1" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,097</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1768-wk-Fact-81B976724AA156678989FF0D677DAE8B" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1787-wk-Fact-3E7A0E8FF43D507ABEDD58B81DA35EB2" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">476</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1806-wk-Fact-109F2A11998F5F3997962155A5E38D09" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">838</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">ProQuad/M-M-R </span><span style="font-family:inherit;font-size:7pt;">II</span><span style="font-family:inherit;font-size:7pt;font-style:italic;">/Varivax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1832-wk-Fact-48FB7AA1C1415AAF83FF1F906D241823" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">333</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1851-wk-Fact-D3C654FD051554829DB3DB796B74F8D1" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1870-wk-Fact-867E967620A05FC5AF96D7A28CE2A13B" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">435</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1890-wk-Fact-DD2217ABB9D65876AFD2A8A240C25A09" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1909-wk-Fact-664842FFFAD85657A1024D09756642DF" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1928-wk-Fact-0C4EF191FE215C3385813B74F26013EC" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">496</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Pneumovax </span><span style="font-family:inherit;font-size:7pt;">23</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1951-wk-Fact-61EB05B8845D58549D6D7107F5E775C8" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1970-wk-Fact-8FD2F112FBF85BA0BE6718ABBC3C22A6" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e1989-wk-Fact-E3EDDC86175751C18EB3EBE2C84475A9" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2009-wk-Fact-7BF8295ACDCB591796A8E8777AF8E3AD" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2028-wk-Fact-F3EE38515C5E5ADDB7DFA5BDD6244AD2" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2047-wk-Fact-F2BDC43CA0385708A5818DD485480F2A" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">RotaTeq</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2068-wk-Fact-EC1B32352DB95A1B8B8DBB68AF4DAA01" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2087-wk-Fact-194EEDCBD74957FA94B54A3271A53D30" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2106-wk-Fact-6E88F7AEE0AA55D686FC7DA51EF4F6A1" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2126-wk-Fact-8B8ECF98BF0B5AA2A762A97EFA429E42" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2145-wk-Fact-A5D092CBA72D50C4880190E1FF818DCE" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2164-wk-Fact-B519A205B69F53CBA2C9C8CF58358FDE" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Vaqta</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2185-wk-Fact-7D9E768C17165D059946EC6113872034" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2204-wk-Fact-EE88EDF5FBC75BF0834AD40FD2B77FC8" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2223-wk-Fact-8BDF710B17D75AE29AA02BDC55124056" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2243-wk-Fact-24EDC426AA17544DBBEDF0A467A68C2B" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2262-wk-Fact-6D182A4452965FA2A3697291EE2EE66C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2281-wk-Fact-FF58109BF1D75914B6F812BCD4B07A8C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VaqtaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Hospital Acute Care</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Bridion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2425-wk-Fact-15DE3100E93554A7827C3CA7432438AC" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2444-wk-Fact-2302129614CB5A25B092504AE334DDD0" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">157</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2463-wk-Fact-B2AD40DE92ED53AA962EA26724D0D747" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">299</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2483-wk-Fact-9C9B7BAD127150A3893B6F9493A6A15B" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2502-wk-Fact-0DE972B76D9055B4ADE725E64DC8E35D" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2521-wk-Fact-892D2EC60FDB58D890605729ED309F4D" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Noxafil</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2542-wk-Fact-AFEEE20E744E5E3680926A54F327FCA8" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2561-wk-Fact-45D7F2A7C27E5FCDB651B61BFF285690" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2580-wk-Fact-14AA6AECC0FA53BB806FCA5321035BE7" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2600-wk-Fact-CC0D03EAD7EC5252952F6E447D2BE1E4" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2619-wk-Fact-30A35DA4803E5061AB09880FFBDF1E1C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2638-wk-Fact-70292C8355945828ABCF46AB38D50278" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Invanz</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2659-wk-Fact-F035934E449D57F9B7906A345483267E" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2678-wk-Fact-6AA4396C4ED258D980752599946E5FEC" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2697-wk-Fact-EAFD88BDF84C5761AAD543EA16D8D29A" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2717-wk-Fact-F28449F724915128BEAFB420807A09F2" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2736-wk-Fact-4C5EF89536595D29B1D968A05266A4D2" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2755-wk-Fact-47A0AB5F4EBB533F9EF1C6984CA21546" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Prevymis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2776-wk-Fact-86012AF3D2473BDBA4CC32A8A34583D8" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2795-wk-Fact-B1AC22A02A3982B3F0CF32A8A33EA17D" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2814-wk-Fact-6C634C232F3F4B00230032A8A3340975" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2834-wk-Fact-8745DAE670A1E180BFA632A8A2A6C4F0" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2853-wk-Fact-3843BBE227EB824229E732A8A31AA1FA" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2872-wk-Fact-A3C4618842FC2FEFFF8232A8A29C06C5" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrevymisMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cancidas</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2893-wk-Fact-8E0707EC70C3505C8ED73D4256481F49" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2912-wk-Fact-54CB504F152750C889AA189F65A0C667" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2931-wk-Fact-A953E824DD8C584AB003BDF3B999BBD8" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2951-wk-Fact-9D2874D442B15A9D8684263E90952522" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2970-wk-Fact-413C3AE348F756B9960511A7E1EEEC3C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e2989-wk-Fact-743548FA550058ABBFDC47D86EEC0C86" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Primaxin</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3010-wk-Fact-44495DAD72A05F8E932F9E2A54E52AC2" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3029-wk-Fact-D8F8F2ECB047582EA91362968D50E1F3" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3048-wk-Fact-996A984FC6BB5F79B7F7136B951E3124" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3068-wk-Fact-A154918A56BD5FF7B7F4C798D7780F36" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3087-wk-Fact-FE1496BE5B745D6EA78DA7270F47BFDC" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3106-wk-Fact-38337F8DAF6752A29AB0CBCDA4506716" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cubicin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3128-wk-Fact-59E7308508105A2BB845264E8074088B" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3147-wk-Fact-96D5B142F8D05327B64EBAB22AC11733" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3166-wk-Fact-52403CEE70065820BFA7D6FB5BD45EA0" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3186-wk-Fact-DE1DB8CBE5D7528AA8A8A7B4A3F90FC9" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3205-wk-Fact-B02F92F857E3542485225F23AE23DAD5" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3224-wk-Fact-A41CFB3C34BF5F0AB861133F166A84BC" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zerbaxa</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3245-wk-Fact-277BE2B0E8EB49D0F2B2931A189F290A" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3264-wk-Fact-3A30989B33BBAEBBCD29931A18DC9078" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3283-wk-Fact-28B2DED90A65D6D3D2BD931A190D9FAA" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3303-wk-Fact-B76A172661583ABD2720931A196B3923" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3322-wk-Fact-430B1DFD17E69470ACC7931A193D43FF" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3341-wk-Fact-539EEBE896697E2E8902931A19977E72" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZerbaxaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Immunology</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Simponi</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3485-wk-Fact-589789D9A2F15FC69EC19D23BE2A60FB" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3504-wk-Fact-B4B4CCE8B07C5F2CB881C1162AA2266F" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3523-wk-Fact-CF6C87CCBFB95769B80D3F166E9132A9" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3543-wk-Fact-9B41A07014CA52369CF7EF175C309831" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3562-wk-Fact-B916790E265D5D32B47597DCA6716194" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">208</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3581-wk-Fact-18AB242F9A0F57A69DDF4468963F6774" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">208</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Remicade</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3602-wk-Fact-C6F0399923BA5326B37B42DE994E7A94" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3621-wk-Fact-44DD28560D365D51B7E369654E8E4705" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3640-wk-Fact-1BEC61F0FF955F888F809C7AFBB7C290" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3660-wk-Fact-31E640DECD075AB0A3D14A839F349483" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3679-wk-Fact-148AB9419B5559B5B1318664F2D73732" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3698-wk-Fact-31F34B7AEEB450DC805A2FF4F3B84D22" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Neuroscience</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Belsomra</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3842-wk-Fact-EC453DF3AB89513ABA6660C62163C089" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3861-wk-Fact-F1E50739619D5FBBB664597DE5BAA44E" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3880-wk-Fact-4CCCEC5268C258D4A4D768B23DB9FC4A" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3900-wk-Fact-E87872E481A35DC596C9FA5F3F098D7E" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3919-wk-Fact-400C194A6AEB5E8D881594489DD87C9A" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e3938-wk-Fact-0BFC473131BE57A994429BD6DBF7D0F3" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Virology</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Isentress/Isentress</span><span style="font-family:inherit;font-size:7pt;">&nbsp;</span><span style="font-family:inherit;font-size:7pt;font-style:italic;">HD</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4086-wk-Fact-D0506FA3132B563AA0783231B27DAB85" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4105-wk-Fact-B040D4C023BF563A82955530384258DB" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4124-wk-Fact-1D55F64051B8503F88C372395F3932CA" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">245</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4144-wk-Fact-374FB441681150959C8F8C38AC6019CD" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4163-wk-Fact-BD5E5B3B3E6550EC87B8AD322BDD68F8" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4182-wk-Fact-6CEC87621EB059FE9FED388F8BA2E4E1" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zepatier</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4203-wk-Fact-AAC9EB6140005C1D973DCD32E7E71CB9" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4222-wk-Fact-2A5351381A0E5D3A919E38A7A297FF1A" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4241-wk-Fact-1072B6D803695AEC8E9CF7BCEBE73894" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4261-wk-Fact-993EDFDBB7F15D69BFCAB0B12048681E" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4280-wk-Fact-BC00FF72CBE759CA872A4CF005737E5D" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4299-wk-Fact-F15E41097197517FA69ABD752089D3BC" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Cardiovascular</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zetia</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonfraction id="d15770370e4444-wk-Fact-7F15E7978A9A5EE89917E1CA302D44FF" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4464-wk-Fact-07EA663BC4A75CEB84546EF85E845592" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4483-wk-Fact-82833580A0AC58898DF8B8C8D10BDF99" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4503-wk-Fact-1759D632BBC551DEAB5930764FA6A3FB" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4522-wk-Fact-2F8786208A2B53DBABCC21F75974AF5A" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4541-wk-Fact-BB178CE0F3D5518CB275227D5BE495CC" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Vytorin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4562-wk-Fact-037B980A4D2B53758CB34B50FAACC780" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4581-wk-Fact-C893929F84EC5BC1A8DF763842B54DF5" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4600-wk-Fact-52BCF37ECEAE5D85AE859BF41221E780" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4620-wk-Fact-927E7B299A8F50BC8868B23A075E6F0F" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4639-wk-Fact-0BD2891DAA5959FB91DF9A4B463DD69E" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4658-wk-Fact-2EF54BD9B60257C1B6396D023984B1F3" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Atozet</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4679-wk-Fact-178637E35A585B869737E65BE96EFB50" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4698-wk-Fact-B25EE02307665BCE930C7EEFA1598968" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4717-wk-Fact-DF3C0E5C1E8B54D3AD00F27B5F656420" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4737-wk-Fact-142122DDCF4E5364A77543088E838B29" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4756-wk-Fact-42A25953C9FB56678B499F7F928854DE" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4775-wk-Fact-72F0A6B1E8325DDFBDF33114D7937CF8" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Adempas</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4796-wk-Fact-22329E17AA0454A4972BEE4B6CD76472" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4815-wk-Fact-7263D70BF50B5A95AA211D6D8B34CF08" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4834-wk-Fact-2B4D86E2C4BB5202AEC4636DC43EC504" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4854-wk-Fact-85B1706B92C858D59A8352860D2D32F8" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4873-wk-Fact-1AB99DB4E2F8547582453627ADA8E20F" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4892-wk-Fact-F902343E31915E298E2626768BB9A9E9" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Adempas </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4915-wk-Fact-F057704A5788BC40E699931DC6F05B78" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4934-wk-Fact-000411CEB4814C9F8CDC931DCC138FA3" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4953-wk-Fact-957F436033F6A3DAD53B931DD07BCE89" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4973-wk-Fact-AF5BCA6ED25B5B5340DF931DD31E87B3" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e4992-wk-Fact-9FC585BC09501128CDDF931DD6792463" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5011-wk-Fact-7E16DB90B627F6F77D01931DDAC64106" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AllianceRevenueAdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Diabetes</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Januvia</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5155-wk-Fact-6DA4B343D5415088B5EC33E7CA98FFBC" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">355</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5174-wk-Fact-E5CB1F05B72D5E7DB8440E5E8891BE22" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">419</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5193-wk-Fact-79EE35F6E4F55D23B65ECFDDC343362F" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">774</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5213-wk-Fact-E69884B079F7526B9ED43700D8423619" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5232-wk-Fact-C73A367F07D95A6A8CD65A706D49A29B" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">440</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5251-wk-Fact-A8C36342B5905D69AC5B05B7A7856153" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">824</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Janumet</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5272-wk-Fact-A493F2062E8A54B79AAD4926F697A4CE" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5291-wk-Fact-EC15D05F939D5FA384E069AB65DFD4EA" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">390</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5310-wk-Fact-247907A9360C5DB4A4CEDB4C155ED2BB" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">503</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5330-wk-Fact-D032A07C2092526E963760C8D07C6CFE" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5349-wk-Fact-CD991D9BA2505E5389E18FB6854A198E" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">364</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5368-wk-Fact-2EDBFDEF352B564496B711E22B5279CD" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">530</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Women’s Health</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Implanon/Nexplanon</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5512-wk-Fact-F46A03D26CBF51C1AB86CE79E217A0AC" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5531-wk-Fact-C17C37AA666C52CBBCAAEC2DF0BAF2DC" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5550-wk-Fact-FFD10AA5F96C53AC902C15F7F9C593A8" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">195</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5570-wk-Fact-49858F2EC3615AF39A0B1936E7BE948E" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5589-wk-Fact-3E9B0F39835D534193F28561983CBA61" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5608-wk-Fact-77F85C40B4A45E158867CF23A3A5742F" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">NuvaRing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5629-wk-Fact-AF79EFEF48AB58928897FDE8A5B9FCF4" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5648-wk-Fact-A317ADC9A10C5D21887AA62906234CED" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5667-wk-Fact-E9028B8EC6595C33A66274BC239A39A2" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5687-wk-Fact-838E1BA5A4A75B24908CBA6FD965B793" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5706-wk-Fact-A2FCCA371DC259F0BE32C3777C2E1D75" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5725-wk-Fact-DC06E55DF7FB57039959824AA41D8F1F" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">219</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Diversified Brands</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Singulair</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5870-wk-Fact-A5492CD6304159919C83F32D9C929AAE" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5889-wk-Fact-BC4D15E6CE105796800E37D7B9449B43" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5908-wk-Fact-CB11A6E62D8B58159CAEE286337192F5" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5928-wk-Fact-B24DBFD77ED156C6886A51E40F78295D" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5947-wk-Fact-C49EF327284D50B1A71C3D3693914AEF" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">186</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5966-wk-Fact-AF20890028E258F1A2F56AE1BC50AC00" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cozaar/Hyzaar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e5987-wk-Fact-BC078614118F5F23B61AA0041B70CBC8" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6006-wk-Fact-4CD91540A91250DE9F6005A695FB24B7" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6025-wk-Fact-AFC6D5EAC42A594485707690A846DB25" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6045-wk-Fact-044A2C5AF8B654B886580EDBBBB49D40" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6064-wk-Fact-82CBC98C43395A619780159C3F4604D3" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6083-wk-Fact-28F0A070B20E507C9CD96B39023E5140" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Nasonex</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6104-wk-Fact-781D52E96B4A527EB688D5B11908ECC3" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6123-wk-Fact-3924149EF041523E8F17DAA09CE94F99" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6142-wk-Fact-041C01CA8D005319A07312D092292A75" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonfraction id="d15770370e6162-wk-Fact-CE90F787F10A5D059825555AC0C58DC1" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6182-wk-Fact-3A18FFE2D1E850CFB69B116BF89884F5" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6201-wk-Fact-ED9BCB1E9DF45DBCA08489C674FD8EA0" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">96</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Arcoxia</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6222-wk-Fact-F9F2B23290765AAF9AC1092399F6DA80" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6241-wk-Fact-6F7C2145337A5D329D6C3BDF9270A8DA" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6260-wk-Fact-FAECE5E148845812A30AC1AF845B7FB4" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6280-wk-Fact-FCC6364423A95C54B6BC0DFD7A1A60E0" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6299-wk-Fact-2CE92F617E185397BA2109CAA1F4B375" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6318-wk-Fact-E2FF8BEBB52F588B861F46AD2B5B8068" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Follistim AQ</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6339-wk-Fact-64E815C5FB5D59068D454466289CA18B" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6358-wk-Fact-50BBF470A7B25AE2AE4065DEFA502117" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6377-wk-Fact-D9181A7FCB5D504E82E133343BB303C1" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6397-wk-Fact-8FAB7ACAC2DA51E182FFF71B89D86DC1" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6416-wk-Fact-2D56820AEB1B5FA6B86C26B71B7C327D" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6435-wk-Fact-B27BFA4CF831513A99D34430532BA8C1" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other pharmaceutical </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6458-wk-Fact-7C06538D7CC459FE867CEA31C233C53F" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">409</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6477-wk-Fact-49D2828BBFEE59DF9A352152DBDD99EA" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">780</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6496-wk-Fact-1E3E31362A99530896918DB169472646" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,194</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6516-wk-Fact-738994E4698F556DACD61DC6996DDFFA" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6535-wk-Fact-AFC4C151EADA50EB84DA17DD6B935B23" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">754</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6554-wk-Fact-5333516A82D95D37B80DDA73DAD6646A" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,082</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total Pharmaceutical segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6575-wk-Fact-0E30BB686D035FF59B94B6180D60CD15" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,714</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6593-wk-Fact-05C56815A2265E8AAB9934DA8964A3F8" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,941</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6611-wk-Fact-707BD1F5B3B6571197AE5F1042FAFBA4" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,655</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6630-wk-Fact-720DE040EEA657B59D7B3F19E065367C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,215</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6648-wk-Fact-8BED6DD6D2DB58159965B79A7CC7145C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,448</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6666-wk-Fact-08A97B6CAE6C567B8EAAFE0F93FBD509" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,663</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Animal Health:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Livestock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6810-wk-Fact-59FFE469D473514788A296BB10F2295C" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6829-wk-Fact-0F3C14CD656B557795B79E60E1419BA9" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">577</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6848-wk-Fact-A865992ECBCE56C691F4B4E8DD4F9890" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">739</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6868-wk-Fact-120BEE7294BA54A4BDB0D027581D466B" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">117</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6887-wk-Fact-D35A6CE4961C549E982605BF37D31A9A" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">494</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6906-wk-Fact-778375EC12055C84900C67292B89295D" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">611</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Companion Animals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6927-wk-Fact-862C3B67C6B25A8CA5195B5594942CF1" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6946-wk-Fact-0D1BDA78CD5B57AE84AD659194E62024" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6965-wk-Fact-55FDE40E4F015C3987629C90CA89F87E" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">475</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e6985-wk-Fact-11B09BE0C573560B8154311E3AEDDF69" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7004-wk-Fact-FE4461E76DEA59298DD2BAFF8C925A51" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">237</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7023-wk-Fact-EC093692E12E5753A08455C65ABC207C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">414</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total Animal Health segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7045-wk-Fact-6895764AA28D50EE83FEC6A0B18D146F" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7063-wk-Fact-EC0ED5C752D257359B9A0397DDC76055" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">830</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7081-wk-Fact-64657A56F2525714968E251DC9300D3D" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,214</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7100-wk-Fact-5A1FA40AEFDA514DB4878CE449A3FF98" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">294</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7118-wk-Fact-2C360BF0DAE855388808E7999F725CD7" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">731</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7136-wk-Fact-21391EA6B67C5891B3F5CC23AB8AD460" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,025</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other segment sales </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7159-wk-Fact-FC95C02992C25EE38AF118E814AABD86" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7178-wk-Fact-1EE7FAEC87115FA9BFCE05DA0936C6D3" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7197-wk-Fact-7E1C6861510851AF81FEA707E8D91CAE" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7217-wk-Fact-78F97BD069615BDDA0BDD26F8AEB6CEB" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7236-wk-Fact-45250C1C763350E0ADBF31C6F44CC334" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:zerodash">—</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7255-wk-Fact-A25599EBCF1B59E48E0155C4E895816A" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7276-wk-Fact-5496C13D13EF56D3A6CEC9D9AEE50367" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,121</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7294-wk-Fact-C0A34A83D3B250A8995E72B4B2657E41" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,771</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7312-wk-Fact-B1282644130454B09E7B709B8197FDC2" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,892</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7331-wk-Fact-0395B8234A80551BA329483B89F0E28C" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,548</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7349-wk-Fact-FC6094755D28533DADBDE8083BC5E527" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,179</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7367-wk-Fact-121F7F753092519DA264F9CD075B1801" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,727</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7390-wk-Fact-C55EFE39C80E5123B87C9E18268BF371" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7409-wk-Fact-7782FC56FA765483AAB00BBD4B845C0B" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7428-wk-Fact-37AFC1825308594AABF213F5C5C681C7" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7448-wk-Fact-6A2889B6435559C9B0D81182D6BCFAF3" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7467-wk-Fact-902B9966E77E51A5BD2A7C867C9670BA" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7486-wk-Fact-653A6FF21034593188932957E2B23D6F" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7512-wk-Fact-AE956BAB5EFB5E6680381FC78A69F43D" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_country_US" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,137</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7531-wk-Fact-91C7F6AB51965B93AA4F69E034DA43E6" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_mrk_InternationalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,920</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7550-wk-Fact-C7D37DB85BC556E9852BBCC58A9EEE17" name="us-gaap:Revenues" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,057</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7570-wk-Fact-4979330754805725A55C85B86F55A381" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_country_US" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,555</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7589-wk-Fact-3152025F203F5642B962C366DB855FFA" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_mrk_InternationalMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,261</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonfraction id="d15770370e7609-wk-Fact-F10A548F31825340A653E3FF20E0EA91" name="us-gaap:Revenues" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,816</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">U.S. plus international may not equal total due to rounding.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&nbsp;3).</span></div></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. </span></div></td></tr></tbody></table></ix:nonnumeric><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-0C96B5B0C00E5FFABAE09F4A85E9E442-1" continuedat="TextSelection-0C96B5B0C00E5FFABAE09F4A85E9E442-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup>&nbsp;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><ix:continuation id="TextSelection-0C96B5B0C00E5FFABAE09F4A85E9E442-2">Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. </ix:continuation>Other in the first quarter of 2020 and 2019 also includes approximately </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><span>$<ix:nonfraction id="d15770370e7675-wk-Fact-3ED79E6524676FB68D294F84E543A4BF" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:7pt;font-style:italic;"> and </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><span>$<ix:nonfraction id="d15770370e7679-wk-Fact-7CE51BEFA85FD290F0C94F846537D18A" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonfraction> million</span></span><span style="font-family:inherit;font-size:7pt;font-style:italic;">, respectively, related to the sale of the marketing rights for certain products.</span></div></td></tr></tbody></table></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">26</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><ix:continuation id="TextSelection-79643DC486A759929D9356592B7F019C-3"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15770370e7686-wk-Fact-0F73DA2B5B6459009F72C18BFDDD9CD2" name="mrk:SalesDiscounts" contextref="FD2020Q1YTD" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.2</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonfraction id="d15770370e7690-wk-Fact-BCF06E7596D65D8F88A4D4F9F0BE427A" name="mrk:SalesDiscounts" contextref="FD2019Q1QTD" unitref="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.6</ix:nonfraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="TextSelection-7EFA2A1217565A94B69C1951E0F0861E-0-wk-Fact-A5F2D88B6DD35DF19F847F660908DF62" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidated sales by geographic area where derived are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7819-wk-Fact-AE956BAB5EFB5E6680381FC78A69F43D" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_country_US" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,137</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7838-wk-Fact-4979330754805725A55C85B86F55A381" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_country_US" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,555</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe, Middle East and Africa</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7853-wk-Fact-EBF4448C0135515EBBD5E861AC83A5E1" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,534</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7872-wk-Fact-53198B002560550984424EDF4E6E5269" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,103</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7892-wk-Fact-ACF269F7018F5A7C93B5780A438E39B1" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_country_CN" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">864</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7911-wk-Fact-9788809567FF5CE7AAF5B02608A79F41" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_country_CN" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">746</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7931-wk-Fact-AEA907F0563D58D9860B0824DF0BB69F" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_country_JP" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7950-wk-Fact-D931F6B756DD521DA5DC7C6A42331136" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_country_JP" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">799</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia Pacific (other than China and Japan)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7970-wk-Fact-3A8BE25915F95E098CBF17FFA4FFFD5B" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">728</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e7989-wk-Fact-51DA3B3A068950D9BBF90178CDC7D3F7" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8009-wk-Fact-D4CC358726665602B001E07F2C5716CE" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">556</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8028-wk-Fact-5C7E568327195EE0B51D4F868A3376D3" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">561</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8048-wk-Fact-C28B3EC76461513FA7B2BA7617B02123" name="us-gaap:Revenues" contextref="FD2020Q1QTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">427</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8067-wk-Fact-36F3D1B4E89950D188D5A14FEBE7CECF" name="us-gaap:Revenues" contextref="FD2019Q1QTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">307</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8092-wk-Fact-C7D37DB85BC556E9852BBCC58A9EEE17" name="us-gaap:Revenues" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,057</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8110-wk-Fact-F10A548F31825340A653E3FF20E0EA91" name="us-gaap:Revenues" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,816</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:nonnumeric><ix:nonnumeric contextref="FD2020Q1YTD" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="TextSelection-B80C6B632A755A70B1D1CC19F1E21617-0-wk-Fact-860E77545EE752D4AFCFC4E5C134ECBB" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of segment profits to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income before taxes</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment profits:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical segment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8288-wk-Fact-F670955724AA5D87A4A9144BB891BCB8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,477</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8307-wk-Fact-07F908422F505AED9C3BF61C86B6696B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,574</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Animal Health segment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8322-wk-Fact-61B9BF19484A5F65AFB834EDAB7D83A9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">478</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8341-wk-Fact-04BF3DF8D1B157798A442B911279A59F" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other segment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8361-wk-Fact-3E139924D0905DB689C385FAC1A8C2F5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8380-wk-Fact-896DCE6E065D57ACB08A7CF1D6999470" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment profits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8400-wk-Fact-43B7101C8F7B5E0EB2339B77E0555815" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,956</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8419-wk-Fact-7D62D5A74619543EB32ABD4D9B5B6A48" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,991</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other profits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8439-wk-Fact-DB1725638A175DB0A2C4A0798880C494" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8458-wk-Fact-41DEA4EB752659E5878699A3D10FCCBA" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unallocated:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8519-wk-Fact-46A8DE20435F5ADD96DA940B949990E2" name="us-gaap:InvestmentIncomeInterest" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8538-wk-Fact-E6ECEA760D6A5B90BC9D44A8E5E4A8FA" name="us-gaap:InvestmentIncomeInterest" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8558-wk-Fact-CAA23B4F84B85117A155CEF7FBF9D1EE" name="us-gaap:InterestExpense" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">212</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8578-wk-Fact-BE141F66EAC25F21A92800F56D35C27F" name="us-gaap:InterestExpense" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8600-wk-Fact-9AFF93D60AA15804AB7A4CCCBD00ECF7" name="us-gaap:DepreciationDepletionAndAmortization" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">381</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8620-wk-Fact-3256B0234860503C8D8571F390E0EFAB" name="us-gaap:DepreciationDepletionAndAmortization" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">359</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8641-wk-Fact-8FF6CD7E069955848BB5D8BED63F387F" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,097</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8661-wk-Fact-A674DD5F545C51C7B849E7743933E5E7" name="us-gaap:ResearchAndDevelopmentExpense" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,843</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of purchase accounting adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8682-wk-Fact-7C615D99A58D502CA47EBC4F2558181B" name="mrk:AmortizationOfPurchaseAccountingAdjustments" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8702-wk-Fact-35FBF42DAFD551ACB456270CE832D016" name="mrk:AmortizationOfPurchaseAccountingAdjustments" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8723-wk-Fact-B61792C93A9D5A92877775833F53EBC7" name="us-gaap:RestructuringCharges" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8743-wk-Fact-BE47F5B9CE655A3AAC314F3FB7A2BD22" name="us-gaap:RestructuringCharges" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8764-wk-Fact-A79F944306CD57468FB5507AA298A6B7" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" contextref="FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,225</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonfraction id="d15770370e8784-wk-Fact-B23D58FD10C05277AE920CE9E6A26A60" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" contextref="FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,082</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8810-wk-Fact-D3CCBE4A2AE854BF8A94C4143491EE09" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2020Q1YTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,838</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonfraction id="d15770370e8829-wk-Fact-9979E9259B3A516894C0D77BA7209E5C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="FD2019Q1QTD" unitref="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,067</ix:nonfraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div><span style="font-family:inherit;font-size:10pt;"><br></span></div></ix:nonnumeric><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">27</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="font-family:inherit;font-size:10pt;"> (continued)</span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><a id="s878C1D5D824054C3B3B404D96866C243"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item&nbsp;2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><a id="sff24876d031745b08aab61442d55dff6"></a></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Planned Spin-Off of Women’s Health, Legacy Brands and Biosimilars into New Company</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, Merck announced its intention to spin-off products from its women’s health, trusted legacy brands and biosimilars businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The legacy brands included in the transaction consist of dermatology, non-opioid pain, respiratory, and select cardiovascular products including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia</span><span style="font-family:inherit;font-size:10pt;"> (ezetimibe) and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vytorin </span><span style="font-family:inherit;font-size:10pt;">(ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the first half of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, legacy brands and biosimilars businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.</span></div><div><a id="s55C35B21D9E2550F8DE47ED1A94B12D8"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Recent Developments</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Developments</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases, for $2.7 billion. ArQule’s lead investigational candidate, MK-1026 (formerly ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies (see Note 2 to the condensed consolidated financial statements). </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Coronavirus Disease 2019 (COVID-19) Update</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overall, in response to the COVID-19 pandemic, Merck is focused on protecting the safety of its employees, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of antiviral and vaccine approaches, and supporting health care providers and Merck’s communities. Merck remains confident in the fundamental underlying demand for its products and its prospects for long-term growth, though COVID-19-related disruptions to patients’ ability to access health care providers will cause near-term challenges.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Business and Financial</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2020, the estimated overall impact of COVID-19 to Merck’s revenue was immaterial. For the full-year 2020, Merck expects an unfavorable impact to revenue of approximately $2.1 billion (excluding the impact of foreign exchange) due to the COVID-19 pandemic, comprised of approximately $1.7 billion for Pharmaceutical revenue and approximately $400 million for Animal Health revenue.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2020, within the Company’s human health business, markets in Asia Pacific, including China, saw a negative impact from social distancing measures and reduced access to health care providers given the earlier prevalence of the virus; whereas other markets, particularly in Europe, saw customers build inventory due to concerns about supply and ability to access health care providers given social distancing measures. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Roughly two-thirds of Merck’s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand, are being affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, are resulting in reduced administration of many of the Company’s human health products, in particular for its vaccines as well as for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> (pembrolizumab) and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Implanon/Nexplanon</span><span style="font-family:inherit;font-size:10pt;"> (etonogestrel implant). The Company anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place. In addition, declines in medical visits and elective surgeries also will have a negative impact on the demand for certain products, including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion</span><span style="font-family:inherit;font-size:10pt;"> (sugammadex) Injection. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In Merck’s Animal Health business, revenue was positively impacted by approximately $60 million in the first quarter of 2020 as customers made advance purchases to secure supply for livestock products and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto</span><span style="font-family:inherit;font-size:10pt;"> (fluralaner), given the uncertainty related to expanding social distancing measures. The Company expects that reduced veterinary visits and decreased protein and milk consumption due to restaurant and school closures will negatively impact the business going forward. Merck also expects that the negative impacts on the economy will have an additional unfavorable effect on its Animal Health business.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While the Company expects to rely on governmental authorities to determine when operations can return to normal, and is cognizant that the duration, spread and severity of the outbreak will be critical determinants for the purposes of the full-year estimates provided above, Merck has assumed the majority of the negative impact will be in the second quarter of 2020, with a gradual return to normal operations beginning late in the second quarter and extending through the third quarter, with a full return to normal operations in the fourth quarter of 2020. </span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">28</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses were positively impacted in the first quarter of 2020 by approximately $100 million, primarily driven by lower promotional and selling costs and delayed clinical program spending due to the COVID-19 pandemic. For the full-year 2020, Merck expects a favorable impact to operating expenses of approximately $400 million.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck’s financial strength and strong balance sheet is allowing it to continue with its capital allocation priorities, including investing in research and development and in growth drivers, investing in manufacturing capacity expansion, paying its dividend and continuing the search for value-enhancing business development. However, given these priorities and the current operating environment, Merck has temporarily suspended its share repurchase program.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Research</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Building on its experience with antivirals and vaccines, Merck has teams of scientists researching COVID-19 and assessing internally available antiviral candidates and vaccine assets for potential to impact COVID-19.&nbsp;The Company also is engaged with a range of research organizations on collaborative efforts to accelerate the development of medicines and vaccines for COVID-19, including participation in the NIH-led ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines), a partnership that aims to develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials and regulatory processes and/or leveraging assets among all partners to rapidly respond to COVID-19 and future pandemics.&nbsp;</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Clinical Trials</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is making every effort to ensure that patients in affected areas who are enrolled in clinical trials are able to continue their treatment and receive appropriate care and monitoring. Conditions are fluid and evolving, but as local conditions allow, Merck is enrolling patients in ongoing studies and is starting new studies.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Manufacturing &amp; Supply</span><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Continuity of supply of the Company’s medicines and vaccines to its patients and customers is a critical priority for Merck. To date, the COVID-19 pandemic has not had a material impact on the production and supply of Merck’s medicines and vaccines. The Company continues to have normal supply levels for most of its products, including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gardasil</span><span style="font-family:inherit;font-size:10pt;"> [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] / </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gardasil</span><span style="font-family:inherit;font-size:10pt;"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), and doubled production capacity for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Esmeron</span><span style="font-family:inherit;font-size:10pt;"> (rocuronium bromide), a muscle relaxant used for intubation in certain countries outside the United States, to address a surge in market demand due to the COVID-19 pandemic. In general, Merck’s total supply chains are 6 to 12 months in length. The Company currently believes supply of its medicines and vaccines will remain at normal levels through the pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Facilities and Employees</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of Merck’s manufacturing plants and clinical supply sites are fully operational and its laboratories are focused on essential operations. The Company is implementing steps to ensure business continuity. In many markets, including the United States, while the Company’s offices and laboratories remain open, Merck’s employees are primarily working from home. In China, most of the Company’s offices, laboratories and plants are now open, although some of Merck’s office- and laboratory-based employees continue to work from home. In many markets, the Company has paused in-person interactions with health care providers and its field-based employees are working from home, including in the United States. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Headquarters</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2020, Merck announced its intention to consolidate its New Jersey campuses into a single New Jersey headquarters location in Rahway by the end of 2023.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Pricing</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. In the United States, pricing pressure continues on many of the Company’s products. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s revenue performance in the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> was negatively affected by other cost-reduction measures taken by governments and other third-parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.</span></div><div><a id="sE64C05B5E2A85457BAB46484F0F7D9CF"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">29</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Operating Results</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,137</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,555</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,920</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,261</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,057</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,816</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">U.S. plus international may not equal total due to rounding.</span></div><div style="line-height:120%;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br></span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide sales were </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.1 billion</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;"> compared with the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Sales growth was driven primarily by higher sales in the oncology franchise reflecting strong growth of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;">, as well as increased alliance revenue from Lynparza (olaparib) and Lenvima (lenvatinib). Also contributing to revenue growth in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> were higher sales of vaccines, including human papillomavirus (HPV) vaccine </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gardasil/Gardasil </span><span style="font-family:inherit;font-size:10pt;">9 and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pneumovax</span><span style="font-family:inherit;font-size:10pt;"> 23 (pneumococcal vaccine polyvalent). Higher sales of certain hospital acute care products, including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Prevymis</span><span style="font-family:inherit;font-size:10pt;"> (letermovir), as well as higher sales of animal health products also drove revenue growth in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales growth was partially offset by the ongoing effects of generic competition for women’s health product </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">NuvaRing </span><span style="font-family:inherit;font-size:10pt;">(etonogestrel/ethinyl estradiol vaginal ring), hospital acute care products </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noxafil</span><span style="font-family:inherit;font-size:10pt;"> (posaconazole) and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cubicin</span><span style="font-family:inherit;font-size:10pt;"> (daptomycin for injection), oncology product </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Emend</span><span style="font-family:inherit;font-size:10pt;"> (aprepitant), virology product </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zepatier</span><span style="font-family:inherit;font-size:10pt;"> (elbasvir and grazoprevir) and cardiovascular product </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vytorin</span><span style="font-family:inherit;font-size:10pt;">. Lower sales of diabetes products </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia </span><span style="font-family:inherit;font-size:10pt;">(sitagliptin) and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> (sitagliptin/metformin HCl) also partially offset revenue growth in the quarter. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 15 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.</span></div><div><a id="sCB61FFE0EE2B57209A39E0E41A19E51D"></a></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical Segment</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Oncology</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,284</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,269</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance Revenue - Lynparza</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&nbsp;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">145</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance Revenue - Lenvima </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">128</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Emend</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">117</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(63</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(63</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">  Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), esophageal cancer, gastric or gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer, primary mediastinal large B-cell lymphoma (PMBCL), and urothelial carcinoma. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy for HNSCC, in combination with axitinib for renal cell carcinoma (RCC), and in combination with lenvatinib for endometrial carcinoma. The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> clinical development program includes studies across a broad range of cancer types (see “Research and Development” below). </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the U.S. Food and Drug Administration (FDA) approved </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> as monotherapy for the treatment of certain patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) based on the results of the KEYNOTE-057 trial.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#333333;">In April 2020, the FDA granted accelerated approval for an additional recommended dosage of 400 mg every six weeks (Q6W) for </span><span style="font-family:inherit;font-size:10pt;color:#333333;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;color:#333333;"> </span><span style="font-family:inherit;font-size:10pt;">across all adult indications, </span><span style="font-family:inherit;font-size:10pt;color:#333333;">including monotherapy and combination therapy. This new dosage option will be available in addition to the current dose of 200 mg every three weeks (Q3W).</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> grew </span><span style="font-family:inherit;font-size:10pt;">45%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> driven by higher demand as the Company continues to launch </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> with multiple new indications globally. Sales in the United States continue to build across the multiple approved indications, in particular for the treatment of NSCLC as monotherapy, and in combination with chemotherapy for both nonsquamous </span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and squamous metastatic NSCLC, along with uptake in the RCC and adjuvant melanoma indications. Other indications contributing to U.S. sales growth include HNSCC, bladder cancer, melanoma, and MSI-H cancer. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> sales growth in international markets was driven by continued uptake in approved indications, particularly in the European Union (EU). </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to a re-pricing rule, the Japanese government reduced the price of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> by 17.5% effective February 2020. Additionally, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> was subject to another price reduction of 20.9% in April 2020 under a provision of the Japanese pricing rules. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lynparza, an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of advanced ovarian, breast and pancreatic cancers. Alliance revenue related to Lynparza increased </span><span style="font-family:inherit;font-size:10pt;">84%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> largely driven by continued uptake across the multiple approved indications in the United States and in the EU. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lenvima, an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of thyroid cancer, HCC, in combination with everolimus for certain patients with RCC, and in combination with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> for the treatment of certain patients with endometrial carcinoma. Alliance revenue related to Lenvima grew </span><span style="font-family:inherit;font-size:10pt;">72%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily due to higher demand in the United States.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Emend</span><span style="font-family:inherit;font-size:10pt;">, for the prevention of chemotherapy-induced nausea and vomiting, declined </span><span style="font-family:inherit;font-size:10pt;">63%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily driven by lower demand and pricing in the United States due to generic competition, including recent generic competition for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Emend</span><span style="font-family:inherit;font-size:10pt;"> for Injection following U.S. patent expiry in September 2019. The patent that provided U.S. market exclusivity for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Emend</span><span style="font-family:inherit;font-size:10pt;"> expired in 2015 and the patent that provided market exclusivity in most major European markets expired in May 2019. Additionally, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Emend</span><span style="font-family:inherit;font-size:10pt;"> for Injection will lose market exclusivity in major European markets in August 2020.&nbsp;The Company anticipates that sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Emend</span><span style="font-family:inherit;font-size:10pt;"> for Injection in these markets will decline significantly thereafter.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2020, the FDA approved </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Koselugo</span><span style="font-family:inherit;font-size:10pt;"> (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA approval is based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase 2 SPRINT Stratum 1 trial coordinated by the NCI’s Center for Cancer Research, Pediatric Oncology Branch. This is the first regulatory approval of a medicine for the treatment of NF1 PN, a rare and debilitating genetic condition. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Koselugo</span><span style="font-family:inherit;font-size:10pt;"> is being jointly developed and commercialized with AstraZeneca globally (see Note 3 to the condensed consolidated financial statements). </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vaccines</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gardasil/Gardasil 9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,097</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">838</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ProQuad</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">157</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">152</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">M-M-R </span><span style="font-family:inherit;font-size:10pt;">II</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">123</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Varivax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">179</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">221</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(19</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(19</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pneumovax </span><span style="font-family:inherit;font-size:10pt;">23</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">256</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">185</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gardasil/Gardasil</span><span style="font-family:inherit;font-size:10pt;"> 9, vaccines to help prevent certain cancers and other diseases caused by certain types of HPV, grew </span><span style="font-family:inherit;font-size:10pt;">31%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. Sales growth was partially driven by the timing of shipments in China, which contributed approximately $120 million of sales in the quarter, and public sector buying patterns in the United States, which benefited sales by approximately $70 million in the quarter. Higher demand in China and in the EU, as well as pricing in the United States also contributed to sales growth in the quarter. Growth was partially offset by the unfavorable effects of the COVID-19 pandemic in certain markets, particularly in Hong Kong and the United States.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">M‑M‑R&nbsp;</span><span style="font-family:inherit;font-size:10pt;">II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, declined </span><span style="font-family:inherit;font-size:10pt;">18%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily driven by lower demand in Brazil and the United States. The Company anticipates that U.S. sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">M-M-R</span><span style="font-family:inherit;font-size:10pt;"> II will decline for the full year of 2020 compared with the full year of 2019 resulting from lower expected demand related to fewer measles outbreaks. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Varivax </span><span style="font-family:inherit;font-size:10pt;">(Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), declined </span><span style="font-family:inherit;font-size:10pt;">19%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> reflecting lower demand and the timing of government tenders in Latin America. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Varivax </span><span style="font-family:inherit;font-size:10pt;">sales are expected to decline for the full year of 2020 compared with the full year of 2019 due in part to the timing of government tenders in select Latin American markets.</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">31</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pneumovax</span><span style="font-family:inherit;font-size:10pt;"> 23, a vaccine to help prevent pneumococcal disease, grew </span><span style="font-family:inherit;font-size:10pt;">39%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of 2020 due to higher demand in the United States and in the EU, driven largely by the COVID-19 pandemic. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hospital Acute Care</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">299</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">255</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noxafil</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">190</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(50</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(49</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cubicin</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(48</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(46</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion</span><span style="font-family:inherit;font-size:10pt;">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew </span><span style="font-family:inherit;font-size:10pt;">17%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> driven by higher demand globally, particularly in the United States. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noxafil</span><span style="font-family:inherit;font-size:10pt;">, for the prevention of invasive fungal infections, declined </span><span style="font-family:inherit;font-size:10pt;">50%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily due to generic competition in the United States and in the EU. The patents that provided U.S.&nbsp;market exclusivity for certain forms of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noxafil</span><span style="font-family:inherit;font-size:10pt;"> representing the majority of U.S. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noxafil</span><span style="font-family:inherit;font-size:10pt;"> sales expired in July 2019. Additionally, the patent for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noxafil</span><span style="font-family:inherit;font-size:10pt;"> expired in a number of major European markets in December 2019. Accordingly, the Company is experiencing significant declines in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noxafil</span><span style="font-family:inherit;font-size:10pt;"> sales in these markets as a result of generic competition and expects the declines to continue. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cubicin</span><span style="font-family:inherit;font-size:10pt;">, an I.V. antibiotic for complicated skin and skin structure infections or bacteremia when caused by designated susceptible organisms, declined </span><span style="font-family:inherit;font-size:10pt;">48%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily due to ongoing generic competition in the United States following expiration of the U.S. composition patent for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cubicin</span><span style="font-family:inherit;font-size:10pt;"> in 2016.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Immunology</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Simponi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">215</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">208</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Remicade</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">123</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(28</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(27</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Simponi</span><span style="font-family:inherit;font-size:10pt;"> (golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), grew </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> driven by higher volumes in Russia.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Remicade</span><span style="font-family:inherit;font-size:10pt;"> (infliximab)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">,</span><span style="font-family:inherit;font-size:10pt;"> a treatment for inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined </span><span style="font-family:inherit;font-size:10pt;">28%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> driven by ongoing biosimilar competition in the Company’s marketing territories in Europe. The Company lost market exclusivity for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Remicade</span><span style="font-family:inherit;font-size:10pt;"> in major European markets in 2015 and no longer has market exclusivity in any of its marketing territories. The Company is experiencing pricing and volume declines in these markets as a result of biosimilar competition and expects the declines to continue. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Virology</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Isentress/Isentress HD</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">245</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">255</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zepatier</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">114</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(52</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(51</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global combined sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Isentress/Isentress HD </span><span style="font-family:inherit;font-size:10pt;">(raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily driven by lower demand and pricing in the United States due to competitive pressure, largely offset by higher volumes in Russia. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zepatier</span><span style="font-family:inherit;font-size:10pt;">, a treatment for adult patients with chronic hepatitis C virus genotype (GT) 1 or GT4 infection, declined </span><span style="font-family:inherit;font-size:10pt;">52%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of 2020 primarily driven by lower demand in the EU, the United States, and Taiwan due to competition and declining patient volumes.</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">32</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cardiovascular</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia/Vytorin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">198</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">238</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(17</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(15</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Atozet</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">122</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rosuzet</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">126</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">133</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adempas</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance Revenue - Adempas</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&nbsp;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">  Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Combined global sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia</span><span style="font-family:inherit;font-size:10pt;"> (marketed in most countries outside the United States as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ezetrol</span><span style="font-family:inherit;font-size:10pt;">) and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vytorin</span><span style="font-family:inherit;font-size:10pt;"> (marketed outside the United States as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inegy</span><span style="font-family:inherit;font-size:10pt;">), medicines for lowering LDL cholesterol, declined </span><span style="font-family:inherit;font-size:10pt;">17%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily driven by generic competition for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inegy</span><span style="font-family:inherit;font-size:10pt;"> in the EU. The EU patents for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ezetrol</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inegy</span><span style="font-family:inherit;font-size:10pt;"> expired in April 2018 and April 2019, respectively. The Company expects the sales decline to continue. The sales decline was partially offset by higher demand for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ezetrol</span><span style="font-family:inherit;font-size:10pt;"> in China.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Atozet</span><span style="font-family:inherit;font-size:10pt;"> (ezetimibe and atorvastatin) (marketed outside of the United States), a medicine for lowering LDL cholesterol, grew </span><span style="font-family:inherit;font-size:10pt;">30%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily due to higher demand in the EU and in Japan.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rosuzet</span><span style="font-family:inherit;font-size:10pt;"> (ezetimibe and rosuvastatin) (marketed outside of the United States), a medicine for lowering LDL cholesterol, more than doubled in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily due to higher demand in Japan and Korea.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adempas (riociguat), a cardiovascular drug for the treatment of pulmonary arterial hypertension, is part of a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Adempas (see Note 3 to the condensed consolidated financial statements). Revenue from Adempas includes sales in Merck’s marketing territories, which grew </span><span style="font-family:inherit;font-size:10pt;">18%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, as well as Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories, which grew </span><span style="font-family:inherit;font-size:10pt;">26%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Diabetes</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia/Janumet</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,277</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,354</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide combined sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;">, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> as a result of continued pricing pressure in the United States. The Company expects U.S. pricing pressure to continue. The patents that provide market exclusivity for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> in the United States expire in July 2022 (although six-month pediatric exclusivity may extend this date). The patent that provides market exclusivity for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;"> in the EU expires in July 2022 (although pediatric exclusivity may extend this date to September 2022). The supplementary patent certificate that provides market exclusivity for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> in the EU expires in April 2023. The Company anticipates sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> in these markets will decline substantially after these patent expiries.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Women’s Health&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Implanon/Nexplanon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">195</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">199</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">NuvaRing</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">219</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(71</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(71</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide sales of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">NuvaRing</span><span style="font-family:inherit;font-size:10pt;">, a vaginal contraceptive product, declined </span><span style="font-family:inherit;font-size:10pt;">71%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> driven by generic competition in the United States. The patent that provided U.S. market exclusivity for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">NuvaRing</span><span style="font-family:inherit;font-size:10pt;"> expired in April 2018 and generic competition began in December 2019. Accordingly, the Company is experiencing a rapid and substantial decline in U.S. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">NuvaRing</span><span style="font-family:inherit;font-size:10pt;"> sales and expects the decline to continue. </span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">33</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Biosimilars&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biosimilars</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biosimilar products are marketed by the Company pursuant to an agreement with Samsung Bioepis Co., Ltd. (Samsung) to develop and commercialize multiple pre-specified biosimilar candidates. Currently, the Company markets Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab) for the treatment of certain inflammatory diseases; Ontruzant (trastuzumab-dttb), a biosimilar to Herceptin (trastuzumab) for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and HER2 overexpressing gastric cancer; and Brenzys (etanercept biosimilar), a biosimilar to Enbrel for the treatment of certain inflammatory diseases. Merck’s commercialization territories under the agreement vary by product. Sale growth of biosimilars in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> was driven by continued uptake of Brenzys since launch in Brazil in 2019, Renflexis in United States since launch in 2017 and Ontruzant in the EU since launch in 2018.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2020, Merck announced the U.S. launch of Ontruzant, which was approved by the FDA in January 2019.</span></div><div><a id="s069F0181AB735C6CA49BEDF5D97EBEAE"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Animal Health Segment</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="14"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Excluding </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Livestock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">739</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">611</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Companion Animal</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">475</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">414</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Animal Health segment sales in the first quarter of 2020 reflect a benefit of approximately $60 million from the timing of customer purchases related to the COVID-19 pandemic. Sales of livestock products grew </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> driven by the April 2019 acquisition of Antelliq Corporation (Antelliq) and COVID-19 related buy-in. Sales of companion animal products grew </span><span style="font-family:inherit;font-size:10pt;">15%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> primarily driven by higher sales of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto</span><span style="font-family:inherit;font-size:10pt;"> line of products for parasitic control, due in part to COVID-19 related buy-in. The Company expects that reduced veterinary visits and decreased protein and milk consumption due to restaurant and school closures will negatively impact the business going forward. Merck also expects that the negative impacts on the economy will have an additional unfavorable effect on its Animal Health business. </span></div><div><a id="sE7595C7FB9B85A2EB02D42A9F91F7E88"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs, Expenses and Other</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="11"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,312</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,052</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,555</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,425</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,209</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,931</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">153</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(53</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">188</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(62</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Sales</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales were </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.3 billion</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;"> compared with the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Cost of sales includes the amortization of intangible assets recorded in connection with business acquisitions, which totaled $292 million and $397 million in the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Cost of sales also includes the amortization of amounts capitalized in connection with collaborations of $90 million and $98 million in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Also included in cost of sales are expenses associated with restructuring activities which amounted to </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$68 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$34 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring costs</span><span style="font-family:inherit;font-size:10pt;"> as discussed below.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin was 72.5% in the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> compared with 71.8% in the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. The gross margin improvement in 2020 was primarily driven by favorable product mix and lower amortization of intangible assets (noted above), partially offset by the unfavorable effects of royalties, manufacturing variances, pricing pressure, inventory write-offs, restructuring costs and foreign exchange.</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">34</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, General and Administrative</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative (SG&amp;A) expenses were </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.6 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> compared with the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, primarily due to costs related to the planned spin-off of Organon and transaction costs related to the acquisition of ArQule (see Note 2 to the condensed consolidated financial statements). These increases were partially offset by lower promotional, selling, and administrative costs, due in part to the COVID-19 pandemic, and the favorable effect of foreign exchange. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development (R&amp;D) expenses increased </span><span style="font-family:inherit;font-size:10pt;">14%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.2 billion</span><span style="font-family:inherit;font-size:10pt;"> driven primarily by higher expenses related to clinical development and increased investment in discovery research and early drug development, as well as higher licensing costs, partially offset by lower costs associated with program delays, reduced travel and fewer meetings due to the COVID-19 pandemic. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $1.5 billion and $1.4 billion in the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $625 million and $545 million for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. In addition, R&amp;D expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business acquisitions. During the first quarter of 2020, the Company recorded net expenses of $33 million compared with a net reduction in expenses of $39 million in the first quarter of 2019 related to the changes in these estimates.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Costs</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In early 2019, Merck&nbsp;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint.&nbsp;This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;">$2.5 billion</span><span style="font-family:inherit;font-size:10pt;">. The Company expects to record charges of approximately </span><span style="font-family:inherit;font-size:10pt;">$800 million</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program to result in annual net cost savings of approximately </span><span style="font-family:inherit;font-size:10pt;">$900 million</span><span style="font-family:inherit;font-size:10pt;"> by the end of 2023. Actions under previous global restructuring programs have been substantially completed. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$72 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$153 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional costs associated with the Company’s restructuring activities are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative</span><span style="font-family:inherit;font-size:10pt;"> expenses and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> costs. The Company recorded aggregate pretax costs of </span><span style="font-family:inherit;font-size:10pt;">$168 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$187 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, related to restructuring program activities (see Note 4 to the condensed consolidated financial statements). </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (Income) Expense, Net</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For details on the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;"> see Note 11 to the condensed consolidated financial statements. </span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">35</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Profits</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical segment profits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,477</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,574</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Animal Health segment profits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">478</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">415</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other non-reportable segment profits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4,118</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3,924</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,838</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,067</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of purchase accounting adjustments, intangible asset impairment charges, and changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical segment profits grew 14% in the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> driven primarily by higher sales, as well as lower selling and promotional costs driven in part by the COVID-19 pandemic, partially offset by the unfavorable effect of foreign exchange and higher administrative costs. Animal Health segment profits grew 15% in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> compared with the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> reflecting higher sales driven by the Antelliq acquisition and COVID-19 related buy-in, partially offset by higher selling and administrative costs and the unfavorable effect of foreign exchange. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Taxes on Income</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective income tax rates of </span><span style="font-family:inherit;font-size:10pt;">16.1%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">6.7%</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. In addition, the effective income tax rate for the first quarter of 2019 reflects the favorable impact of a </span><span style="font-family:inherit;font-size:10pt;">$360 million</span><span style="font-family:inherit;font-size:10pt;"> net tax benefit related to the settlement of certain federal income tax matters.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of </span><span style="font-family:inherit;font-size:10pt;">$107 million</span><span style="font-family:inherit;font-size:10pt;">. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a </span><span style="font-family:inherit;font-size:10pt;">$360 million</span><span style="font-family:inherit;font-size:10pt;"> net tax benefit in the first quarter of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss Attributable to Noncontrolling Interests</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to noncontrolling interests of </span><span style="font-family:inherit;font-size:10pt;">$53 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> includes the portion of goodwill impairment charges related to certain businesses in the Healthcare Services segment that are attributable to noncontrolling interests.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Income and Earnings per Common Share</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Merck&nbsp;&amp; Co., Inc. was </span><span style="font-family:inherit;font-size:10pt;">$3.2 billion</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$2.9 billion</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Earnings per common share assuming dilution attributable to Merck&nbsp;&amp; Co., Inc. common shareholders (EPS) for the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;">$1.26</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$1.12</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-GAAP Income and Non-GAAP EPS</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP income and non-GAAP&nbsp;EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results as it permits investors to understand how management assesses performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs and certain other items. These excluded items are significant components in understanding and assessing financial performance. Non-</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">36</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GAAP income and non-GAAP&nbsp;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes non-GAAP&nbsp;EPS. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. Since non-GAAP income and non-GAAP&nbsp;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&nbsp;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the United States (GAAP). </span></div><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended&nbsp;<br>&nbsp;March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes as reported under GAAP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,838</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,067</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increase (decrease) for excluded items:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition and divestiture-related costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">600</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">548</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">168</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">187</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP income before taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,606</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,802</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes on income as reported under GAAP</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">619</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">205</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated tax benefit on excluded items</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&nbsp;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">165</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">129</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net tax benefit from the settlement of certain federal income tax matters</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">360</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax charge related to finalization of treasury regulations for the Tax Cuts and Job Act of 2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(67</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP taxes on income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">784</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">627</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP net income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,822</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,175</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net loss attributable to noncontrolling interests as reported under GAAP</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(53</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;Acquisition and divestiture-related costs attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP net income attributable to Merck&nbsp;&amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,822</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,175</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EPS assuming dilution as reported under GAAP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.12</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EPS difference</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.24</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP EPS assuming dilution</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.50</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.22</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr></tbody></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.</span></div></td></tr></tbody></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition and Divestiture-Related Costs</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP income and non-GAAP&nbsp;EPS exclude the impact of certain amounts recorded in connection with business acquisitions and divestitures. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with business acquisitions and divestitures. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring Costs</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP income and non-GAAP&nbsp;EPS exclude costs related to restructuring actions (see Note&nbsp;4 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain Other Items</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2019 is a net tax benefit related to the settlement of certain federal income tax matters (see Note </span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">37</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12 to the condensed consolidated financial statements) and a tax charge related to the finalization of U.S. treasury regulations related to the Tax Cuts and Jobs Act of 2017. </span></div><div><a id="sE839D962BD8B5DC291599B82B8FC0BCE"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Update</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,200 clinical trials, including more than 850 trials that combine </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> with other cancer treatments. These studies encompass more than 30 cancer types including: biliary tract, cervical, colorectal, cutaneous squamous cell, endometrial, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, melanoma, mesothelioma, nasopharyngeal, non-small-cell lung, ovarian, PMBCL, prostate, renal, small-cell lung, triple-negative breast and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> is under review in Japan as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma based on results from the pivotal Phase 3 KEYNOTE-062 trial.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> is also under review in Japan as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma based on the results of the Phase 3 KEYNOTE-181 trial. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2019, the FDA accepted a supplemental Biologics License Application (BLA) seeking use of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> for the treatment of patients with recurrent and/or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation based on the results of the KEYNOTE-629 trial. The FDA set a Prescription Drug User Fee Act (PDUFA) date of June 29, 2020.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2020, the FDA accepted for Priority Review a supplemental BLA for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> seeking accelerated approval as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high ≥10 mutations/megabase, as determined by an FDA-approved test, who have progressed following prior treatment and who have no satisfactory alternative treatment options based in part on results from the Phase 2 KEYNOTE-158 trial.&nbsp;The FDA set a PDUFA date of June 16, 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> received Breakthrough Therapy designation from the FDA in September 2019 for the combination of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> with neoadjuvant chemotherapy for the treatment of high-risk, early-stage triple-negative breast cancer (TNBC) and in February 2020 for the combination of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> with PADCEV (enfortumab vedotin-ejfv), in the first-line setting for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 30, 2020, the European Medicines Agency (EMA) announced that the Committee for Medicinal Products for Human Use&nbsp;(CHMP) did not recommend extending the use of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> to the population of patients with NSCLC whose tumors express PD-L1 on fewer than 50% of cells.&nbsp;However, the CHMP did recommend that study data from the KEYNOTE-042 trial be included in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> product information, so that physicians would have access to the most contemporary information regarding use of this drug.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, Merck announced that the Phase 3 KEYNOTE-204 trial evaluating </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> for the treatment of adult patients with relapsed or refractory cHL met one of its dual primary endpoints of progression-free survival (PFS). Based on an interim analysis conducted by an independent Data Monitoring Committee (DMC), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> demonstrated a statistically significant and clinically meaningful improvement in PFS compared with brentuximab vedotin in this patient population. Per the pre-specified analysis plan, the other dual primary endpoint of overall survival (OS) was not formally tested at this interim analysis. The study will continue to evaluate OS. Results will be presented at an upcoming medical meeting and submitted to regulatory authorities. In March 2017, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> was approved by the FDA for the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after three or more prior lines of therapy. This accelerated approval was based on results of the Phase 2 KEYNOTE-087 trial; the Phase 3 KEYNOTE-204 trial is a confirmatory trial for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;">’s current indication in cHL.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2020, Merck announced that the Phase 3 KEYNOTE-177 trial evaluating first-line treatment of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> in patients with MSI-H or mismatch repair deficient unresectable or metastatic colorectal cancer met one of its dual primary endpoints of PFS. Based on an interim analysis conducted by an independent DMC, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> monotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy (investigator’s choice of mFOLFOX6 or FOLFIRI, with or without bevacizumab or cetuximab). Based on the recommendation of the DMC, the study will continue without changes to evaluate OS, the other dual primary endpoint. </span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">38</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lynparza is an oral PARP inhibitor currently approved for certain types of advanced ovarian, breast and pancreatic cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca (see Note 3 to the condensed consolidated financial statements).</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lynparza is under review in the EU as a first-line maintenance monotherapy for patients with germline </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">BRCA</span><span style="font-family:inherit;font-size:10pt;">-mutated metastatic pancreatic cancer whose disease has not progressed following first-line platinum-based chemotherapy. Lynparza was approved for this indication by the FDA in December 2019 based on the results from the Phase 3 POLO trial. A decision from the EMA is expected in the second half of 2020.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the FDA accepted a supplemental New Drug Application (NDA) for Lynparza in combination with bevacizumab for the maintenance treatment of women with advanced ovarian cancer whose disease showed a complete or partial response to first-line treatment with platinum-based chemotherapy and bevacizumab based on the results from the pivotal Phase 3 PAOLA-1 trial. A PDUFA date is set for the second quarter of 2020. This indication is also under review in the EU.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also in January 2020, the FDA accepted for Priority Review a supplemental NDA for Lynparza for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new hormonal agent based on positive results from the Phase 3 PROfound trial. A PDUFA date is set for the second quarter of 2020. This indication is also under review in the EU and in other jurisdictions. In April 2020, Merck and AstraZeneca announced further positive results from the Phase 3 PROfound trial which showed a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS with Lynparza vs. enzalutamide or abiraterone in men with mCRPC selected for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">BRCA</span><span style="font-family:inherit;font-size:10pt;">1/2 or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ATM</span><span style="font-family:inherit;font-size:10pt;"> gene mutations, a subpopulation of HRR gene mutations. These data will be presented at a forthcoming medical meeting. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, Merck and AstraZeneca announced high-level results from the Phase 3 GY004 trial, led by NRG Oncology and sponsored by the U.S. NCI, that examined primarily the efficacy and safety of investigational medicine cediranib in combination with Lynparza versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. The trial did not meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in PFS with cediranib in combination with Lynparza vs. platinum-based chemotherapy. The NCI and NRG Oncology will present the full data at a forthcoming medical meeting.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">V503 is under&nbsp;review in Japan for an initial indication in females for the prevention of certain HPV-related diseases and precursors.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, the FDA accepted for Priority Review a supplemental BLA for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gardasil</span><span style="font-family:inherit;font-size:10pt;"> 9 for the prevention of certain head and neck cancers caused by vaccine-type HPV in females and males 9 through 45 years of age. The FDA set a PDUFA date of June 2020.</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, Merck announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough. In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms - demonstrating a statistically significant decrease in 24-hour coughs per hour versus placebo. The gefapixant 15 mg twice daily treatment arms did not meet the primary efficacy endpoint in either Phase 3 study. The detailed findings will be shared at an upcoming medical meeting.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also in March 2020, Merck announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally administered sGC stimulator being developed to treat patients with heart failure with reduced ejection fraction and following a worsening event. Vericiguat, when given in combination with available heart failure therapies, met the primary efficacy endpoint of reducing the risk for the composite endpoint of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction, compared to placebo. The results were presented at the virtual American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology and published in&nbsp;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The New England Journal of Medicine</span><span style="font-family:inherit;font-size:10pt;">. Vericiguat is being jointly developed with Bayer (see Note 3 to the condensed consolidated financial statements). Merck and Bayer plan to share VICTORIA data with regulatory authorities worldwide. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck and Pfizer Inc.’s Phase 3 VERTIS CV cardiovascular (CV) outcomes trial for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Steglatro</span><span style="font-family:inherit;font-size:10pt;"> (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, achieved its primary endpoint of non-inferiority for major adverse CV events (MACE) compared to placebo in patients with type 2 diabetes mellitus and established atherosclerotic CV disease. MACE was defined as time to the first event of CV death, nonfatal myocardial infarction or nonfatal stroke. The key secondary endpoints of superiority for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Steglatro</span><span style="font-family:inherit;font-size:10pt;"> versus placebo for time to composite of CV death or hospitalization for heart failure, CV death alone and the composite of renal death, dialysis/transplant or doubling of serum creatinine from baseline were not met. While not a pre-specified hypothesis for statistical testing, a reduction in hospitalization for heart failure was observed with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Steglatro</span><span style="font-family:inherit;font-size:10pt;">. The safety profile of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Steglatro</span><span style="font-family:inherit;font-size:10pt;"> was consistent with that reported in previous studies. Detailed results of VERTIS CV are scheduled to be presented on June 16, 2020 at the virtual American Diabetes Association’s 80th Scientific Sessions.</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">39</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The chart below reflects the Company’s research pipeline as of May 1, 2020. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="3"></td></tr><tr><td style="width:27%;"></td><td style="width:33%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Phase 3 (Phase 3 entry date)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Under Review</span></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Cancer</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-1026 </span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hematological Malignancies</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-1308</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div><div style="padding-left:36px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Melanoma</span></div><div style="padding-left:36px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Non-Small-Cell Lung </span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-1454</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div><div style="padding-left:36px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Head and Neck</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-3475 </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Keytruda</span></div><div style="padding-left:36px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced Solid Tumors</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-4280</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hematological Malignancies</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-5890</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7339 Lynparza</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)(3)</sup></span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced Solid Tumors</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7684</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung </span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7902 Lenvima</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2)</sup></span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced Solid Tumors</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">V937</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Melanoma</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Cytomegalovirus</span></div><div style="text-indent:13px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">V160</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">HIV-1 Infection</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-8591 (islatravir)</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Overgrowth Syndrome</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7075</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Respiratory Syncytial Virus</span></div><div style="text-indent:13px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-1654</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Schizophrenia</span></div><div style="text-indent:13px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-8189</span></div><div style="text-indent:13px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br></span></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Cancer</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-3475 </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Biliary Tract (September 2019)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Breast (October 2015)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Cervical (October 2018) (EU)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Colorectal (November 2015)</span></div><div style="padding-left:36px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Endometrial (August 2019) (EU)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Esophageal (December 2015) (EU)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Gastric (May 2015) (EU)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:36px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Mesothelioma (May 2018)</span></div><div style="padding-left:36px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nasopharyngeal (April 2016)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Ovarian (December 2018)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Prostate (May 2019)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Small-Cell Lung (May 2017) (EU)</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-6482</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Renal Cell (February 2020)</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7339 Lynparza</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2)</sup></span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Non-Small-Cell Lung (June 2019)</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7902 Lenvima</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2)</sup></span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bladder (May 2019)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Endometrial (June 2018) (EU)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Head and Neck (February 2020)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Melanoma (March 2019)</span></div><div style="text-indent:24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Non-Small-Cell Lung (March 2019)</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Cough</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7264 (gefapixant) (March 2018)</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Heart Failure</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-1242 (vericiguat) (September 2016)</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">HIV-1 Infection</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-family:inherit;font-size:7.5pt;">MK-8591A (doravirine/islatravir) (February 2020)</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Pneumoconjugate Vaccine</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">V114 (June 2018)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">New Molecular Entities/Vaccines</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Pediatric Neurofibromatosis Type 1</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-5618 (selumetinib)</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;(EU)</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">HPV Vaccine</span></div><div style="text-indent:13px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">V503 Human Papillomavirus 9-valent Vaccine, </span></div><div style="text-indent:13px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recombinant (JPN)</span></div><div style="text-indent:13px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br></span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Certain Supplemental Filings</span></div><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Cancer</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-3475 </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Keytruda</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">•    First-Line Metastatic Gastric Cancer </span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(KEYNOTE-062) (JPN)</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">•    Recurrent Locally Advanced or Metastatic Esophageal</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancer (KEYNOTE-180/KEYNOTE-181) (JPN)</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">•    Recurrent and/or Metastatic Cutaneous Squamous Cell</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Carcinoma (KEYNOTE-629) (U.S.)</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">•    Previously Treated Tumor Mutational Burden-High </span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(KEYNOTE-158) (U.S.)</span></div><div style="padding-top:4px;padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7339 Lynparza</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">•    First-Line g</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">BRCA</span><span style="font-family:inherit;font-size:7.5pt;">m Metastatic Pancreatic Cancer </span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(POLO) (EU)</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">•    First-Line Maintenance Newly Diagnosed Advanced</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ovarian Cancer (PAOLA) (U.S.) (EU)</span></div><div style="text-indent:12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">•    Metastatic Prostate Cancer (PROfound) (U.S.) (EU)</span></div><div style="padding-top:4px;padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">MK-7902 Lenvima</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2)</sup></span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">•    First-Line Metastatic Hepatocellular Carcinoma</span></div><div style="padding-left:36px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(KEYNOTE-524) (U.S.)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Footnotes:</span></div><div style="padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;Being developed in combination with </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:7.5pt;">.</span></div><div style="padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">&nbsp;&nbsp;</span><span style="font-family:inherit;font-size:7.5pt;">Being developed in a collaboration.</span></div><div style="padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></span><span style="font-family:inherit;font-size:7.5pt;">&nbsp;&nbsp;Being developed as monotherapy and in combination with </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Keytruda.</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><a id="s6E285E23B0AC53F8B637FEC15911B772"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,987</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,919</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Working capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,691</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,263</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt to total liabilities and equity</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33.0</span></div></td><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by operating activities was </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$707 million</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$1.3 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Cash provided by operating activities in the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of 2020 includes $750 million of payments related to collaborations with AstraZeneca and Eisai (see Note 3 to the condensed consolidated financial statements). Cash provided by operating activities continues to be the Company’s primary source of funds to finance operating needs, capital expenditures, treasury stock purchases and dividends paid to shareholders. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities was </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.6 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> compared with cash provided by investing activities of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$368 million</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. The change was driven primarily by the acquisition of ArQule in 2020 and higher capital expenditures, partially offset by lower purchases of securities and other investments. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in financing activities was </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.5 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.6 billion</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. The lower use of cash in financing activities was driven primarily by a net increase in short-term borrowings in 2020 compared with a net decrease in short-term borrowing in 2019, partially offset by proceeds from the issuance of debt in 2019 (see below) and higher payments on debt (see below), higher purchases of treasury stock, lower proceeds from exercise of stock options and higher dividends paid to shareholders in 2020. </span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">40</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital expenditures totaled </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$986 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$595 million</span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The increased capital expenditures reflect investment in new capital projects focused primarily on increasing manufacturing capacity for Merck’s key products.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored </span><span style="font-family:inherit;font-size:10pt;">$1.9 billion</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$2.7 billion</span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and the fourth quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividends paid to stockholders were </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.6 billion</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$1.4 billion</span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.&nbsp;In January 2020, the Board of Directors declared a quarterly dividend of $0.61 per share on the Company’s common stock for the second quarter that was paid in April 2020. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, the Company’s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were repaid.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, the Company issued $5.0 billion principal amount of senior unsecured notes consisting of $750 million of 2.90% notes due 2024, $1.75 billion of 3.40% notes due 2029, $1.0 billion of 3.90% notes due 2039, and $1.5 billion of 4.00% notes due 2049. The Company used the net proceeds from the offering of $5.0 billion for general corporate purposes, including the repayment of outstanding commercial paper borrowings.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. During the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, the Company purchased </span><span style="font-family:inherit;font-size:10pt;">$1.3 billion</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">16 million</span><span style="font-family:inherit;font-size:10pt;"> shares) of its common stock for its treasury under this share repurchase program. As of </span><span style="font-family:inherit;font-size:10pt;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company’s remaining share repurchase authorization was </span><span style="font-family:inherit;font-size:10pt;">$5.9 billion</span><span style="font-family:inherit;font-size:10pt;">. As noted above, the Company has temporarily suspended its share repurchase program.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a $6.0 billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div><a id="sEAC7F9BD4630571799E7247CE90DC5C7"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> included in Merck’s Form 10‑K filed on February&nbsp;26, 2020. Certain of these accounting policies are considered critical as disclosed in the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates. There have been no significant changes in the Company’s critical accounting policies since </span><span style="font-family:inherit;font-size:10pt;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. See Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><a id="s99B74C894E4C5341B9FA151063F51A01"></a></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.</span></div><div><a id="s870A5853D92353CD901AA6532B52E6A4"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item&nbsp;4. Controls and Procedures</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company’s disclosure controls and procedures are effective. For the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.</span></div><div><a id="s8284B946225E566E97C9D92D590D9673"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">41</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can&nbsp;also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product development, product approvals, product potential and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including the impact of the recent global outbreak of COVID-19 and other risks and uncertainties some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item&nbsp;1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&nbsp;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, as filed on February&nbsp;26, 2020, and in this Form 10-Q, the Company discusses in&nbsp;more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list&nbsp;to be a&nbsp;complete statement of all potential risks or uncertainties.</span></div><div><a id="sD03B8D230CD7569A82634929FB37129D"></a></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">PART II - Other Information</span></div><div><a id="s7620D0D35468544F9A3ABD013CF5C58A"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item&nbsp;1. Legal Proceedings</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information called for by this Item is incorporated herein by reference to Note 7 included in Part I, Item&nbsp;1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.</span></div><div><a id="s68902b065e894c3988d7853410d3b0ba"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item&nbsp;1A. Risk Factors</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a discussion of risks that affect the Company’s business, please refer to Part I, Item IA, “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.&nbsp;There have been no material changes to the risk factors as previously disclosed in the Company’s Annual Report on Form 10-K, except as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;font-weight:bold;">The global COVID-19 pandemic is having an adverse impact on the Company’s business, operations and financial performance. The Company is unable to predict the extent to which the pandemic and related impacts will continue to adversely impact its business, operations, financial performance, results of operations, and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s business and financial results will be negatively impacted by the recent outbreak of&nbsp;Coronavirus Disease 2019 (COVID-19). The severity, magnitude and duration of the COVID-19&nbsp;pandemic is uncertain, rapidly changing and difficult to predict. The degree to which&nbsp;COVID-19&nbsp;impacts the Company’s results will depend on future developments, including, but not limited to, the duration and spread of the outbreak, its severity, the actions taken to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thus far in 2020,&nbsp;the COVID-19&nbsp;pandemic has impacted the Company’s business and the Company continues to expect that it will impact the business in numerous ways, including but not limited to those outlined below: </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Business and Financial:</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2020, the estimated overall impact of COVID-19 to Merck’s revenue was immaterial. While difficult to predict the impact to the Company, using a set of assumptions, for the full-year 2020, Merck expects an unfavorable impact to revenue of approximately $2.1 billion (excluding the impact of foreign exchange) due to the COVID-19 pandemic, comprised of approximately $1.7 billion for Pharmaceutical revenue and approximately $400 million for Animal Health revenue. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2020, within the Company’s human health business, markets in Asia Pacific, including China, saw a negative impact from social distancing measures and reduced access to health care providers given the earlier prevalence of the virus; whereas other markets, particularly in Europe, saw customers build inventory due to concerns about supply and ability to access health care providers given social distancing measures. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Roughly two-thirds of Merck’s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand, are being affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, are resulting in reduced administration of many of the Company’s human health products, in particular for its vaccines as well as for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Implanon/Nexplanon</span><span style="font-family:inherit;font-size:10pt;">. The Company anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place. In addition, declines in medical visits and elective surgeries also will have a negative impact on the demand for certain products, including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">42</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In Merck’s Animal Health business, revenue was positively impacted by approximately $60 million in the first-quarter of 2020 as customers made advance purchases to secure supply for livestock products and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto</span><span style="font-family:inherit;font-size:10pt;">, given the uncertainty related to expanding social distancing measures. The Company expects that reduced veterinary visits and decreased protein and milk consumption due to restaurant and school closures will negatively impact the business going forward. Merck also expects that the negative impacts on the economy will have an additional unfavorable effect on its Animal Health business. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While the Company expects to rely on governmental authorities to determine when operations can return to normal, and is cognizant that the duration, spread and severity of the outbreak will be critical determinants for the purposes of the full-year estimates provided above, Merck has assumed the majority of the negative impact will be in the second quarter of 2020, with a gradual return to normal operations beginning late in the second quarter and extending through the third quarter, with a full return to normal operations in the fourth quarter of 2020. To the extent these assumptions prove to be incorrect, the Company’s results may differ materially from the estimates set forth herein.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses were positively impacted in the first quarter of 2020 by approximately $100 million, primarily driven by lower promotional and selling costs and delayed clinical program spending due to the COVID-19 pandemic. While difficult to predict the impact to the Company, using a set of assumptions, for the full-year 2020, Merck expects a favorable impact to operating expenses of approximately $400 million. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck’s financial strength and strong balance sheet is allowing it to continue with its capital allocation priorities, including investing in research and development and in growth drivers, investing in manufacturing capacity expansion, paying its dividend and continuing the search for value-enhancing business development. However, given these priorities and the current operating environment, Merck has temporarily suspended its share repurchase program.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Clinical Trials:</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is making every effort to ensure that patients in affected areas who are enrolled in clinical trials are able to continue their treatment and receive appropriate care and monitoring. Conditions are fluid and evolving, but as local conditions allow, Merck is enrolling patients in ongoing studies and starting new studies. If the pandemic is prolonged, clinical trials could experience enrollment delays or new studies might experience delays in commencement which could cause delays in the Company’s ability to register products for new approvals or new indications. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Manufacturing &amp; Supply:</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Continuity of supply of the Company’s medicines and vaccines to its patients and customers is a critical priority for Merck. To date, the COVID-19 pandemic has not had a material impact on the production and supply of Merck’s medicines and vaccines. The Company continues to have normal supply levels for most of its products, including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gardasil/Gardasil </span><span style="font-family:inherit;font-size:10pt;">9. In general, Merck’s total supply chains are 6 to 12 months in length. The Company currently believes supply of its medicines and vaccines will remain at normal levels through the pandemic. However, if the pandemic is prolonged and the Company’s supply chains are disrupted, the Company’s business could be materially adversely affected.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Facilities and Employees:</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of Merck’s manufacturing plants and clinical supply sites are fully operational, and its laboratories are focused on essential operations. The Company is implementing steps to ensure business continuity. In many markets, including the United States, while the Company’s offices and laboratories remain open, Merck’s employees are primarily working from home. In China, most of the Company’s offices, laboratories and plants are now open; although some of Merck’s office- and laboratory-based employees continue to work from home. In many markets, the Company has paused in-person interactions with health care providers and its field-based employees are working from home, including in the United States. If the pandemic is prolonged, the Company’s operations could be adversely affected by these working conditions. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite the Company’s efforts to manage these impacts, their ultimate impact also depends on factors beyond the Company’s knowledge or control, including the duration and severity of the COVID-19 outbreak as well as third-party and government actions taken to contain its spread and mitigate its public health effects.</span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">43</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><a id="sF9875514127B5BE4AE6AC38BEA1017EB"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuer purchases of equity securities for the three months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&nbsp;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="7"></td></tr><tr><td style="width:52%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($&nbsp;in&nbsp;millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total&nbsp;Number</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">of Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Purchased </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Average&nbsp;Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Paid Per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approximate&nbsp;Dollar&nbsp;Value&nbsp;of&nbsp;Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">That May Yet Be Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Under the Plans or Programs </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1 - January 31</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,940,290</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$89.35</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6,906</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 1 - February 29</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,170,086</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$83.67</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6,557</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1 - March 31</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,050,466</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$74.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$5,888</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,160,842</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$79.29</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$5,888</span></div></td></tr></tbody></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tbody><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&nbsp;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury. </span></div></td></tr></tbody></table><div><a id="s794F07382BF8513C97BEE390E6FFCFE8"></a></div><div style="line-height:120%;padding-top:16px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item&nbsp;6. Exhibits</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:85%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm"><span style="font-family:inherit;font-size:10pt;">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009) – Incorporated by reference to Current Report on Form 8-K filed on November&nbsp;4, 2009 (No. 1-6571)</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/310158/000031015815000048/exhibit32-byxlawsxmerckcoi.htm"><span style="font-family:inherit;font-size:10pt;">By-Laws of Merck &amp; Co., Inc. (effective July 22, 2015) – Incorporated by reference to Current Report on Form 8-K filed on July 28, 2015 (No. 1-6571)</span></a><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit311rule13a-14a1.htm"><span style="font-family:inherit;font-size:10pt;">Rule 13a – 14(a)/15d – 14(a) Certification of Chief Executive Officer</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit312rule13a-14a1.htm"><span style="font-family:inherit;font-size:10pt;">Rule 13a – 14(a)/15d – 14(a) Certification of Chief Financial Officer</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321section1350c.htm"><span style="font-family:inherit;font-size:10pt;">Section 1350 Certification of Chief Executive Officer</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit322section1350c.htm"><span style="font-family:inherit;font-size:10pt;">Section 1350 Certification of Chief Financial Officer</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.INS</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.SCH</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.CAL</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.DEF</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.LAB</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.PRE</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></div></td></tr></tbody></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">44</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div><hr style="page-break-after:always"><div><a id="s01E7433B40975D74839862292B66024D"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Signatures</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&nbsp;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tbody><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:23%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MERCK &amp; CO., INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date:  May&nbsp;6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Jennifer Zachary</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">JENNIFER ZACHARY</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Executive Vice President and General Counsel</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date:  May&nbsp;6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Rita A. Karachun</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RITA A. KARACHUN</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&nbsp;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Senior Vice President Finance - Global Controller</span></div></td></tr></tbody></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">- </span><span style="font-family:inherit;font-size:10pt;">45</span><span style="font-family:inherit;font-size:10pt;"> -</span></div></div>	</div>

</div>


	</div>

	<div id="form-information-modal" data-test="form-information-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="form-information-modal-title" data-test="form-information-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">
				<i id="form-information-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="14"></i>

				<i id="dialog-box-copy-content" title="Click to Copy all Dialog Box Content." class="reboot fas fa-copy m-1 click" tabindex="14"></i>

				<i id="dialog-box-close" data-name="Form Information Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="14"></i>

			</div>
		</div>
		<div class="reboot dialog-content">
			<div id="form-information-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="dialog-content-copy-content" class="reboot float-right click color-inherit" tabindex="14">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="14"></textarea>
			</div>
			<div id="form-information-modal-carousel" class="reboot carousel pointer-event" data-interval="false" data-ride="carousel">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-1" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-2" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-3" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-4" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button id="form-information-prev" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="prev" tabindex="14">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="form-information-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button id="form-information-next" data-test="form-information-next" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="next" tabindex="14">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="settings-modal" data-test="settings-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="settings-modal-title" data-test="settings-modal-title" class="reboot lead mb-0">Settings</p>
			<div class="reboot dialog-header-actions">
				<i id="settings-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="15"></i>

				<i id="settings-modal-close" data-name="Settings Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="15"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<form class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Hover
						over Fact for quick information.</label>
					<select id="hover-option-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="true">On</option>
						<option class="reboot" value="false">Off</option>
					</select>
				</div>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Auto
						Scrolling Position</label>
					<select id="scroll-position-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="start">Top</option>
						<option class="reboot" value="center">Center</option>
					</select>
					<small class="reboot form-text text-muted col-sm-12" tabindex="15">Selecting
						a fact from the Sections Menu or the Fact Menu will automatically
						scroll that element to the (Top, or Middle) of the viewer window.
						This setting will have no use on IE 10, or Safari.</small>
				</div>
				<hr class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tagged-data-example-1">Tagged Data</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tagged-data-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 6.66667%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 102, 0); color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 102, 0), rgba(255, 102, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 102, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot search-results-example-1">Search
							Results</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="search-results-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 14.0523%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 215, 0); color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 215, 0), rgba(255, 215, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 215, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot selected-fact-example-1">Selected Fact</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="selected-fact-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tag-shading-exmple-1">Tag Shading
							(hover)</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tag-shading-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 0%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 0, 0); color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 0, 0), rgba(255, 0, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 70%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgba(255, 0, 0, 0.3);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot text-block-exmple-1">Text Block Indicators</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="text-block-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
			</form>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around"></div>
	</div>

	<div id="taxonomy-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="taxonomy-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">

				<i id="taxonomy-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="16"></i>

				<i id="taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="16"></i>
				<i id="taxonomy-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="16"></i>

				<i id="taxonomy-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-close" class="reboot fas fa-times m-1 click" tabindex="16"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<p id="taxonomy-modal-subtitle" class="reboot text-center font-weight-bold"></p>
			<div id="taxonomy-copy-paste" class="reboot form-group d-none">
				<label>Copy and Paste Below Content.</label>
				<a id="taxonomy-copy-content" class="reboot float-right click color-inherit" tabindex="16">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="16"></textarea>
			</div>
			<div id="taxonomy-modal-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-1" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-2" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-3" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-4" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="prev" tabindex="16">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="next" tabindex="16">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="taxonomy-nested-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p class="reboot lead mb-0">
				Nested Facts
				<span class="reboot" id="nested-page"></span>
				<span class="reboot">/</span>
				<span class="reboot" id="nested-count"></span>
			</p>
			<div class="reboot dialog-header-actions">
				<i id="taxonomy-nested-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="17"></i>

				<i id="nested-taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-close" class="reboot fas fa-times m-1 click" tabindex="17"></i>
			</div>
		</div>
		<div class="reboot dialog-content pt-0">
			<div id="modal-nested-fact-labels" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot d-flex">
					<button data-test="modal-taxonomy-nested-prev" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="prev" tabindex="17">
						<i class="reboot fas fa-chevron-left" title="Previous"></i>
						<span class="reboot sr-only">Previous</span>
					</button>
					<div id="modal-taxonomy-nested-label-carousel" class="reboot carousel-inner">
						<!-- Below is populated dynamically VIA JS -->
					</div>
					<button data-test="modal-taxonomy-nested-next" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="next" tabindex="17">
						<i class="reboot fas fa-chevron-right" title="Next"></i>
						<span class="reboot sr-only">Next</span>
					</button>
				</div>
			</div>
			<div id="taxonomy-nested-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="taxonomy-nested-copy-content" class="reboot float-right click color-inherit" tabindex="17">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="17"></textarea>
			</div>
			<div id="modal-taxonomy-nested-content-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-1" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-2" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-3" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-4" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div id="taxonomy-nested-nav-controls" class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="prev" tabindex="17">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-nested-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
				<!-- Below is populated dynamically VIA JS -->
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="next" tabindex="17">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>



</body></html>